Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A phase 1, Open-Label Dose-Finding Study to Evaluate Safety, Tolerability, and Immunogenicity and Phase 2/3 Placebo-Controlled, Observer-Blinded Safety, Tolerability, and Immunogenicity Study of a SARS-COV-2 RNA Vaccine Candidate Against COVID-19 in Healthy Children

    Summary
    EudraCT number
    2020-005442-42
    Trial protocol
    FI   PL  
    Global end of trial date
    08 Dec 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    21 Jun 2024
    First version publication date
    21 Jun 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    C4591007
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04816643
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    BioNTech SE
    Sponsor organisation address
    An der Goldgrube 12, Mainz, Germany, 55131
    Public contact
    BioNTech clinical trials patient information, BioNTech SE, +49 6131 90840, patients@biontech.de
    Scientific contact
    BioNTech clinical trials patient information, BioNTech SE, +49 6131 90840, patients@biontech.de
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    Yes
    EMA paediatric investigation plan number(s)
    EMEA-002861-PIP02-20
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    05 Jan 2024
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    08 Dec 2023
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    Phase 1: To describe the safety and tolerability profiles of prophylactic BNT162b2 at each dose level in each age group. Phase 2/3: To define the safety profile of prophylactic BNT162b2 in all participants (selected-dose and obtaining-serum-samples-for potential- troponin I-testing portions of the study) in each age group. To immunobridge the immune response elicited by prophylactic BNT162b2 between Phase 2/3 participants at the dose selected in each age group and participants 16 to 25 years of age from the C4591001 study without serological or virological evidence (up to 1 month after receipt of Dose 2) of past SARS-CoV-2 infection. To immunobridge the immune response elicited by prophylactic BNT162b2 between Phase 2/3 participants at the dose selected in each age group and participants 16 to 25 years of age from the C4591001 study without serological or virological evidence (up to 1 month after receipt of Dose 3) of past SARS-CoV-2 infection.
    Protection of trial subjects
    The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trials participants were followed.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    24 Mar 2021
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United States: 9608
    Country: Number of subjects enrolled
    Mexico: 353
    Country: Number of subjects enrolled
    Spain: 413
    Country: Number of subjects enrolled
    Brazil: 262
    Country: Number of subjects enrolled
    Finland: 414
    Country: Number of subjects enrolled
    Poland: 691
    Worldwide total number of subjects
    11741
    EEA total number of subjects
    1518
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    2192
    Children (2-11 years)
    9062
    Adolescents (12-17 years)
    487
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The study consisted of 2 parts, Phase 1 and Phase 2/3. The overall baseline period presented below was created to support display of the demographic characteristics for all study phases. The complete disposition information is presented below in separate tables for each individual phase, respectively.

    Pre-assignment
    Screening details
    Out of 11837 participants enrolled, 11836 were randomized. However, one participant was enrolled in error and assigned to treatment, of which 11741 were vaccinated.

    Period 1
    Period 1 title
    Baseline Period
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Phase 1:BNT162b2 (3 mcg):6 Months to < 2 years of age
    Arm description
    Participants aged 6 months to less than (<) 2 years of age received 2 doses of 3 microgram (mcg) BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 3 doses of 3 mcg BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Arm title
    Phase 1: BNT162b2 (3 mcg): 2 to <5 years of age
    Arm description
    Participants aged 2 to <5 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 3 doses of 3 mcg BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Arm title
    Phase 1: BNT162b2 (10 mcg): 2 to <5 years of age
    Arm description
    Participants aged 2 to <5 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 3 doses of 10 mcg BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Arm title
    Phase 1: BNT162b2 (10 mcg): 5 to <12 years of age
    Arm description
    Participants aged 5 to <12 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 3 doses of 10 mcg BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Arm title
    Phase 1: BNT162b2 (20 mcg): 5 to <12 years of age
    Arm description
    Participants aged 5 to <12 years of age received 2 doses of 20 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 2 doses of 20 mcg and 1 dose of 10 mcg BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Arm title
    Phase 1: 5 to <12 Years 30/30 mcg
    Arm description
    Participants aged 5 to <12 years of age received 2 doses of 30 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 2 doses of 30 mcg and 1 dose of 10 mcg BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Arm title
    Phase 1: 5 to <12 Years 30/10 mcg
    Arm description
    Participants aged 5 to <12 years of age received 30 mcg in dose 1 and 10 mcg in dose 2 of BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 30 mcg in dose 1 and 10 mcg in dose 2 of BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Arm title
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age
    Arm description
    Participants aged 6 months to <2 years were randomised to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 3 doses of 3 mcg BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Arm title
    Phase 2/3: Placebo: 6 months to <2 years of age
    Arm description
    Participants aged 6 months to <2 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly separated by 21 days interval as part of this study.
    Arm type
    Experimental

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received normal saline (0.9% sodium chloride solution for injection) administered intramuscularly separated by 21 days interval as part of this study.

    Arm title
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age
    Arm description
    Participants aged 2 to <5 years were randomised to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 3 doses of 3 mcg BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Arm title
    Phase 2/3: Placebo: 2 to <5 years of age
    Arm description
    Participants aged 2 to <5 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly separated by 21 days interval as part of this study.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received normal saline (0.9% sodium chloride solution for injection) administered intramuscularly separated by 21 days interval as part of this study.

    Arm title
    Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age
    Arm description
    Participants aged 5 to <12 years were randomised to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 3 doses of 10 mcg BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Arm title
    Phase 2/3: Placebo: 5 to <12 years of age
    Arm description
    Participants aged 5 to <12 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly separated by 21 days interval as part of this study.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received normal saline (0.9% sodium chloride solution for injection) administered intramuscularly separated by 21 days interval as part of this study.

    Arm title
    Phase 2/3:Troponin group:BNT162b2(10 mcg):5 to<12 years of age
    Arm description
    Participants aged 5 to <12 years were randomised to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 3 doses of 10 mcg BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Arm title
    Phase 2/3: Troponin group: Placebo: 5 to <12 years of age
    Arm description
    Participants aged 5 to <12 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly separated by 21 days interval as part of this study.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received normal saline (0.9% sodium chloride solution for injection) administered intramuscularly separated by 21 days interval as part of this study.

    Arm title
    Phase 2/3:Troponin group:BNT162b2(30 mcg):12 to<16years of age
    Arm description
    Participants aged 12 to <16 years received 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 30 mcg BNT162b2 approximately 175 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 3 doses of 30 mcg BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Number of subjects in period 1
    Phase 1:BNT162b2 (3 mcg):6 Months to < 2 years of age Phase 1: BNT162b2 (3 mcg): 2 to <5 years of age Phase 1: BNT162b2 (10 mcg): 2 to <5 years of age Phase 1: BNT162b2 (10 mcg): 5 to <12 years of age Phase 1: BNT162b2 (20 mcg): 5 to <12 years of age Phase 1: 5 to <12 Years 30/30 mcg Phase 1: 5 to <12 Years 30/10 mcg Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age Phase 2/3: Placebo: 6 months to <2 years of age Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age Phase 2/3: Placebo: 2 to <5 years of age Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age Phase 2/3: Placebo: 5 to <12 years of age Phase 2/3:Troponin group:BNT162b2(10 mcg):5 to<12 years of age Phase 2/3: Troponin group: Placebo: 5 to <12 years of age Phase 2/3:Troponin group:BNT162b2(30 mcg):12 to<16years of age
    Started
    16
    16
    32
    16
    16
    4
    12
    1458
    718
    2368
    1173
    3109
    1538
    518
    260
    487
    Completed
    16
    16
    32
    16
    16
    4
    12
    1458
    718
    2368
    1173
    3109
    1538
    518
    260
    487
    Period 2
    Period 2 title
    Phase 1
    Is this the baseline period?
    No
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 years of age
    Arm description
    Participants aged 6 months to less than (<) 2 years of age received 2 doses of 3 microgram (mcg) BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 3 doses of 3 mcg BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Arm title
    Phase 1: BNT162b2 (3 mcg): 2 to <5 years of age
    Arm description
    Participants aged 2 to <5 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 3 doses of 3 mcg BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Arm title
    Phase 1: BNT162b2 (10 mcg): 2 to <5 years of age
    Arm description
    Participants aged 2 to <5 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 3 doses of 10 mcg BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Arm title
    Phase 1: BNT162b2 (10 mcg): 5 to <12 years of age
    Arm description
    Participants aged 5 to <12 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 3 doses of 10 mcg BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Arm title
    Phase 1: BNT162b2 (20 mcg): 5 to <12 years of age
    Arm description
    Participants aged 5 to <12 years of age received 2 doses of 20 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 2 doses of 20 mcg and 1 dose of 10 mcg BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Arm title
    Phase 1:BNT162b2 (30/30 mcg): 5 to < 12 years of age
    Arm description
    Participants aged 5 to <12 years of age received 2 doses of 30 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 2 doses of 30 mcg and 1 dose of 10 mcg BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Arm title
    Phase 1:BNT162b2 (30/10 mcg): 5 to < 12 years of age
    Arm description
    Participants aged 5 to <12 years of age received 30 mcg in dose 1 and 10 mcg in dose 2 of BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 30 mcg in dose 1 and 10 mcg in dose 2 of BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Number of subjects in period 2 [1]
    Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 years of age Phase 1: BNT162b2 (3 mcg): 2 to <5 years of age Phase 1: BNT162b2 (10 mcg): 2 to <5 years of age Phase 1: BNT162b2 (10 mcg): 5 to <12 years of age Phase 1: BNT162b2 (20 mcg): 5 to <12 years of age Phase 1:BNT162b2 (30/30 mcg): 5 to < 12 years of age Phase 1:BNT162b2 (30/10 mcg): 5 to < 12 years of age
    Started
    16
    16
    32
    16
    16
    4
    12
    Completed
    8
    7
    14
    2
    3
    2
    1
    Not completed
    8
    9
    18
    14
    13
    2
    11
         Withdrawal by parent/guardian/subject
    1
    3
    4
    1
    2
    -
    1
         Unspecified
    6
    3
    4
    8
    2
    1
    4
         Lost to follow-up
    -
    1
    2
    -
    -
    -
    -
         Protocol deviation
    1
    2
    8
    5
    9
    1
    6
    Notes
    [1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
    Justification: The participants enrolled in both periods are different.
    Period 3
    Period 3 title
    Phase 2/3
    Is this the baseline period?
    No
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator

    Arms
    Are arms mutually exclusive
    No

    Arm title
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age
    Arm description
    Participants aged 6 months to <2 years were randomized to received 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 3 doses of 3 mcg BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Arm title
    Phase 2/3: Placebo: 6 months to <2 years
    Arm description
    Participants aged 6 months to <2 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received normal saline (0.9% sodium chloride solution for injection) administered intramuscularly.

    Arm title
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age
    Arm description
    Participants aged 2 to <5 years were randomised to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 3 doses of 3 mcg BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Arm title
    Phase 2/3: Placebo: 2 to <5 years of age
    Arm description
    Participants aged 2 to <5 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly separated by 21 days interval as part of this study.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received normal saline (0.9% sodium chloride solution for injection) administered intramuscularly separated by 21 days interval as part of this study.

    Arm title
    Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age
    Arm description
    Participants aged 5 to <12 years were randomised to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 3 doses of 10 mcg BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Arm title
    Phase 2/3: Placebo: 5 to <12 years of age
    Arm description
    Participants aged 5 to <12 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly separated by 21 days interval as part of this study.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received normal saline (0.9% sodium chloride solution for injection) administered intramuscularly separated by 21 days interval as part of this study.

    Arm title
    Phase 2/3:Troponin group:BNT162b2 (10 mcg):5 to <12 years
    Arm description
    Participants aged 5 to <12 years were randomised to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 3 doses of 10 mcg BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Arm title
    Phase 2/3:Troponin group:Placebo:5 to <12 years
    Arm description
    Participants aged 5 to <12 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly separated by 21 days interval as part of this study.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received normal saline (0.9% sodium chloride solution for injection) administered intramuscularly separated by 21 days interval as part of this study.

    Arm title
    Phase 2/3:Troponin group:BNT162b2 (30 mcg):12 to <16 years
    Arm description
    Participants aged 12 to <16 years were received 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 30 mcg BNT162b2 approximately 175 days after vaccination 2.
    Arm type
    Experimental

    Investigational medicinal product name
    BNT162b2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Participants received 3 doses of 30 mcg BNT162b2 RNA-LNP vaccine utilizing modRNA (100 microgram/milliliter) administered intramuscularly.

    Number of subjects in period 3
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age Phase 2/3: Placebo: 6 months to <2 years Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age Phase 2/3: Placebo: 2 to <5 years of age Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age Phase 2/3: Placebo: 5 to <12 years of age Phase 2/3:Troponin group:BNT162b2 (10 mcg):5 to <12 years Phase 2/3:Troponin group:Placebo:5 to <12 years Phase 2/3:Troponin group:BNT162b2 (30 mcg):12 to <16 years
    Started
    1458
    718
    2368
    1173
    3109
    1538
    518
    260
    487
    Completed
    712
    261
    1215
    406
    1604
    636
    395
    188
    424
    Not completed
    746
    457
    1153
    767
    1505
    902
    123
    72
    63
         Withdrawal by parent/guardian/subject
    199
    196
    427
    458
    816
    543
    66
    37
    40
         Physician decision
    3
    1
    2
    1
    -
    -
    1
    1
    -
         Refused further study procedures
    -
    -
    -
    -
    2
    -
    -
    -
    -
         Pregnancy
    -
    -
    -
    -
    -
    -
    -
    -
    2
         Adverse event
    1
    -
    3
    -
    -
    -
    -
    -
    -
         Unspecified
    465
    221
    464
    171
    86
    47
    11
    4
    -
         Lost to follow-up
    53
    23
    109
    55
    126
    41
    14
    10
    15
         Protocol deviation
    25
    16
    148
    82
    475
    271
    31
    20
    6

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Phase 1:BNT162b2 (3 mcg):6 Months to < 2 years of age
    Reporting group description
    Participants aged 6 months to less than (<) 2 years of age received 2 doses of 3 microgram (mcg) BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.

    Reporting group title
    Phase 1: BNT162b2 (3 mcg): 2 to <5 years of age
    Reporting group description
    Participants aged 2 to <5 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.

    Reporting group title
    Phase 1: BNT162b2 (10 mcg): 2 to <5 years of age
    Reporting group description
    Participants aged 2 to <5 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.

    Reporting group title
    Phase 1: BNT162b2 (10 mcg): 5 to <12 years of age
    Reporting group description
    Participants aged 5 to <12 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.

    Reporting group title
    Phase 1: BNT162b2 (20 mcg): 5 to <12 years of age
    Reporting group description
    Participants aged 5 to <12 years of age received 2 doses of 20 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.

    Reporting group title
    Phase 1: 5 to <12 Years 30/30 mcg
    Reporting group description
    Participants aged 5 to <12 years of age received 2 doses of 30 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.

    Reporting group title
    Phase 1: 5 to <12 Years 30/10 mcg
    Reporting group description
    Participants aged 5 to <12 years of age received 30 mcg in dose 1 and 10 mcg in dose 2 of BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.

    Reporting group title
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age
    Reporting group description
    Participants aged 6 months to <2 years were randomised to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.

    Reporting group title
    Phase 2/3: Placebo: 6 months to <2 years of age
    Reporting group description
    Participants aged 6 months to <2 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly separated by 21 days interval as part of this study.

    Reporting group title
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age
    Reporting group description
    Participants aged 2 to <5 years were randomised to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.

    Reporting group title
    Phase 2/3: Placebo: 2 to <5 years of age
    Reporting group description
    Participants aged 2 to <5 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly separated by 21 days interval as part of this study.

    Reporting group title
    Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age
    Reporting group description
    Participants aged 5 to <12 years were randomised to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.

    Reporting group title
    Phase 2/3: Placebo: 5 to <12 years of age
    Reporting group description
    Participants aged 5 to <12 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly separated by 21 days interval as part of this study.

    Reporting group title
    Phase 2/3:Troponin group:BNT162b2(10 mcg):5 to<12 years of age
    Reporting group description
    Participants aged 5 to <12 years were randomised to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.

    Reporting group title
    Phase 2/3: Troponin group: Placebo: 5 to <12 years of age
    Reporting group description
    Participants aged 5 to <12 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly separated by 21 days interval as part of this study.

    Reporting group title
    Phase 2/3:Troponin group:BNT162b2(30 mcg):12 to<16years of age
    Reporting group description
    Participants aged 12 to <16 years received 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 30 mcg BNT162b2 approximately 175 days after vaccination 2.

    Reporting group values
    Phase 1:BNT162b2 (3 mcg):6 Months to < 2 years of age Phase 1: BNT162b2 (3 mcg): 2 to <5 years of age Phase 1: BNT162b2 (10 mcg): 2 to <5 years of age Phase 1: BNT162b2 (10 mcg): 5 to <12 years of age Phase 1: BNT162b2 (20 mcg): 5 to <12 years of age Phase 1: 5 to <12 Years 30/30 mcg Phase 1: 5 to <12 Years 30/10 mcg Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age Phase 2/3: Placebo: 6 months to <2 years of age Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age Phase 2/3: Placebo: 2 to <5 years of age Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age Phase 2/3: Placebo: 5 to <12 years of age Phase 2/3:Troponin group:BNT162b2(10 mcg):5 to<12 years of age Phase 2/3: Troponin group: Placebo: 5 to <12 years of age Phase 2/3:Troponin group:BNT162b2(30 mcg):12 to<16years of age Total
    Number of subjects
    16 16 32 16 16 4 12 1458 718 2368 1173 3109 1538 518 260 487 11741
    Age Categorical
    Units: Participants
        In utero
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
        Newborns (0-27 days)
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
        Infants and toddlers (28 days-23 months)
    16 0 0 0 0 0 0 1458 718 0 0 0 0 0 0 0 2192
        Children (2-11 years)
    0 16 32 16 16 4 12 0 0 2368 1173 3109 1538 518 260 0 9062
        Adolescents (12-17 years)
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 487 487
        Adults (18-64 years)
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
        From 65-84 years
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
        85 years and over
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
    Gender Categorical
    Units: Participants
        Female
    6 7 13 11 6 1 6 728 372 1197 570 1500 759 252 120 216 5764
        Male
    10 9 19 5 10 3 6 730 346 1171 603 1609 779 266 140 271 5977
    Race
    Units: Subjects
        White
    13 12 25 11 13 4 10 1126 562 1870 913 2404 1199 425 219 228 9034
        Black or African American
    0 0 2 3 0 0 0 73 34 138 71 179 101 19 11 40 671
        Asian
    1 1 2 2 2 0 1 101 51 147 92 256 118 49 16 4 843
        Multiracial
    2 3 2 0 1 0 1 149 65 189 86 235 106 23 13 1 876
        American Indian or Alaska Native
    0 0 1 0 0 0 0 4 1 4 4 13 4 1 1 209 242
        Native Hawaiian or other Pacific Islander
    0 0 0 0 0 0 0 0 0 2 1 10 0 0 0 0 13
        Not reported
    0 0 0 0 0 0 0 5 5 18 6 12 10 1 0 5 62
    Ethnicity
    Units: Subjects
        Hispanic/Latino
    3 0 1 2 0 2 0 248 93 426 193 526 265 52 34 422 2267
        Non-Hispanic/non-Latino
    13 16 31 14 16 2 12 1205 620 1934 979 2579 1273 466 226 65 9451
        Not reported
    0 0 0 0 0 0 0 5 5 8 1 4 0 0 0 0 23

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Phase 1:BNT162b2 (3 mcg):6 Months to < 2 years of age
    Reporting group description
    Participants aged 6 months to less than (<) 2 years of age received 2 doses of 3 microgram (mcg) BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.

    Reporting group title
    Phase 1: BNT162b2 (3 mcg): 2 to <5 years of age
    Reporting group description
    Participants aged 2 to <5 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.

    Reporting group title
    Phase 1: BNT162b2 (10 mcg): 2 to <5 years of age
    Reporting group description
    Participants aged 2 to <5 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.

    Reporting group title
    Phase 1: BNT162b2 (10 mcg): 5 to <12 years of age
    Reporting group description
    Participants aged 5 to <12 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.

    Reporting group title
    Phase 1: BNT162b2 (20 mcg): 5 to <12 years of age
    Reporting group description
    Participants aged 5 to <12 years of age received 2 doses of 20 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.

    Reporting group title
    Phase 1: 5 to <12 Years 30/30 mcg
    Reporting group description
    Participants aged 5 to <12 years of age received 2 doses of 30 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.

    Reporting group title
    Phase 1: 5 to <12 Years 30/10 mcg
    Reporting group description
    Participants aged 5 to <12 years of age received 30 mcg in dose 1 and 10 mcg in dose 2 of BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.

    Reporting group title
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age
    Reporting group description
    Participants aged 6 months to <2 years were randomised to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.

    Reporting group title
    Phase 2/3: Placebo: 6 months to <2 years of age
    Reporting group description
    Participants aged 6 months to <2 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly separated by 21 days interval as part of this study.

    Reporting group title
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age
    Reporting group description
    Participants aged 2 to <5 years were randomised to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.

    Reporting group title
    Phase 2/3: Placebo: 2 to <5 years of age
    Reporting group description
    Participants aged 2 to <5 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly separated by 21 days interval as part of this study.

    Reporting group title
    Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age
    Reporting group description
    Participants aged 5 to <12 years were randomised to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.

    Reporting group title
    Phase 2/3: Placebo: 5 to <12 years of age
    Reporting group description
    Participants aged 5 to <12 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly separated by 21 days interval as part of this study.

    Reporting group title
    Phase 2/3:Troponin group:BNT162b2(10 mcg):5 to<12 years of age
    Reporting group description
    Participants aged 5 to <12 years were randomised to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.

    Reporting group title
    Phase 2/3: Troponin group: Placebo: 5 to <12 years of age
    Reporting group description
    Participants aged 5 to <12 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly separated by 21 days interval as part of this study.

    Reporting group title
    Phase 2/3:Troponin group:BNT162b2(30 mcg):12 to<16years of age
    Reporting group description
    Participants aged 12 to <16 years received 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 30 mcg BNT162b2 approximately 175 days after vaccination 2.
    Reporting group title
    Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 years of age
    Reporting group description
    Participants aged 6 months to less than (<) 2 years of age received 2 doses of 3 microgram (mcg) BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.

    Reporting group title
    Phase 1: BNT162b2 (3 mcg): 2 to <5 years of age
    Reporting group description
    Participants aged 2 to <5 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.

    Reporting group title
    Phase 1: BNT162b2 (10 mcg): 2 to <5 years of age
    Reporting group description
    Participants aged 2 to <5 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.

    Reporting group title
    Phase 1: BNT162b2 (10 mcg): 5 to <12 years of age
    Reporting group description
    Participants aged 5 to <12 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.

    Reporting group title
    Phase 1: BNT162b2 (20 mcg): 5 to <12 years of age
    Reporting group description
    Participants aged 5 to <12 years of age received 2 doses of 20 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.

    Reporting group title
    Phase 1:BNT162b2 (30/30 mcg): 5 to < 12 years of age
    Reporting group description
    Participants aged 5 to <12 years of age received 2 doses of 30 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.

    Reporting group title
    Phase 1:BNT162b2 (30/10 mcg): 5 to < 12 years of age
    Reporting group description
    Participants aged 5 to <12 years of age received 30 mcg in dose 1 and 10 mcg in dose 2 of BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.
    Reporting group title
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age
    Reporting group description
    Participants aged 6 months to <2 years were randomized to received 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.

    Reporting group title
    Phase 2/3: Placebo: 6 months to <2 years
    Reporting group description
    Participants aged 6 months to <2 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly.

    Reporting group title
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age
    Reporting group description
    Participants aged 2 to <5 years were randomised to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.

    Reporting group title
    Phase 2/3: Placebo: 2 to <5 years of age
    Reporting group description
    Participants aged 2 to <5 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly separated by 21 days interval as part of this study.

    Reporting group title
    Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age
    Reporting group description
    Participants aged 5 to <12 years were randomised to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.

    Reporting group title
    Phase 2/3: Placebo: 5 to <12 years of age
    Reporting group description
    Participants aged 5 to <12 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly separated by 21 days interval as part of this study.

    Reporting group title
    Phase 2/3:Troponin group:BNT162b2 (10 mcg):5 to <12 years
    Reporting group description
    Participants aged 5 to <12 years were randomised to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.

    Reporting group title
    Phase 2/3:Troponin group:Placebo:5 to <12 years
    Reporting group description
    Participants aged 5 to <12 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly separated by 21 days interval as part of this study.

    Reporting group title
    Phase 2/3:Troponin group:BNT162b2 (30 mcg):12 to <16 years
    Reporting group description
    Participants aged 12 to <16 years were received 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 30 mcg BNT162b2 approximately 175 days after vaccination 2.

    Subject analysis set title
    Phase 1: 5 to <12 Years BNT162b2 10 mcg
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants aged 5 to <12 years who received the third dose of 10 mcg BNT162b2 as part of this study were included.

    Subject analysis set title
    Historical cohort:C4591001 BNT162b2(30 mcg)16 Through 25 Years
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants aged 16 to 25 years from study C4591001 (NCT04816643) who received 2 doses of original BNT162b2 30 mcg were included.

    Subject analysis set title
    Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 3 mcg)
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants aged 2 to <5 years at the time of receiving third dose received 3 mcg BNT162b2intramuscularly as part of this study.

    Subject analysis set title
    Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 10 mcg)
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants in the 2 to < 5years of age group who aged up to 5 years at the time of the 3rd dose received the age-appropriate dose of 10 mcg BNT162b2 intramuscularly.

    Subject analysis set title
    Phase 2/3: BNT162b2 (10 mcg) 3-Dose Set
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Participants aged 5 to <12 years who received Dose 3 and completed 1 month post-Dose 3 visit in the Dose 3 evaluable immunogenicity population without evidence of prior infection up 1 month post-Dose 3 were included.

    Subject analysis set title
    Phase 2/3: BNT162b2 30 mcg 16-25 Years
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants aged >=12 to <16 years who received 3 doses of original BNT162b2 30 mcg were included.

    Subject analysis set title
    Phase 2/3: C4591001: Placebo 16-25 Years
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants aged >=12 to <16 years who received placebo in Phase 2/3 were included.

    Subject analysis set title
    Ph2/3:BNT162b2 3mcg:6M-<5Y:WoEI:evaluable efficacy(3dose)set
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Phase 2/3 (Ph2/3):Participants aged >=6 months to <5 years (6M-<5Y) in evaluable efficacy (3-Dose) population who received 3 doses of original BNT162b2 3 mcg during the blinded follow up period without evidence of infection(WoEI) prior to 7 days after Dose 3.

    Subject analysis set title
    Phase2/3:Placebo:6M-<5Y):WoEI:evaluable efficacy(3-dose)set
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Participants aged >=6 months to <5 years in evaluable efficacy (3-Dose) population who received 3 doses of placebo during the blinded follow up period without evidence of infection prior to 7 days after Dose 3.

    Subject analysis set title
    Phase 2/3:BNT162b2 3 mcg 6M<5Y:evaluable efficacy(3-dose)set
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Participants aged >=6 months to <5 years in evaluable efficacy (3-Dose) population who received 3 doses of original BNT162b2 3 mcg during the blinded follow up period with and without evidence of infection prior to 7 days after Dose 3.

    Subject analysis set title
    Phase 2/3:Placebo 6M-<5Y:evaluable efficacy(3-dose)set
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Participants aged >=6 months to <5 years in evaluable efficacy (3-Dose) population who received 3 doses of placebo during the blinded follow up period with and without evidence of infection prior to 7 days after Dose 3.

    Subject analysis set title
    Ph2/3:BNT162b2 3 mcg 5-<12Y:WoEI:evaluable efficacy(3-dose)set
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Phase 2/3(Ph2/3):Participants aged 5 to <12 years in evaluable efficacy (3-Dose) population who received 3 doses of original BNT162b2 3 mcg during the blinded follow up period without evidence of infection (WoEI)prior to 7 days after Dose 3.

    Subject analysis set title
    Phase 2/3:Placebo 5 to <12Y:WoEI:evaluable efficacy(3-dose)set
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Participants aged 5 to <12 years in evaluable efficacy (3-Dose) population who received 3 doses of placebo during the blinded follow up period without evidence of infection prior to 7 days after Dose 3.

    Subject analysis set title
    Phase 2/3:BNT162b2 3 mcg 5-<12Y:evaluable efficacy(3-dose)set
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Participants aged 5 to <12 years in evaluable efficacy (3-Dose) population who received 3 doses of original BNT162b2 3 mcg during the blinded follow up period with and without evidence of infection prior to 7 days after Dose 3.

    Subject analysis set title
    Phase 2/3:Placebo 5-<12Y:evaluable efficacy(3-dose)set
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Participants aged 5 to <12 years in evaluable efficacy (3-Dose) population who received 3 doses of placebo during the blinded follow up period with and without evidence of infection prior to 7 days after Dose 3.

    Primary: Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=5 to <12 Years of age [1]
    End point description
    Local reactions were collected in electronic diary (e-diary) or during unscheduled clinical assessments from Day 1 to 7 after Dose 1. Redness and swelling were measured and recorded in measuring device unit (mdu) where, 1 mdu =0.5 centimeter(cm) & were graded as mild(>=0.5 to 2.0 cm),moderate (>2.0 to 7.0 cm), severe(>7.0 cm)& Grade 4 (G4) (necrosis[redness and swelling]or exfoliative dermatitis[redness]).Pain at injection site was graded as mild(did not interfere with activity),moderate (interfered with activity),severe (prevented daily activity) & G4 Emergency room (ER) visit or hospitalisation).G4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% Confidence interval was based on Clopper and Pearson method. Safety population consisted of all participants who received at least 1 dose of study intervention.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 1
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2 (10 mcg): 5 to <12 years of age Phase 1: BNT162b2 (20 mcg): 5 to <12 years of age Phase 1:BNT162b2 (30/30 mcg): 5 to < 12 years of age Phase 1:BNT162b2 (30/10 mcg): 5 to < 12 years of age
    Number of subjects analysed
    16
    16
    4
    12
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any
    12.5 (1.6 to 38.3)
    0 (0.0 to 20.6)
    100.0 (39.8 to 100.0)
    16.7 (2.1 to 48.4)
        Redness: Mild
    6.3 (0.2 to 30.2)
    0 (0.0 to 20.6)
    25.0 (0.6 to 80.6)
    0 (0.0 to 26.5)
        Redness: Moderate
    6.3 (0.2 to 30.2)
    0 (0.0 to 20.6)
    75.0 (19.4 to 99.4)
    16.7 (2.1 to 48.4)
        Redness: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Redness: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Swelling: Any
    18.8 (4.0 to 45.6)
    6.3 (0.2 to 30.2)
    50.0 (6.8 to 93.2)
    8.3 (0.2 to 38.5)
        Swelling: Mild
    6.3 (0.2 to 30.2)
    0 (0.0 to 20.6)
    25.0 (0.6 to 80.6)
    0 (0.0 to 26.5)
        Swelling: Moderate
    12.5 (1.6 to 38.3)
    6.3 (0.2 to 30.2)
    25.0 (0.6 to 80.6)
    8.3 (0.2 to 38.5)
        Swelling: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Swelling: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Pain at the injection site: Any
    87.5 (61.7 to 98.4)
    93.8 (69.8 to 99.8)
    100.0 (39.8 to 100.0)
    83.3 (51.6 to 97.9)
        Pain at the injection site: Mild
    68.8 (41.3 to 89.0)
    56.3 (29.9 to 80.2)
    50.0 (6.8 to 93.2)
    50.0 (21.1 to 78.9)
        Pain at the injection site: Moderate
    18.8 (4.0 to 45.6)
    37.5 (15.2 to 64.6)
    50.0 (6.8 to 93.2)
    33.3 (9.9 to 65.1)
        Pain at the injection site: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Pain at the injection site: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=5 to <12 Years of age [2]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (>=0.5 to 2.0 cm),moderate (>2.0 to 7.0 cm), severe (>7.0 cm) and Grade 4(necrosis [redness and swelling] or exfoliative dermatitis [redness]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalisation. G4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method. Safety population =all participants who received at least 1 dose of study intervention.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 2
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2 (10 mcg): 5 to <12 years of age Phase 1: BNT162b2 (20 mcg): 5 to <12 years of age Phase 1:BNT162b2 (30/30 mcg): 5 to < 12 years of age Phase 1:BNT162b2 (30/10 mcg): 5 to < 12 years of age
    Number of subjects analysed
    16
    16
    4
    12
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any
    37.5 (15.2 to 64.6)
    18.8 (4.0 to 45.6)
    75.0 (19.4 to 99.4)
    16.7 (2.1 to 48.4)
        Redness: Mild
    25.0 (7.3 to 52.4)
    6.3 (0.2 to 30.2)
    25.0 (0.6 to 80.6)
    8.3 (0.2 to 38.5)
        Redness: Moderate
    12.5 (1.6 to 38.3)
    12.5 (1.6 to 38.3)
    25.0 (0.6 to 80.6)
    8.3 (0.2 to 38.5)
        Redness: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    25.0 (0.6 to 80.6)
    0 (0.0 to 26.5)
        Redness: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Swelling: Any
    31.3 (11.0 to 58.7)
    18.8 (4.0 to 45.6)
    50.0 (6.8 to 93.2)
    0 (0.0 to 26.5)
        Swelling: Mild
    12.5 (1.6 to 38.3)
    0 (0.0 to 20.6)
    50.0 (6.8 to 93.2)
    0 (0.0 to 26.5)
        Swelling: Moderate
    18.8 (4.0 to 45.6)
    18.8 (4.0 to 45.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Swelling: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Swelling: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Pain at the injection site: Any
    87.5 (61.7 to 98.4)
    75.0 (47.6 to 92.7)
    100.0 (39.8 to 100.0)
    91.7 (61.5 to 99.8)
        Pain at the injection site: Mild
    75.0 (47.6 to 92.7)
    50.0 (24.7 to 75.3)
    50.0 (6.8 to 93.2)
    83.3 (51.6 to 97.9)
        Pain at the injection site: Moderate
    12.5 (1.6 to 38.3)
    25.0 (7.3 to 52.4)
    50.0 (6.8 to 93.2)
    8.3 (0.2 to 38.5)
        Pain at the injection site: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Pain at the injection site: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=5 to <12 Years of age [3]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (>=0.5 to 2.0 cm),moderate (>2.0 to 7.0 cm), severe (>7.0 cm) and Grade 4(necrosis [redness and swelling] or exfoliative dermatitis [redness]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and G4 ER visit or hospitalisation. Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method. Safety population =all participants who received at least 1 dose of study intervention. All participants aged 5 to <12 years were administered BNT 10 mcg at Dose 3; hence, only BNT 10 mcg arm is reported.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 3
    Notes
    [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: 5 to <12 Years BNT162b2 10 mcg
    Number of subjects analysed
    38
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any
    28.9 (15.4 to 45.9)
        Redness: Mild
    21.1 (9.6 to 37.3)
        Redness: Moderate
    7.9 (1.7 to 21.4)
        Redness: Severe
    0 (0.0 to 9.3)
        Redness: Grade 4
    0 (0.0 to 9.3)
        Swelling: Any
    13.2 (4.4 to 28.1)
        Swelling: Mild
    10.5 (2.9 to 24.8)
        Swelling: Moderate
    2.6 (0.1 to 13.8)
        Swelling: Severe
    0 (0.0 to 9.3)
        Swelling: Grade 4
    0 (0.0 to 9.3)
        Pain at the injection site: Any
    86.8 (71.9 to 95.6)
        Pain at the injection site: Mild
    68.4 (51.3 to 82.5)
        Pain at the injection site: Moderate
    18.4 (7.7 to 34.3)
        Pain at the injection site: Severe
    0 (0.0 to 9.3)
        Pain at the injection site: Grade 4
    0 (0.0 to 9.3)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=5 to <12 Years of age [4]
    End point description
    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 1.Fever:oral temperature >= 38.0 degree Celsius (deg C);categorised as Fever:oral temperature >=38.0 deg C;categorised as >=38.0 to 38.4 deg C, >38.4 to 38.9 deg C,>38.9 to 40.0 deg C& >40.0 deg C.Fatigue,headache,chills,new or worsened muscle pain and new or worsened joint pain:mild (did not interfere with activity),moderate(some interference with activity),severe(prevented daily routine activity).Vomiting:mild:1-2 times in 24 hours(h),moderate:>2 times in 24h,severe:required intravenous hydration.Diarrhea:mild: 2-3 loose stools in 24h,moderate:4-5 loose stools in 24h,severe:6 or more loose stools in 24h.G4 for all events:ER visit/hospitalisation and were classified by investigator or medically qualified person.Events reported as AEs in CRF within 7 days after vaccination were also included.Exact 95%CI based on Clopper and Pearson method. Safety population was used.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 1
    Notes
    [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2 (10 mcg): 5 to <12 years of age Phase 1: BNT162b2 (20 mcg): 5 to <12 years of age Phase 1:BNT162b2 (30/30 mcg): 5 to < 12 years of age Phase 1:BNT162b2 (30/10 mcg): 5 to < 12 years of age
    Number of subjects analysed
    16
    16
    4
    12
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever: >=38.0 deg C
    6.3 (0.2 to 30.2)
    6.3 (0.2 to 30.2)
    0 (0.0 to 60.2)
    33.3 (9.9 to 65.1)
        Fever:38.0 to 38.4 deg C
    6.3 (0.2 to 30.2)
    6.3 (0.2 to 30.2)
    0 (0.0 to 60.2)
    16.7 (2.1 to 48.4)
        Fever: >38.4 to 38.9 deg C
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    16.7 (2.1 to 48.4)
        Fever: >38.9 to 40.0 deg C
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Fever: >40.0 deg C
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Fatigue: Any
    50.0 (24.7 to 75.3)
    68.8 (41.3 to 89.0)
    100.0 (39.8 to 100.0)
    50.0 (21.1 to 78.9)
        Fatigue: Mild
    37.5 (15.2 to 64.6)
    31.3 (11.0 to 58.7)
    25.0 (0.6 to 80.6)
    16.7 (2.1 to 48.4)
        Fatigue: Moderate
    12.5 (1.6 to 38.3)
    37.5 (15.2 to 64.6)
    75.0 (19.4 to 99.4)
    33.3 (9.9 to 65.1)
        Fatigue: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Fatigue: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Headache: Any
    25.0 (7.3 to 52.4)
    31.3 (11.0 to 58.7)
    75.0 (19.4 to 99.4)
    33.3 (9.9 to 65.1)
        Headache: Mild
    18.8 (4.0 to 45.6)
    31.3 (11.0 to 58.7)
    50.0 (6.8 to 93.2)
    25.0 (5.5 to 57.2)
        Headache: Moderate
    6.3 (0.2 to 30.2)
    0 (0.0 to 20.6)
    25.0 (0.6 to 80.6)
    8.3 (0.2 to 38.5)
        Headache: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Headache: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Chills: Any
    0 (0.0 to 20.6)
    25.0 (7.3 to 52.4)
    50.0 (6.8 to 93.2)
    16.7 (2.1 to 48.4)
        Chills: Mild
    0 (0.0 to 20.6)
    18.8 (4.0 to 45.6)
    0 (0.0 to 60.2)
    8.3 (0.2 to 38.5)
        Chills: Moderate
    0 (0.0 to 20.6)
    6.3 (0.2 to 30.2)
    50.0 (6.8 to 93.2)
    8.3 (0.2 to 38.5)
        Chills: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Chills: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Vomiting: Any
    0 (0.0 to 20.6)
    6.3 (0.2 to 30.2)
    0 (0.0 to 60.2)
    8.3 (0.2 to 38.5)
        Vomiting: Mild
    0 (0.0 to 20.6)
    6.3 (0.2 to 30.2)
    0 (0.0 to 60.2)
    8.3 (0.2 to 38.5)
        Vomiting: Moderate
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Vomiting: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Vomiting: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Diarrhea: Any
    6.3 (0.2 to 30.2)
    6.3 (0.2 to 30.2)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Diarrhea: Mild
    6.3 (0.2 to 30.2)
    6.3 (0.2 to 30.2)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Diarrhea: Moderate
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Diarrhea: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Diarrhea: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        New or worsened muscle pain: Any
    12.5 (1.6 to 38.3)
    25.0 (7.3 to 52.4)
    100.0 (39.8 to 100.0)
    0 (0.0 to 26.5)
        New or worsened muscle pain: Mild
    6.3 (0.2 to 30.2)
    25.0 (7.3 to 52.4)
    25.0 (0.6 to 80.6)
    0 (0.0 to 26.5)
        New or worsened muscle pain: Moderate
    6.3 (0.2 to 30.2)
    0 (0.0 to 20.6)
    75.0 (19.4 to 99.4)
    0 (0.0 to 26.5)
        New or worsened muscle pain: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        New or worsened muscle pain: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        New or worsened joint pain: Any
    6.3 (0.2 to 30.2)
    6.3 (0.2 to 30.2)
    25.0 (0.6 to 80.6)
    8.3 (0.2 to 38.5)
        New or worsened joint pain: Mild
    6.3 (0.2 to 30.2)
    6.3 (0.2 to 30.2)
    0 (0.0 to 60.2)
    8.3 (0.2 to 38.5)
        New or worsened joint pain: Moderate
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    25.0 (0.6 to 80.6)
    0 (0.0 to 26.5)
        New or worsened joint pain: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        New or worsened joint pain: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=5 to <12 Years of age [5]
    End point description
    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 2.Fever: oral temperature >= 38.0 deg C;categorised as >=38.0 to 38.4 deg C, >38.4 to 38.9 deg C, >38.9 to 40.0 deg C and >40.0 deg C.Fatigue, headache,chills, new or worsened muscle pain and new or worsened joint pain:mild (did not interfere with activity),moderate (some interference with activity),severe (prevented daily routine activity).Vomiting:mild: 1-2 times in 24 hours, moderate: >2 times in 24 hours,severe: required intravenous hydration.Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalisation and were classified by investigator or medically qualified person.Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method. Safety population.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 2
    Notes
    [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2 (10 mcg): 5 to <12 years of age Phase 1: BNT162b2 (20 mcg): 5 to <12 years of age Phase 1:BNT162b2 (30/30 mcg): 5 to < 12 years of age Phase 1:BNT162b2 (30/10 mcg): 5 to < 12 years of age
    Number of subjects analysed
    16
    16
    4
    12
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever: >=38.0 deg C
    12.5 (1.6 to 38.3)
    18.8 (4.0 to 45.6)
    100.0 (39.8 to 100.0)
    0 (0.0 to 26.5)
        Fever: 38.0 to 38.4 deg C
    0 (0.0 to 20.6)
    6.3 (0.2 to 30.2)
    75.0 (19.4 to 99.4)
    0 (0.0 to 26.5)
        Fever: >38.4 to 38.9 deg C
    6.3 (0.2 to 30.2)
    6.3 (0.2 to 30.2)
    25.0 (0.6 to 80.6)
    0 (0.0 to 26.5)
        Fever: >38.9 to 40.0 deg C
    6.3 (0.2 to 30.2)
    6.3 (0.2 to 30.2)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Fever: >40.0 deg C
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Fatigue: Any
    68.8 (41.3 to 89.0)
    62.5 (35.4 to 84.8)
    100.0 (39.8 to 100.0)
    75.0 (42.8 to 94.5)
        Fatigue: Mild
    43.8 (19.8 to 70.1)
    25.0 (7.3 to 52.4)
    25.0 (0.6 to 80.6)
    58.3 (27.7 to 84.8)
        Fatigue: Moderate
    25.0 (7.3 to 52.4)
    37.5 (15.2 to 64.6)
    75.0 (19.4 to 99.4)
    16.7 (2.1 to 48.4)
        Fatigue: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Fatigue: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Headache: Any
    50.0 (24.7 to 75.3)
    56.3 (29.9 to 80.2)
    75.0 (19.4 to 99.4)
    33.3 (9.9 to 65.1)
        Headache: Mild
    25.0 (7.3 to 52.4)
    25.0 (7.3 to 52.4)
    25.0 (0.6 to 80.6)
    25.0 (5.5 to 57.2)
        Headache: Moderate
    25.0 (7.3 to 52.4)
    31.3 (11.0 to 58.7)
    50.0 (6.8 to 93.2)
    8.3 (0.2 to 38.5)
        Headache: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Headache: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Chills: Any
    31.3 (11.0 to 58.7)
    43.8 (19.8 to 70.1)
    75.0 (19.4 to 99.4)
    33.3 (9.9 to 65.1)
        Chills: Mild
    25.0 (7.3 to 52.4)
    25.0 (7.3 to 52.4)
    75.0 (19.4 to 99.4)
    33.3 (9.9 to 65.1)
        Chills: Moderate
    6.3 (0.2 to 30.2)
    18.8 (4.0 to 45.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Chills: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Chills: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Vomiting: Any
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    25.0 (0.6 to 80.6)
    8.3 (0.2 to 38.5)
        Vomiting: Mild
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    25.0 (0.6 to 80.6)
    8.3 (0.2 to 38.5)
        Vomiting: Moderate
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Vomiting: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Vomiting: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Diarrhea: Any
    6.3 (0.2 to 30.2)
    0 (0.0 to 20.6)
    50.0 (6.8 to 93.2)
    0 (0.0 to 26.5)
        Diarrhea: Mild
    6.3 (0.2 to 30.2)
    0 (0.0 to 20.6)
    50.0 (6.8 to 93.2)
    0 (0.0 to 26.5)
        Diarrhea: Moderate
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Diarrhea: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        Diarrhea: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        New or worsened muscle pain: Any
    0 (0.0 to 20.6)
    18.8 (4.0 to 45.6)
    50.0 (6.8 to 93.2)
    8.3 (0.2 to 38.5)
        New or worsened muscle pain: Mild
    0 (0.0 to 20.6)
    18.8 (4.0 to 45.6)
    0 (0.0 to 60.2)
    8.3 (0.2 to 38.5)
        New or worsened muscle pain: Moderate
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    50.0 (6.8 to 93.2)
    0 (0.0 to 26.5)
        New or worsened muscle pain: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        New or worsened muscle pain: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        New or worsened joint pain: Any
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    25.0 (0.6 to 80.6)
    0 (0.0 to 26.5)
        New or worsened joint pain: Mild
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        New or worsened joint pain: Moderate
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    25.0 (0.6 to 80.6)
    0 (0.0 to 26.5)
        New or worsened joint pain: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
        New or worsened joint pain: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 20.6)
    0 (0.0 to 60.2)
    0 (0.0 to 26.5)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3:>=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3:>=5 to <12 Years of age [6]
    End point description
    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 3.Fever: oral temperature >= 38.0 deg C;categorised as >=38.0 to 38.4 deg C, >38.4 to 38.9 deg C, >38.9 to 40.0 deg C and >40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain:mild (did not interfere with activity),moderate (some interference with activity),severe (prevented daily routine activity).Vomiting:mild: 1-2 times in 24 hours, moderate: >2 times in 24 hours,severe: required intravenous hydration.Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalisation and were classified by investigator or medically qualified person.Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method. Safety population was used.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 3
    Notes
    [6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: 5 to <12 Years BNT162b2 10 mcg
    Number of subjects analysed
    38
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever:>=38.0 deg C
    2.6 (0.1 to 13.8)
        Fever:38.0 to 38.4 deg C
    0 (0.0 to 9.3)
        Fever: >38.4 to 38.9 deg C
    0 (0.0 to 9.3)
        Fever: >38.9 to 40.0 deg C
    2.6 (0.1 to 13.8)
        Fever: >40.0 deg C
    0 (0.0 to 9.3)
        Fatigue: Any
    39.5 (24.0 to 56.6)
        Fatigue: Mild
    21.1 (9.6 to 37.3)
        Fatigue: Moderate
    15.8 (6.0 to 31.3)
        Fatigue: Severe
    2.6 (0.1 to 13.8)
        Fatigue: Grade 4
    0 (0.0 to 9.3)
        Headache: Any
    34.2 (19.6 to 51.4)
        Headache: Mild
    21.1 (9.6 to 37.3)
        Headache: Moderate
    10.5 (2.9 to 24.8)
        Headache: Severe
    2.6 (0.1 to 13.8)
        Headache: Grade 4
    0 (0.0 to 9.3)
        Chills: Any
    15.8 (6.0 to 31.3)
        Chills: Mild
    13.2 (4.4 to 28.1)
        Chills: Moderate
    2.6 (0.1 to 13.8)
        Chills: Severe
    0 (0.0 to 9.3)
        Chills: Grade 4
    0 (0.0 to 9.3)
        Vomiting: Any
    2.6 (0.1 to 13.8)
        Vomiting: Mild
    2.6 (0.1 to 13.8)
        Vomiting: Moderate
    0 (0.0 to 9.3)
        Vomiting: Severe
    0 (0.0 to 9.3)
        Vomiting: Grade 4
    0 (0.0 to 9.3)
        Diarrhea: Any
    0 (0.0 to 9.3)
        Diarrhea: Mild
    0 (0.0 to 9.3)
        Diarrhea: Moderate
    0 (0.0 to 9.3)
        Diarrhea: Severe
    0 (0.0 to 9.3)
        Diarrhea: Grade 4
    0 (0.0 to 9.3)
        New or worsened muscle pain: Any
    7.9 (1.7 to 21.4)
        New or worsened muscle pain: Mild
    2.6 (0.1 to 13.8)
        New or worsened muscle pain: Moderate
    5.3 (0.6 to 17.7)
        New or worsened muscle pain: Severe
    0 (0.0 to 9.3)
        New or worsened muscle pain: Grade 4
    0 (0.0 to 9.3)
        New or worsened joint pain: Any
    2.6 (0.1 to 13.8)
        New or worsened joint pain: Mild
    0 (0.0 to 9.3)
        New or worsened joint pain: Moderate
    2.6 (0.1 to 13.8)
        New or worsened joint pain: Severe
    0 (0.0 to 9.3)
        New or worsened joint pain: Grade 4
    0 (0.0 to 9.3)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=2 to <5 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=2 to <5 Years of age [7]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (>=0.5 to 2.0 cm),moderate (>2.0 to 7.0 cm), severe (>7.0 cm) and Grade 4(necrosis [redness and swelling] or exfoliative dermatitis [redness]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalisation. Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method. Safety population =all participants who received at least 1 dose of study intervention.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 1
    Notes
    [7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2 (3 mcg): 2 to <5 years of age Phase 1: BNT162b2 (10 mcg): 2 to <5 years of age
    Number of subjects analysed
    16
    32
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any
    0 (0.0 to 20.6)
    28.1 (13.7 to 46.7)
        Redness: Mild
    0 (0.0 to 20.6)
    25.0 (11.5 to 43.4)
        Redness: Moderate
    0 (0.0 to 20.6)
    3.1 (0.1 to 16.2)
        Redness: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Redness: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Swelling: Any
    0 (0.0 to 20.6)
    9.4 (2.0 to 25.0)
        Swelling: Mild
    0 (0.0 to 20.6)
    6.3 (0.8 to 20.8)
        Swelling: Moderate
    0 (0.0 to 20.6)
    3.1 (0.1 to 16.2)
        Swelling: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Swelling: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Pain at the injection site: Any
    31.3 (11.0 to 58.7)
    62.5 (43.7 to 78.9)
        Pain at the injection site: Mild
    25.0 (7.3 to 52.4)
    56.3 (37.7 to 73.6)
        Pain at the injection site: Moderate
    6.3 (0.2 to 30.2)
    6.3 (0.8 to 20.8)
        Pain at the injection site: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Pain at the injection site: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=2 to <5 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=2 to <5 Years of age [8]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (>=0.5 to 2.0 cm),moderate (>2.0 to 7.0 cm), severe (>7.0 cm) and Grade 4(necrosis [redness and swelling] or exfoliative dermatitis [redness]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalisation. Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method. Safety population =all participants who received at least 1 dose of study intervention.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 2
    Notes
    [8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2 (3 mcg): 2 to <5 years of age Phase 1: BNT162b2 (10 mcg): 2 to <5 years of age
    Number of subjects analysed
    16
    32
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any
    0 (0.0 to 20.6)
    15.6 (5.3 to 32.8)
        Redness: Mild
    0 (0.0 to 20.6)
    15.6 (5.3 to 32.8)
        Redness: Moderate
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Redness: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Redness: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Swelling: Any
    0 (0.0 to 20.6)
    3.1 (0.1 to 16.2)
        Swelling: Mild
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Swelling: Moderate
    0 (0.0 to 20.6)
    3.1 (0.1 to 16.2)
        Swelling: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Swelling: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Pain at the injection site: Any
    37.5 (15.2 to 64.6)
    53.1 (34.7 to 70.9)
        Pain at the injection site: Mild
    37.5 (15.2 to 64.6)
    43.8 (26.4 to 62.3)
        Pain at the injection site: Moderate
    0 (0.0 to 20.6)
    9.4 (2.0 to 25.0)
        Pain at the injection site: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Pain at the injection site: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=2 to <5 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=2 to <5 Years of age [9]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (>=0.5 to 2.0 cm),moderate (>2.0 to 7.0 cm), severe (>7.0 cm) and Grade 4(necrosis [redness and swelling] or exfoliative dermatitis [redness]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalisation. Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method. Safety population =all participants who received at least 1 dose of study intervention.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 3
    Notes
    [9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 3 mcg) Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 10 mcg)
    Number of subjects analysed
    26
    13
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any
    3.8 (0.1 to 19.6)
    15.4 (1.9 to 45.4)
        Redness: Mild
    3.8 (0.1 to 19.6)
    15.4 (1.9 to 45.4)
        Redness: Moderate
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        Redness: Severe
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        Redness: Grade 4
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        Swelling: Any
    0 (0.0 to 13.2)
    7.7 (0.2 to 36.0)
        Swelling: Mild
    0 (0.0 to 13.2)
    7.7 (0.2 to 36.0)
        Swelling: Moderate
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        Swelling: Severe
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        Swelling: Grade 4
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        Pain at the injection site: Any
    34.6 (17.2 to 55.7)
    84.6 (54.6 to 98.1)
        Pain at the injection site: Mild
    34.6 (17.2 to 55.7)
    38.5 (13.9 to 68.4)
        Pain at the injection site: Moderate
    0 (0.0 to 13.2)
    38.5 (13.9 to 68.4)
        Pain at the injection site: Severe
    0 (0.0 to 13.2)
    7.7 (0.2 to 36.0)
        Pain at the injection site: Grade 4
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=2 to <5 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=2 to <5 Years of age [10]
    End point description
    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 1.Fever: oral temperature >= 38.0 deg C;categorised as >=38.0 to 38.4 deg C, >38.4 to 38.9 deg C, >38.9 to 40.0 deg C and >40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain:mild (did not interfere with activity),moderate (some interference with activity),severe (prevented daily routine activity).Vomiting:mild: 1-2 times in 24 hours, moderate: >2 times in 24 hours,severe: required intravenous hydration.Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalisation and were classified by investigator or medically qualified person.Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method. Safety population was used.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 1
    Notes
    [10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2 (3 mcg): 2 to <5 years of age Phase 1: BNT162b2 (10 mcg): 2 to <5 years of age
    Number of subjects analysed
    16
    32
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever: >=38.0 deg C
    0 (0.0 to 20.6)
    18.8 (7.2 to 36.4)
        Fever: 38.0 to 38.4 deg C
    0 (0.0 to 20.6)
    6.3 (0.8 to 20.8)
        Fever: >38.4 to 38.9 deg C
    0 (0.0 to 20.6)
    6.3 (0.8 to 20.8)
        Fever: >38.9 to 40.0 deg C
    0 (0.0 to 20.6)
    6.3 (0.8 to 20.8)
        Fever: >40.0 deg C
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Fatigue: Any
    25.0 (7.3 to 52.4)
    46.9 (29.1 to 65.3)
        Fatigue: Mild
    18.8 (4.0 to 45.6)
    34.4 (18.6 to 53.2)
        Fatigue: Moderate
    6.3 (0.2 to 30.2)
    12.5 (3.5 to 29.0)
        Fatigue: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Fatigue: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Headache: Any
    12.5 (1.6 to 38.3)
    9.4 (2.0 to 25.0)
        Headache: Mild
    6.3 (0.2 to 30.2)
    6.3 (0.8 to 20.8)
        Headache: Moderate
    6.3 (0.2 to 30.2)
    3.1 (0.1 to 16.2)
        Headache: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Headache: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Chills: Any
    6.3 (0.2 to 30.2)
    6.3 (0.8 to 20.8)
        Chills: Mild
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Chills: Moderate
    6.3 (0.2 to 30.2)
    6.3 (0.8 to 20.8)
        Chills: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Chills: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Vomiting: Any
    0 (0.0 to 20.6)
    3.1 (0.1 to 16.2)
        Vomiting: Mild
    0 (0.0 to 20.6)
    3.1 (0.1 to 16.2)
        Vomiting: Moderate
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Vomiting: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Vomiting: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Diarrhea: Any
    6.3 (0.2 to 30.2)
    6.3 (0.8 to 20.8)
        Diarrhea: Mild
    6.3 (0.2 to 30.2)
    6.3 (0.8 to 20.8)
        Diarrhea: Moderate
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Diarrhea: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Diarrhea: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        New or worsened muscle pain: Any
    0 (0.0 to 20.6)
    6.3 (0.8 to 20.8)
        New or worsened muscle pain: Mild
    0 (0.0 to 20.6)
    3.1 (0.1 to 16.2)
        New or worsened muscle pain: Moderate
    0 (0.0 to 20.6)
    3.1 (0.1 to 16.2)
        New or worsened muscle pain: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        New or worsened muscle pain: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        New or worsened joint pain: Any
    6.3 (0.2 to 30.2)
    0 (0.0 to 10.9)
        New or worsened joint pain: Mild
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        New or worsened joint pain: Moderate
    6.3 (0.2 to 30.2)
    0 (0.0 to 10.9)
        New or worsened joint pain: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        New or worsened joint pain: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=2 to <5 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=2 to <5 Years of age [11]
    End point description
    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 2.Fever: oral temperature >= 38.0 deg C;categorised as >=38.0 to 38.4 deg C, >38.4 to 38.9 deg C, >38.9 to 40.0 deg C and >40.0 deg C.Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain:mild (did not interfere with activity),moderate (some interference with activity),severe (prevented daily routine activity).Vomiting:mild: 1-2 times in 24 hours, moderate: >2 times in 24 hours,severe: required intravenous hydration.Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalisation and were classified by investigator or medically qualified person.Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method. Safety population was used.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 2
    Notes
    [11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2 (3 mcg): 2 to <5 years of age Phase 1: BNT162b2 (10 mcg): 2 to <5 years of age
    Number of subjects analysed
    16
    32
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever: >=38.0 deg C
    6.3 (0.2 to 30.2)
    18.8 (7.2 to 36.4)
        Fever: 38.0 to 38.4 deg C
    0 (0.0 to 20.6)
    9.4 (2.0 to 25.0)
        Fever: >38.4 to 38.9 deg C
    6.3 (0.2 to 30.2)
    3.1 (0.1 to 16.2)
        Fever: >38.9 to 40.0 deg C
    0 (0.0 to 20.6)
    6.3 (0.8 to 20.8)
        Fever: >40.0 deg C
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Fatigue: Any
    25.0 (7.3 to 52.4)
    59.4 (40.6 to 76.3)
        Fatigue: Mild
    12.5 (1.6 to 38.3)
    31.3 (16.1 to 50.0)
        Fatigue: Moderate
    12.5 (1.6 to 38.3)
    28.1 (13.7 to 46.7)
        Fatigue: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Fatigue: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Headache: Any
    12.5 (1.6 to 38.3)
    15.6 (5.3 to 32.8)
        Headache: Mild
    6.3 (0.2 to 30.2)
    9.4 (2.0 to 25.0)
        Headache: Moderate
    6.3 (0.2 to 30.2)
    6.3 (0.8 to 20.8)
        Headache: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Headache: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Chills: Any
    6.3 (0.2 to 30.2)
    6.3 (0.8 to 20.8)
        Chills: Mild
    0 (0.0 to 20.6)
    6.3 (0.8 to 20.8)
        Chills: Moderate
    6.3 (0.2 to 30.2)
    0 (0.0 to 10.9)
        Chills: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Chills: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Vomiting: Any
    6.3 (0.2 to 30.2)
    6.3 (0.8 to 20.8)
        Vomiting: Mild
    6.3 (0.2 to 30.2)
    3.1 (0.1 to 16.2)
        Vomiting: Moderate
    0 (0.0 to 20.6)
    3.1 (0.1 to 16.2)
        Vomiting: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Vomiting: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Diarrhea: Any
    6.3 (0.2 to 30.2)
    12.5 (3.5 to 29.0)
        Diarrhea: Mild
    6.3 (0.2 to 30.2)
    12.5 (3.5 to 29.0)
        Diarrhea: Moderate
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Diarrhea: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        Diarrhea: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        New or worsened muscle pain: Any
    0 (0.0 to 20.6)
    9.4 (2.0 to 25.0)
        New or worsened muscle pain: Mild
    0 (0.0 to 20.6)
    6.3 (0.8 to 20.8)
        New or worsened muscle pain: Moderate
    0 (0.0 to 20.6)
    3.1 (0.1 to 16.2)
        New or worsened muscle pain: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        New or worsened muscle pain: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        New or worsened joint pain: Any
    0 (0.0 to 20.6)
    3.1 (0.1 to 16.2)
        New or worsened joint pain: Mild
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        New or worsened joint pain: Moderate
    0 (0.0 to 20.6)
    3.1 (0.1 to 16.2)
        New or worsened joint pain: Severe
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
        New or worsened joint pain: Grade 4
    0 (0.0 to 20.6)
    0 (0.0 to 10.9)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=2 to <5 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=2 to <5 Years of age [12]
    End point description
    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 3.Fever: oral temperature >= 38.0 deg C;categorised as >=38.0 to 38.4 deg C, >38.4 to 38.9 deg C, >38.9 to 40.0 deg C and >40.0 deg C.Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain:mild (did not interfere with activity),moderate (some interference with activity),severe (prevented daily routine activity).Vomiting:mild: 1-2 times in 24 hours, moderate: >2 times in 24 hours,severe: required intravenous hydration.Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalisation and were classified by investigator or medically qualified person.Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method. Safety population was used.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 3
    Notes
    [12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 3 mcg) Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 10 mcg)
    Number of subjects analysed
    26
    13
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever: >=38.0 deg C
    0 (0.0 to 13.2)
    15.4 (1.9 to 45.4)
        Fever: 38.0 to 38.4 deg C
    0 (0.0 to 13.2)
    7.7 (0.2 to 36.0)
        Fever: >38.4 to 38.9 deg C
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        Fever: >38.9 to 40.0 deg C
    0 (0.0 to 13.2)
    7.7 (0.2 to 36.0)
        Fever: >40.0 deg C
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        Fatigue: Any
    30.8 (14.3 to 51.8)
    53.8 (25.1 to 80.8)
        Fatigue: Mild
    19.2 (6.6 to 39.4)
    23.1 (5.0 to 53.8)
        Fatigue: Moderate
    11.5 (2.4 to 30.2)
    30.8 (9.1 to 61.4)
        Fatigue: Severe
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        Fatigue: Grade 4
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        Headache: Any
    3.8 (0.1 to 19.6)
    23.1 (5.0 to 53.8)
        Headache: Mild
    3.8 (0.1 to 19.6)
    15.4 (1.9 to 45.4)
        Headache: Moderate
    0 (0.0 to 13.2)
    7.7 (0.2 to 36.0)
        Headache: Severe
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        Headache: Grade 4
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        Chills: Any
    0 (0.0 to 13.2)
    15.4 (1.9 to 45.4)
        Chills: Mild
    0 (0.0 to 13.2)
    7.7 (0.2 to 36.0)
        Chills: Moderate
    0 (0.0 to 13.2)
    7.7 (0.2 to 36.0)
        Chills: Severe
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        Chills: Grade 4
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        Vomiting: Any
    0 (0.0 to 13.2)
    23.1 (5.0 to 53.8)
        Vomiting: Mild
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        Vomiting: Moderate
    0 (0.0 to 13.2)
    23.1 (5.0 to 53.8)
        Vomiting: Severe
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        Vomiting: Grade 4
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        Diarrhea: Any
    3.8 (0.1 to 19.6)
    7.7 (0.2 to 36.0)
        Diarrhea: Mild
    3.8 (0.1 to 19.6)
    7.7 (0.2 to 36.0)
        Diarrhea: Moderate
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        Diarrhea: Severe
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        Diarrhea: Grade 4
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        New or worsened muscle pain: Any
    0 (0.0 to 13.2)
    15.4 (1.9 to 45.4)
        New or worsened muscle pain: Mild
    0 (0.0 to 13.2)
    7.7 (0.2 to 36.0)
        New or worsened muscle pain: Moderate
    0 (0.0 to 13.2)
    7.7 (0.2 to 36.0)
        New or worsened muscle pain: Severe
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        New or worsened muscle pain: Grade 4
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        New or worsened joint pain: Any
    0 (0.0 to 13.2)
    7.7 (0.2 to 36.0)
        New or worsened joint pain: Mild
    0 (0.0 to 13.2)
    7.7 (0.2 to 36.0)
        New or worsened joint pain: Moderate
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        New or worsened joint pain: Severe
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
        New or worsened joint pain: Grade 4
    0 (0.0 to 13.2)
    0 (0.0 to 24.7)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=6 Months to <2 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=6 Months to <2 Years of age [13]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild(>=0.5 to 2.0 cm),moderate(>2.0 to 7.0 cm),severe(>7.0 cm)&Grade (G) 4(necrosis [redness and swelling] or exfoliative dermatitis [redness]).Tenderness at injection site was graded as mild(hurts if gently touched),moderate(hurts if gently touched with crying),severe(causes limitation of limb movement)&G4 ER visit or hospitalisation.G4 were classified by investigator or medically qualified person.Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method. Safety population =all participants who received at least 1 dose of study intervention.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 1
    Notes
    [13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 years of age
    Number of subjects analysed
    16
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any
    18.8 (4.0 to 45.6)
        Redness: Mild
    18.8 (4.0 to 45.6)
        Redness: Moderate
    0 (0.0 to 20.6)
        Redness: Severe
    0 (0.0 to 20.6)
        Redness: Grade 4
    0 (0.0 to 20.6)
        Swelling: Any
    6.3 (0.2 to 30.2)
        Swelling: Mild
    6.3 (0.2 to 30.2)
        Swelling: Moderate
    0 (0.0 to 20.6)
        Swelling: Severe
    0 (0.0 to 20.6)
        Swelling: Grade 4
    0 (0.0 to 20.6)
        Tenderness at the injection site: Any
    0 (0.0 to 20.6)
        Tenderness at the injection site: Mild
    0 (0.0 to 20.6)
        Tenderness at the injection site: Moderate
    0 (0.0 to 20.6)
        Tenderness at the injection site: Severe
    0 (0.0 to 20.6)
        Tenderness at the injection site: Grade 4
    0 (0.0 to 20.6)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=6 Months to <2 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=6 Months to <2 Years of age [14]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild(>=0.5 to 2.0 cm),moderate(>2.0 to 7.0 cm),severe(>7.0 cm)&Grade (G) 4(necrosis [redness and swelling] or exfoliative dermatitis [redness]).Tenderness at injection site was graded as mild(hurts if gently touched),moderate(hurts if gently touched with crying),severe(causes limitation of limb movement)&G4 ER visit or hospitalisation.G4 were classified by investigator or medically qualified person.Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method. Safety population =all participants who received at least 1 dose of study intervention.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 2
    Notes
    [14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 years of age
    Number of subjects analysed
    16
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any
    0 (0.0 to 20.6)
        Redness: Mild
    0 (0.0 to 20.6)
        Redness: Moderate
    0 (0.0 to 20.6)
        Redness: Severe
    0 (0.0 to 20.6)
        Redness: Grade 4
    0 (0.0 to 20.6)
        Swelling: Any
    0 (0.0 to 20.6)
        Swelling: Mild
    0 (0.0 to 20.6)
        Swelling: Moderate
    0 (0.0 to 20.6)
        Swelling: Severe
    0 (0.0 to 20.6)
        Swelling: Grade 4
    0 (0.0 to 20.6)
        Tenderness at the injection site: Any
    6.3 (0.2 to 30.2)
        Tenderness at the injection site: Mild
    6.3 (0.2 to 30.2)
        Tenderness at the injection site: Moderate
    0 (0.0 to 20.6)
        Tenderness at the injection site: Severe
    0 (0.0 to 20.6)
        Tenderness at the injection site: Grade 4
    0 (0.0 to 20.6)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=6 Months to <2 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=6 Months to <2 Years of age [15]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild(>=0.5 to 2.0 cm),moderate(>2.0 to 7.0 cm),severe(>7.0 cm)&G4(necrosis [redness and swelling] or exfoliative dermatitis [redness]).Tenderness at injection site was graded as mild(hurts if gently touched),moderate(hurts if gently touched with crying),severe(causes limitation of limb movement)&G4 ER visit or hospitalisation for severe tenderness at injection site).G4 were classified by investigator or medically qualified person.Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method. Safety population =all participants who received at least 1 dose of study intervention. 'N'= participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 3
    Notes
    [15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 years of age
    Number of subjects analysed
    15
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any
    13.3 (1.7 to 40.5)
        Redness: Mild
    13.3 (1.7 to 40.5)
        Redness: Moderate
    0 (0.0 to 21.8)
        Redness: Severe
    0 (0.0 to 21.8)
        Redness: Grade 4
    0 (0.0 to 21.8)
        Swelling: Any
    6.7 (0.2 to 31.9)
        Swelling: Mild
    6.7 (0.2 to 31.9)
        Swelling: Moderate
    0 (0.0 to 21.8)
        Swelling: Severe
    0 (0.0 to 21.8)
        Swelling: Grade 4
    0 (0.0 to 21.8)
        Tenderness at the injection site: Any
    26.7 (7.8 to 55.1)
        Tenderness at the injection site: Mild
    26.7 (7.8 to 55.1)
        Tenderness at the injection site: Moderate
    0 (0.0 to 21.8)
        Tenderness at the injection site: Severe
    0 (0.0 to 21.8)
        Tenderness at the injection site: Grade 4
    0 (0.0 to 21.8)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=6 Months to <2 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=6 Months to <2 Years of age [16]
    End point description
    Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after Dose 1.Fever: oral temperature >= 38.0 deg C;categorised as >=38.0 to 38.4 deg C, >38.4 to 38.9 deg C, >38.9 to 40.0 deg C and >40.0 deg C.Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake),severe (refusal to feed).Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity).Irritability: mild (easily consolable), moderate(requiring increased attention),severe(Inconsolable; crying cannot be comforted).G4 for all events: ER visit/hospitalisation and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method. Safety population was used.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 1
    Notes
    [16] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 years of age
    Number of subjects analysed
    16
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever: >=38.0
    6.3 (0.2 to 30.2)
        Fever: 38.0 to 38.4 deg C
    6.3 (0.2 to 30.2)
        Fever: >38.4 to 38.9 deg C
    0 (0.0 to 20.6)
        Fever: >38.9 to 40.0 deg C
    0 (0.0 to 20.6)
        Fever: >40.0 deg C
    0 (0.0 to 20.6)
        Decreased appetite: Any
    6.3 (0.2 to 30.2)
        Decreased appetite: Mild
    0 (0.0 to 20.6)
        Decreased appetite: Moderate
    6.3 (0.2 to 30.2)
        Decreased appetite: Severe
    0 (0.0 to 20.6)
        Decreased appetite: Grade 4
    0 (0.0 to 20.6)
        Drowsiness: Any
    25.0 (7.3 to 52.4)
        Drowsiness: Mild
    18.8 (4.0 to 45.6)
        Drowsiness: Moderate
    6.3 (0.2 to 30.2)
        Drowsiness: Severe
    0 (0.0 to 20.6)
        Drowsiness: Grade 4
    0 (0.0 to 20.6)
        Irritability: Any
    43.8 (19.8 to 70.1)
        Irritability: Mild
    18.8 (4.0 to 45.6)
        Irritability: Moderate
    25.0 (7.3 to 52.4)
        Irritability: Severe
    0 (0.0 to 20.6)
        Irritability: Grade 4
    0 (0.0 to 20.6)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=6 Months to <2 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=6 Months to <2 Years of age [17]
    End point description
    Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after Dose 2.Fever: oral temperature >= 38.0 deg C;categorised as >=38.0 to 38.4 deg C, >38.4 to 38.9 deg C, >38.9 to 40.0 deg C and >40.0 deg C.Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake),severe (refusal to feed).Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity).Irritability: mild (easily consolable), moderate(requiring increased attention),severe(Inconsolable; crying cannot be comforted).G4 for all events: ER visit/hospitalisation and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method. Safety population was used.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 2
    Notes
    [17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 years of age
    Number of subjects analysed
    16
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever: >=38.0
    12.5 (1.6 to 38.3)
        Fever: 8.0 to 38.4 deg C
    12.5 (1.6 to 38.3)
        Fever: >38.4 to 38.9 deg C
    0 (0.0 to 20.6)
        Fever: >38.9 to 40.0 deg C
    0 (0.0 to 20.6)
        Fever: >40.0 deg C
    0 (0.0 to 20.6)
        Decreased appetite: Any
    12.5 (1.6 to 38.3)
        Decreased appetite: Mild
    12.5 (1.6 to 38.3)
        Decreased appetite: Moderate
    0 (0.0 to 20.6)
        Decreased appetite: Severe
    0 (0.0 to 20.6)
        Decreased appetite: Grade 4
    0 (0.0 to 20.6)
        Drowsiness: Any
    6.3 (0.2 to 30.2)
        Drowsiness: Mild
    6.3 (0.2 to 30.2)
        Drowsiness: Moderate
    0 (0.0 to 20.6)
        Drowsiness: Severe
    0 (0.0 to 20.6)
        Drowsiness: Grade 4
    0 (0.0 to 20.6)
        Irritability: Any
    31.3 (11.0 to 58.7)
        Irritability: Mild
    31.3 (11.0 to 58.7)
        Irritability: Moderate
    0 (0.0 to 20.6)
        Irritability: Severe
    0 (0.0 to 20.6)
        Irritability: Grade 4
    0 (0.0 to 20.6)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=6 Months to <2 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=6 Months to <2 Years of age [18]
    End point description
    Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after Dose 3. Fever: oral temperature >= 38.0 deg C;categorised as >=38.0 to 38.4 deg C, >38.4 to 38.9 deg C, >38.9 to 40.0 deg C and >40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake),severe (refusal to feed).Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity).Irritability: mild (easily consolable), moderate(requiring increased attention),severe(Inconsolable; crying cannot be comforted).G4 for all events: ER visit/hospitalisation and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method. Safety population was used.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 3
    Notes
    [18] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 years of age
    Number of subjects analysed
    15
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever: >=38.0
    6.7 (0.2 to 31.9)
        Fever: 38.0 to 38.4 deg C
    0 (0.0 to 21.8)
        Fever: >38.4 to 38.9 deg C
    0 (0.0 to 21.8)
        Fever: >38.9 to 40.0 deg C
    6.7 (0.2 to 31.9)
        Fever: >40.0 deg C
    0 (0.0 to 21.8)
        Decreased appetite: Any
    13.3 (1.7 to 40.5)
        Decreased appetite: Mild
    6.7 (0.2 to 31.9)
        Decreased appetite: Moderate
    6.7 (0.2 to 31.9)
        Decreased appetite: Severe
    0 (0.0 to 21.8)
        Decreased appetite: Grade 4
    0 (0.0 to 21.8)
        Drowsiness: Any
    6.7 (0.2 to 31.9)
        Drowsiness: Mild
    0 (0.0 to 21.8)
        Drowsiness: Moderate
    6.7 (0.2 to 31.9)
        Drowsiness: Severe
    0 (0.0 to 21.8)
        Drowsiness: Grade 4
    0 (0.0 to 21.8)
        Irritability: Any
    26.7 (7.8 to 55.1)
        Irritability: Mild
    13.3 (1.7 to 40.5)
        Irritability: Moderate
    13.3 (1.7 to 40.5)
        Irritability: Severe
    0 (0.0 to 21.8)
        Irritability: Grade 4
    0 (0.0 to 21.8)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=5 to <12 Years of age [19]
    End point description
    An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 1 to 1 month after dose 2 were reported in this endpoint. Exact 2-sided 95% CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this endpoint. Safety population included all participants who received at least 1 dose of the study intervention.
    End point type
    Primary
    End point timeframe
    From Dose 1 to 1 month after Dose 2
    Notes
    [19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2 (10 mcg): 5 to <12 years of age Phase 1: BNT162b2 (20 mcg): 5 to <12 years of age Phase 1:BNT162b2 (30/30 mcg): 5 to < 12 years of age Phase 1:BNT162b2 (30/10 mcg): 5 to < 12 years of age
    Number of subjects analysed
    16
    16
    4
    12
    Units: Percentage of participants
        number (confidence interval 95%)
    43.8 (19.8 to 70.1)
    31.3 (11.0 to 58.7)
    50.0 (6.8 to 93.2)
    25.0 (5.5 to 57.2)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=5 to <12 Years of age [20]
    End point description
    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 3 to 1 month after dose 3 were reported in this endpoint. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this endpoint. Exact 2-sided 95% CI based on the Clopper and Pearson method. Safety population included all participants who received at least 1 dose of the study intervention.
    End point type
    Primary
    End point timeframe
    From Dose 3 to 1 month after Dose 3
    Notes
    [20] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: 5 to <12 Years BNT162b2 10 mcg
    Number of subjects analysed
    38
    Units: Percentage of participants
        number (confidence interval 95%)
    15.8 (6.0 to 31.3)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=5 to <12 Years of age [21]
    End point description
    A serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalisation or prolongation of existing hospitalisation, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic.Exact 2-sided 95% CI based on the Clopper and Pearson method. Safety population included all participants who received at least 1 dose of the study intervention.
    End point type
    Primary
    End point timeframe
    From Dose 1 to 6 months after Dose 2
    Notes
    [21] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2 (10 mcg): 5 to <12 years of age Phase 1: BNT162b2 (20 mcg): 5 to <12 years of age Phase 1:BNT162b2 (30/30 mcg): 5 to < 12 years of age Phase 1:BNT162b2 (30/10 mcg): 5 to < 12 years of age
    Number of subjects analysed
    16
    16
    4
    12
    Units: Percentage of participants
        number (confidence interval 95%)
    0 (0 to 0)
    0 (0 to 0)
    0 (0 to 0)
    0 (0 to 0)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=5 to <12 Years of age [22]
    End point description
    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalisation or prolongation of existing hospitalisation, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic Exact 2-sided 95% CI based on the Clopper and Pearson method.Safety population included all participants who received at least 1 dose of the study intervention.
    End point type
    Primary
    End point timeframe
    From Dose 3 to 6 Months after Dose 3 (Approximately 6 months)
    Notes
    [22] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: 5 to <12 Years BNT162b2 10 mcg
    Number of subjects analysed
    38
    Units: Percentage of participants
        number (confidence interval 95%)
    0 (0 to 0)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=2 to <5 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=2 to <5 Years of age [23]
    End point description
    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.Exact 2-sided 95% CI based on the Clopper and Pearson method. Percentage of participants reporting AEs after dose 3 to 1 month after dose 3 were reported in this endpoint. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this endpoint. Safety population included all participants who received at least 1 dose of the study intervention.
    End point type
    Primary
    End point timeframe
    From Dose 3 to 1 month after Dose 3
    Notes
    [23] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 3 mcg) Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 10 mcg)
    Number of subjects analysed
    27
    13
    Units: Percentage of participants
        number (confidence interval 95%)
    11.1 (2.4 to 29.2)
    0 (0.0 to 24.7)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=2 to <5 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=2 to <5 Years of age [24]
    End point description
    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 1 to 1 month after dose 2 were reported in this endpoint. Exact 2-sided 95% CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this endpoint. Safety population included all participants who received at least 1 dose of the study intervention.
    End point type
    Primary
    End point timeframe
    From Dose 1 to 1 month after Dose 2
    Notes
    [24] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2 (3 mcg): 2 to <5 years of age Phase 1: BNT162b2 (10 mcg): 2 to <5 years of age
    Number of subjects analysed
    16
    32
    Units: Percentage of participants
        number (confidence interval 95%)
    25.0 (7.3 to 52.4)
    37.5 (21.1 to 56.3)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=6 Months to <2 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=6 Months to <2 Years of age [25]
    End point description
    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 3 to 1 month after dose 3 were reported in this endpoint. Exact 2-sided 95% CI based on the Clopper and Pearson method.Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this endpoint. Safety population included all participants who received at least 1 dose of the study intervention. ‘N’ signifies participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    From dose 3 to 1 month after dose 3
    Notes
    [25] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 years of age
    Number of subjects analysed
    15
    Units: Percentage of participants
        number (confidence interval 95%)
    6.7 (0.2 to 31.9)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=6 Months to <2 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=6 Months to <2 Years of age [26]
    End point description
    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 1 to 1 month after dose 2 were reported in this endpoint. Exact 2-sided 95% CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this endpoint. Safety population included all participants who received at least 1 dose of the study intervention.
    End point type
    Primary
    End point timeframe
    From dose 1 to 1 month after dose 2
    Notes
    [26] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 years of age
    Number of subjects analysed
    16
    Units: Percentage of participants
        number (confidence interval 95%)
    12.5 (1.6 to 38.3)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=2 to <5 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=2 to <5 Years of age [27]
    End point description
    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalisation or prolongation of existing hospitalisation, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method. Safety population included all participants who received at least 1 dose of the study intervention.
    End point type
    Primary
    End point timeframe
    From dose 3 to 6 months after dose 3 (Approximately 6 months)
    Notes
    [27] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 3 mcg) Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 10 mcg)
    Number of subjects analysed
    27
    13
    Units: Percentage of participants
        number (confidence interval 95%)
    0 (0 to 0)
    0 (0 to 0)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=2 to <5 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=2 to <5 Years of age [28]
    End point description
    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalisation or prolongation of existing hospitalisation, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.Safety population included all participants who received at least 1 dose of the study intervention.
    End point type
    Primary
    End point timeframe
    From Dose 1 to 6 months after Dose 2
    Notes
    [28] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2 (3 mcg): 2 to <5 years of age Phase 1: BNT162b2 (10 mcg): 2 to <5 years of age
    Number of subjects analysed
    16
    32
    Units: Percentage of participants
        number (confidence interval 95%)
    0 (0 to 0)
    0 (0 to 0)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=6 Months to <2 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=6 Months to <2 Years of age [29]
    End point description
    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalisation or prolongation of existing hospitalisation, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic.Exact 2-sided 95% CI based on the Clopper and Pearson method.Safety population included all participants who received at least 1 dose of the study intervention.
    End point type
    Primary
    End point timeframe
    From dose 3 to 6 months after dose 3 (Approximately 6 months)
    Notes
    [29] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 years of age
    Number of subjects analysed
    15
    Units: Percentage of participants
        number (confidence interval 95%)
    0 (0 to 0)
    No statistical analyses for this end point

    Primary: Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=6 Months to <2 Years of age

    Close Top of page
    End point title
    Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=6 Months to <2 Years of age [30]
    End point description
    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalisation or prolongation of existing hospitalisation, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic.Exact 2-sided 95% CI based on the Clopper and Pearson method.Safety population included all participants who received at least 1 dose of the study intervention.
    End point type
    Primary
    End point timeframe
    From Dose 1 to 6 months after Dose 2
    Notes
    [30] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 years of age
    Number of subjects analysed
    16
    Units: Percentage of participants
        number (confidence interval 95%)
    0 (0 to 0)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1:Troponin Group: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1:Troponin Group: >=5 to <12 Years of age [31]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild >2.0 to 5.0 cm),moderate (>5.0 to 10.0), severe >10.0 cm) and G4(necrosis [redness and swelling] or exfoliative dermatitis [redness]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and G4 ER visit or hospitalisation for severe pain at injection site). G4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method. Safety population =all participants who received at least 1 dose of study intervention. ‘N’ signifies participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 1
    Notes
    [31] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3:Troponin group:BNT162b2 (10 mcg):5 to <12 years Phase 2/3:Troponin group:Placebo:5 to <12 years
    Number of subjects analysed
    515
    260
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any
    15.5 (12.5 to 19.0)
    6.2 (3.6 to 9.8)
        Redness: Mild
    11.8 (9.2 to 15.0)
    5.4 (3.0 to 8.9)
        Redness: Moderate
    3.7 (2.2 to 5.7)
    0.4 (0.0 to 2.1)
        Redness: Severe
    0 (0.0 to 0.7)
    0.4 (0.0 to 2.1)
        Redness: Grade 4
    0 (0.0 to 0.7)
    0 (0.0 to 1.4)
        Swelling: Any
    10.9 (8.3 to 13.9)
    4.6 (2.4 to 7.9)
        Swelling: Mild
    7.6 (5.4 to 10.2)
    2.7 (1.1 to 5.5)
        Swelling: Moderate
    3.3 (1.9 to 5.2)
    1.9 (0.6 to 4.4)
        Swelling: Severe
    0 (0.0 to 0.7)
    0 (0.0 to 1.4)
        Swelling: Grade 4
    0 (0.0 to 0.7)
    0 (0.0 to 1.4)
        Pain at the injection site: Any
    72.4 (68.3 to 76.2)
    28.1 (22.7 to 34.0)
        Pain at the injection site: Mild
    57.7 (53.3 to 62.0)
    23.5 (18.4 to 29.1)
        Pain at the injection site: Moderate
    14.8 (11.8 to 18.1)
    4.6 (2.4 to 7.9)
        Pain at the injection site: Severe
    0 (0.0 to 0.7)
    0 (0.0 to 1.4)
        Pain at the injection site: Grade 4
    0 (0.0 to 0.7)
    0 (0.0 to 1.4)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Troponin Group: >=12 to <16 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Troponin Group: >=12 to <16 Years of age [32]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild >2.0 to 5.0 cm),moderate (>5.0 to 10.0), severe >10.0 cm) and G4(necrosis [redness and swelling] or exfoliative dermatitis [redness]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and G4 ER visit or hospitalisation for severe pain at injection site). G4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method. Safety population =all participants who received at least 1 dose of study intervention. ‘N’ signifies participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 1
    Notes
    [32] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3:Troponin group:BNT162b2 (30 mcg):12 to <16 years
    Number of subjects analysed
    475
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any
    2.1 (1.0 to 3.8)
        Redness: Mild
    1.5 (0.6 to 3.0)
        Redness: Moderate
    0.6 (0.1 to 1.8)
        Redness: Severe
    0 (0.0 to 0.8)
        Redness: Grade 4
    0 (0.0 to 0.8)
        Swelling: Any
    4.4 (2.8 to 6.7)
        Swelling: Mild
    2.7 (1.5 to 4.6)
        Swelling: Moderate
    1.7 (0.7 to 3.3)
        Swelling: Severe
    0 (0.0 to 0.8)
        Swelling: Grade 4
    0 (0.0 to 0.8)
        Pain at the injection site: Any
    72.4 (68.2 to 76.4)
        Pain at the injection site: Mild
    43.8 (39.3 to 48.4)
        Pain at the injection site: Moderate
    28.2 (24.2 to 32.5)
        Pain at the injection site: Severe
    0.4 (0.1 to 1.5)
        Pain at the injection site: Grade 4
    0 (0.0 to 0.8)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Troponin Group: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Troponin Group: >=5 to <12 Years of age [33]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (>=0.5 to 2.0 cm),moderate (>2.0 to 7.0 cm), severe (>7.0 cm) and Grade 4(necrosis [redness and swelling] or exfoliative dermatitis [redness]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalisation for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method. Safety population =all participants who received at least 1 dose of study intervention. 'N'= participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 2
    Notes
    [33] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3:Troponin group:BNT162b2 (10 mcg):5 to <12 years Phase 2/3:Troponin group:Placebo:5 to <12 years
    Number of subjects analysed
    497
    107
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any
    16.7 (13.5 to 20.3)
    1.9 (0.2 to 6.6)
        Redness: Mild
    9.9 (7.4 to 12.8)
    1.9 (0.2 to 6.6)
        Redness: Moderate
    6.8 (4.8 to 9.4)
    0 (0.0 to 3.4)
        Redness: Severe
    0 (0.0 to 0.7)
    0 (0.0 to 3.4)
        Redness: Grade 4
    0 (0.0 to 0.7)
    0 (0.0 to 3.4)
        Swelling: Any
    11.5 (8.8 to 14.6)
    4.7 (1.5 to 10.6)
        Swelling: Mild
    6.8 (4.8 to 9.4)
    2.8 (0.6 to 8.0)
        Swelling: Moderate
    4.6 (3.0 to 6.9)
    1.9 (0.2 to 6.6)
        Swelling: Severe
    0 (0.0 to 0.7)
    0 (0.0 to 3.4)
        Swelling: Grade 4
    0 (0.0 to 0.7)
    0 (0.0 to 3.4)
        Pain at the injection site: Any
    66.8 (62.5 to 70.9)
    23.4 (15.7 to 32.5)
        Pain at the injection site: Mild
    48.3 (43.8 to 52.8)
    19.6 (12.6 to 28.4)
        Pain at the injection site: Moderate
    18.5 (15.2 to 22.2)
    3.7 (1.0 to 9.3)
        Pain at the injection site: Severe
    0 (0.0 to 0.7)
    0 (0.0 to 3.4)
        Pain at the injection site: Grade 4
    0 (0.0 to 0.7)
    0 (0.0 to 3.4)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Troponin Group: >=12 to <16 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Troponin Group: >=12 to <16 Years of age [34]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild >2.0 to 5.0 cm),moderate (>5.0 to 10.0), severe >10.0 cm) and G4(necrosis [redness and swelling] or exfoliative dermatitis [redness]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and G4 ER visit or hospitalisation for severe pain at injection site). G4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method. Safety population =all participants who received at least 1 dose of study intervention. ‘N’ signifies participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 2
    Notes
    [34] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3:Troponin group:BNT162b2 (30 mcg):12 to <16 years
    Number of subjects analysed
    448
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any
    0.9 (0.2 to 2.3)
        Redness: Mild
    0.4 (0.1 to 1.6)
        Redness: Moderate
    0.2 (0.0 to 1.2)
        Redness: Severe
    0.2 (0.0 to 1.2)
        Redness: Grade 4
    0 (0.0 to 0.8)
        Swelling: Any
    1.8 (0.8 to 3.5)
        Swelling: Mild
    0.9 (0.2 to 2.3)
        Swelling: Moderate
    0.9 (0.2 to 2.3)
        Swelling: Severe
    0 (0.0 to 0.8)
        Swelling: Grade 4
    0 (0.0 to 0.8)
        Pain at the injection site: Any
    57.8 (53.1 to 62.4)
        Pain at the injection site: Mild
    36.6 (32.1 to 41.3)
        Pain at the injection site: Moderate
    20.8 (17.1 to 24.8)
        Pain at the injection site: Severe
    0.4 (0.1 to 1.6)
        Pain at the injection site: Grade 4
    0 (0.0 to 0.8)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Troponin Group: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Troponin Group: >=5 to <12 Years of age [35]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (>=0.5 to 2.0 cm),moderate (>2.0 to 7.0 cm), severe (>7.0 cm) and Grade 4(necrosis [redness and swelling] or exfoliative dermatitis [redness]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalisation for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method. Safety population =all participants who received at least 1 dose of study intervention. 'N'= participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 3
    Notes
    [35] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3:Troponin group:BNT162b2 (10 mcg):5 to <12 years Phase 2/3:Troponin group:Placebo:5 to <12 years
    Number of subjects analysed
    394
    0 [36]
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any
    17.0 (13.4 to 21.1)
    ( to )
        Redness: Mild
    11.2 (8.2 to 14.7)
    ( to )
        Redness: Moderate
    5.8 (3.7 to 8.6)
    ( to )
        Redness: Severe
    0 (0.0 to 0.9)
    ( to )
        Redness: Grade 4
    0 (0.0 to 0.9)
    ( to )
        Swelling: Any
    12.7 (9.6 to 16.4)
    ( to )
        Swelling: Mild
    9.4 (6.7 to 12.7)
    ( to )
        Swelling: Moderate
    3.3 (1.8 to 5.6)
    ( to )
        Swelling: Severe
    0 (0.0 to 0.9)
    ( to )
        Swelling: Grade 4
    0 (0.0 to 0.9)
    ( to )
        Pain at the injection site: Any
    69.3 (64.5 to 73.8)
    ( to )
        Pain at the injection site: Mild
    48.0 (42.9 to 53.0)
    ( to )
        Pain at the injection site: Moderate
    20.8 (16.9 to 25.2)
    ( to )
        Pain at the injection site: Severe
    0.5 (0.1 to 1.8)
    ( to )
        Pain at the injection site: Grade 4
    0 (0.0 to 0.9)
    ( to )
    Notes
    [36] - No participants received dose 3 from this cohort.
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Troponin Group: >=12 to <16 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Troponin Group: >=12 to <16 Years of age [37]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild >2.0 to 5.0 cm),moderate (>5.0 to 10.0), severe >10.0 cm) and G4(necrosis [redness and swelling] or exfoliative dermatitis [redness]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and G4 ER visit or hospitalisation for severe pain at injection site). G4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method. Safety population =all participants who received at least 1 dose of study intervention. ‘N’ signifies participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 3
    Notes
    [37] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3:Troponin group:BNT162b2 (30 mcg):12 to <16 years
    Number of subjects analysed
    405
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any
    3.5 (1.9 to 5.7)
        Redness: Mild
    3.0 (1.5 to 5.1)
        Redness: Moderate
    0.5 (0.1 to 1.8)
        Redness: Severe
    0 (0.0 to 0.9)
        Redness: Grade 4
    0 (0.0 to 0.9)
        Swelling: Any
    3.0 (1.5 to 5.1)
        Swelling: Mild
    2.0 (0.9 to 3.9)
        Swelling: Moderate
    1.0 (0.3 to 2.5)
        Swelling: Severe
    0 (0.0 to 0.9)
        Swelling: Grade 4
    0 (0.0 to 0.9)
        Pain at the injection site: Any
    63.5 (58.6 to 68.2)
        Pain at the injection site: Mild
    35.8 (31.1 to 40.7)
        Pain at the injection site: Moderate
    27.4 (23.1 to 32.0)
        Pain at the injection site: Severe
    0.2 (0.0 to 1.4)
        Pain at the injection site: Grade 4
    0 (0.0 to 0.9)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1:Troponin Group: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1:Troponin Group: >=5 to <12 Years of age [38]
    End point description
    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from upto Day 7 after Dose 1.Fever: oral temperature >= 38.0 deg C;categorised as >=38.0 to 38.4 deg C, >38.4 to 38.9 deg C,>38.9 to 40.0 deg C and >40.0 deg C.Fatigue,headache,chills,new or worsened muscle pain and new or worsened joint pain:mild (did not interfere with activity),moderate (some interference with activity),severe (prevented daily routine activity).Vomiting:mild:1-2 times in 24 hours,moderate: >2 times in 24 hours,severe: required intravenous hydration.Diarrhea:mild: 2-3 loose stools in 24 hours, moderate:4-5 loose stools in 24 hours,severe: 6 or more loose stools in 24 hours.Grade 4 for all events: ER visit/hospitalisation and were classified by investigator or medically qualified person.Events reported as AEs in the CRF within 7 days after vaccination were also included.Exact 95% CI based on Clopper and Pearson method.Safety population.'N'= participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 1
    Notes
    [38] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3:Troponin group:BNT162b2 (10 mcg):5 to <12 years Phase 2/3:Troponin group:Placebo:5 to <12 years
    Number of subjects analysed
    515
    260
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever: >= 38.0
    1.4 (0.5 to 2.8)
    3.1 (1.3 to 6.0)
        Fever: 38.0 to 38.4 deg C
    0.8 (0.2 to 2.0)
    1.9 (0.6 to 4.4)
        Fever: >38.4 to 38.9 deg C
    0.6 (0.1 to 1.7)
    1.2 (0.2 to 3.3)
        Fever: >38.9 to 40.0 deg C
    0 (0.0 to 0.7)
    0 (0.0 to 1.4)
        Fever: >40.0 deg C
    0 (0.0 to 0.7)
    0 (0.0 to 1.4)
        Fatigue: Any
    37.1 (32.9 to 41.4)
    37.7 (31.8 to 43.9)
        Fatigue: Mild
    24.1 (20.4 to 28.0)
    23.8 (18.8 to 29.5)
        Fatigue: Moderate
    13.0 (10.2 to 16.2)
    13.1 (9.2 to 17.8)
        Fatigue: Severe
    0 (0.0 to 0.7)
    0.8 (0.1 to 2.8)
        Fatigue: Grade 4
    0 (0.0 to 0.7)
    0 (0.0 to 1.4)
        Headache: Any
    25.4 (21.7 to 29.4)
    25.8 (20.6 to 31.5)
        Headache: Mild
    18.3 (15.0 to 21.9)
    19.2 (14.6 to 24.6)
        Headache: Moderate
    6.8 (4.8 to 9.3)
    6.5 (3.9 to 10.3)
        Headache: Severe
    0.4 (0.0 to 1.4)
    0 (0.0 to 1.4)
        Headache: Grade 4
    0 (0.0 to 0.7)
    0 (0.0 to 1.4)
        Chills: Any
    7.2 (5.1 to 9.8)
    9.6 (6.3 to 13.9)
        Chills: Mild
    5.6 (3.8 to 8.0)
    6.5 (3.9 to 10.3)
        Chills: Moderate
    1.4 (0.5 to 2.8)
    3.1 (1.3 to 6.0)
        Chills: Severe
    0.2 (0.0 to 1.1)
    0 (0.0 to 1.4)
        Chills: Grade 4
    0 (0.0 to 0.7)
    0 (0.0 to 1.4)
        Vomiting: Any
    1.7 (0.8 to 3.3)
    2.3 (0.9 to 5.0)
        Vomiting: Mild
    1.6 (0.7 to 3.0)
    1.9 (0.6 to 4.4)
        Vomiting: Moderate
    0.2 (0.0 to 1.1)
    0.4 (0.0 to 2.1)
        Vomiting: Severe
    0 (0.0 to 0.7)
    0 (0.0 to 1.4)
        Vomiting: Grade 4
    0 (0.0 to 0.7)
    0 (0.0 to 1.4)
        Diarrhea: Any
    6.2 (4.3 to 8.7)
    8.5 (5.4 to 12.5)
        Diarrhea: Mild
    6.0 (4.1 to 8.4)
    8.1 (5.1 to 12.1)
        Diarrhea: Moderate
    0.2 (0.0 to 1.1)
    0.4 (0.0 to 2.1)
        Diarrhea: Severe
    0 (0.0 to 0.7)
    0 (0.0 to 1.4)
        Diarrhea: Grade 4
    0 (0.0 to 0.7)
    0 (0.0 to 1.4)
        New or worsened muscle pain: Any
    11.7 (9.0 to 14.7)
    10.0 (6.6 to 14.3)
        New or worsened muscle pain: Mild
    8.2 (5.9 to 10.9)
    7.7 (4.8 to 11.6)
        New or worsened muscle pain: Moderate
    3.5 (2.1 to 5.5)
    2.3 (0.9 to 5.0)
        New or worsened muscle pain: Severe
    0 (0.0 to 0.7)
    0 (0.0 to 1.4)
        New or worsened muscle pain: Grade 4
    0 (0.0 to 0.7)
    0 (0.0 to 1.4)
        New or worsened joint pain: Any
    5.2 (3.5 to 7.5)
    6.9 (4.2 to 10.7)
        New or worsened joint pain: Mild
    4.5 (2.9 to 6.6)
    5.4 (3.0 to 8.9)
        New or worsened joint pain: Moderate
    0.8 (0.2 to 2.0)
    1.5 (0.4 to 3.9)
        New or worsened joint pain: Severe
    0 (0.0 to 0.7)
    0 (0.0 to 1.4)
        New or worsened joint pain: Grade 4
    0 (0.0 to 0.7)
    0 (0.0 to 1.4)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Troponin Group: >=12 to <16 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Troponin Group: >=12 to <16 Years of age [39]
    End point description
    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from upto Day 7 after Dose 1.Fever: oral temperature >= 38.0 deg C;categorised as >=38.0 to 38.4 deg C, >38.4 to 38.9 deg C,>38.9 to 40.0 deg C and >40.0 deg C.Fatigue,headache,chills,new or worsened muscle pain and new or worsened joint pain:mild (did not interfere with activity),moderate (some interference with activity),severe (prevented daily routine activity).Vomiting:mild:1-2 times in 24 hours,moderate: >2 times in 24 hours,severe: required intravenous hydration.Diarrhea:mild: 2-3 loose stools in 24 hours, moderate:4-5 loose stools in 24 hours,severe: 6 or more loose stools in 24 hours.Grade 4 for all events: ER visit/hospitalisation and were classified by investigator or medically qualified person.Events reported as AEs in the CRF within 7 days after vaccination were also included.Exact 95% CI based on Clopper and Pearson method.Safety population.'N'= participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 1
    Notes
    [39] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3:Troponin group:BNT162b2 (30 mcg):12 to <16 years
    Number of subjects analysed
    475
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever:>=38.0
    4.2 (2.6 to 6.4)
        Fever: 8.0 to 38.4 deg C
    2.3 (1.2 to 4.1)
        Fever: >38.4 to 38.9 deg C
    1.3 (0.5 to 2.7)
        Fever: >38.9 to 40.0 deg C
    0.6 (0.1 to 1.8)
        Fever: >40.0 deg C
    0 (0.0 to 0.8)
        Fatigue: Any
    42.3 (37.8 to 46.9)
        Fatigue: Mild
    26.3 (22.4 to 30.5)
        Fatigue: Moderate
    15.6 (12.4 to 19.2)
        Fatigue: Severe
    0.4 (0.1 to 1.5)
        Fatigue: Grade 4
    0 (0.0 to 0.8)
        Headache: Any
    33.3 (29.0 to 37.7)
        Headache: Mild
    22.9 (19.2 to 27.0)
        Headache: Moderate
    10.3 (7.7 to 13.4)
        Headache: Severe
    0 (0.0 to 0.8)
        Headache: Grade 4
    0 (0.0 to 0.8)
        Chills: Any
    11.4 (8.7 to 14.6)
        Chills: Mild
    8.6 (6.3 to 11.5)
        Chills: Moderate
    2.5 (1.3 to 4.4)
        Chills: Severe
    0.2 (0.0 to 1.2)
        Chills: Grade 4
    0 (0.0 to 0.8)
        Vomiting: Any
    2.9 (1.6 to 4.9)
        Vomiting: Mild
    2.7 (1.5 to 4.6)
        Vomiting: Moderate
    0.2 (0.0 to 1.2)
        Vomiting: Severe
    0 (0.0 to 0.8)
        Vomiting: Grade 4
    0 (0.0 to 0.8)
        Diarrhea: Any
    9.1 (6.6 to 12.0)
        Diarrhea: Mild
    6.9 (4.8 to 9.6)
        Diarrhea: Moderate
    2.1 (1.0 to 3.8)
        Diarrhea: Severe
    0 (0.0 to 0.8)
        Diarrhea: Grade 4
    0 (0.0 to 0.8)
        New or worsened muscle pain: Any
    26.3 (22.4 to 30.5)
        New or worsened muscle pain: Mild
    14.7 (11.7 to 18.2)
        New or worsened muscle pain: Moderate
    10.9 (8.3 to 14.1)
        New or worsened muscle pain: Severe
    0.6 (0.1 to 1.8)
        New or worsened muscle pain: Grade 4
    0 (0.0 to 0.8)
        New or worsened joint pain: Any
    10.5 (7.9 to 13.6)
        New or worsened joint pain: Mild
    5.1 (3.3 to 7.4)
        New or worsened joint pain: Moderate
    5.5 (3.6 to 7.9)
        New or worsened joint pain: Severe
    0 (0.0 to 0.8)
        New or worsened joint pain: Grade 4
    0 (0.0 to 0.8)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2:Troponin Group: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2:Troponin Group: >=5 to <12 Years of age [40]
    End point description
    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from upto Day 7 after Dose 2.Fever: oral temperature >= 38.0 deg C;categorised as >=38.0 to 38.4 deg C, >38.4 to 38.9 deg C,>38.9 to 40.0 deg C and >40.0 deg C.Fatigue,headache,chills,new or worsened muscle pain and new or worsened joint pain:mild (did not interfere with activity),moderate (some interference with activity),severe (prevented daily routine activity).Vomiting:mild:1-2 times in 24 hours,moderate: >2 times in 24 hours,severe: required intravenous hydration.Diarrhea:mild: 2-3 loose stools in 24 hours, moderate:4-5 loose stools in 24 hours,severe: 6 or more loose stools in 24 hours.Grade 4 for all events: ER visit/hospitalisation and were classified by investigator or medically qualified person.Events reported as AEs in the CRF within 7 days after vaccination were also included.Exact 95% CI based on Clopper and Pearson method.Safety population.'N'= participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 2
    Notes
    [40] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3:Troponin group:BNT162b2 (10 mcg):5 to <12 years Phase 2/3:Troponin group:Placebo:5 to <12 years
    Number of subjects analysed
    497
    107
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever: >=38.0
    5.0 (3.3 to 7.3)
    0 (0.0 to 3.4)
        Fever:38.0 to 38.4 deg C
    2.2 (1.1 to 3.9)
    0 (0.0 to 3.4)
        Fever: >38.4 to 38.9 deg C
    1.8 (0.8 to 3.4)
    0 (0.0 to 3.4)
        Fever: >38.9 to 40.0 deg C
    1.0 (0.3 to 2.3)
    0 (0.0 to 3.4)
        Fever: >40.0 deg C
    0 (0.0 to 0.7)
    0 (0.0 to 3.4)
        Fatigue: Any
    38.2 (33.9 to 42.7)
    29.0 (20.6 to 38.5)
        Fatigue: Mild
    22.5 (18.9 to 26.5)
    15.9 (9.5 to 24.2)
        Fatigue: Moderate
    15.5 (12.4 to 19.0)
    13.1 (7.3 to 21.0)
        Fatigue: Severe
    0.2 (0.0 to 1.1)
    0 (0.0 to 3.4)
        Fatigue: Grade 4
    0 (0.0 to 0.7)
    0 (0.0 to 3.4)
        Headache: Any
    30.2 (26.2 to 34.4)
    20.6 (13.4 to 29.5)
        Headache: Mild
    20.1 (16.7 to 23.9)
    14.0 (8.1 to 22.1)
        Headache: Moderate
    9.9 (7.4 to 12.8)
    6.5 (2.7 to 13.0)
        Headache: Severe
    0.2 (0.0 to 1.1)
    0 (0.0 to 3.4)
        Headache: Grade 4
    0 (0.0 to 0.7)
    0 (0.0 to 3.4)
        Chills: Any
    9.1 (6.7 to 11.9)
    7.5 (3.3 to 14.2)
        Chills: Mild
    5.8 (3.9 to 8.3)
    6.5 (2.7 to 13.0)
        Chills: Moderate
    3.2 (1.9 to 5.2)
    0.9 (0.0 to 5.1)
        Chills: Severe
    0 (0.0 to 0.7)
    0 (0.0 to 3.4)
        Chills: Grade 4
    0 (0.0 to 0.7)
    0 (0.0 to 3.4)
        Vomiting: Any
    2.0 (1.0 to 3.7)
    3.7 (1.0 to 9.3)
        Vomiting: Mild
    1.8 (0.8 to 3.4)
    2.8 (0.6 to 8.0)
        Vomiting: Moderate
    0.2 (0.0 to 1.1)
    0.9 (0.0 to 5.1)
        Vomiting: Severe
    0 (0.0 to 0.7)
    0 (0.0 to 3.4)
        Vomiting: Grade 4
    0 (0.0 to 0.7)
    0 (0.0 to 3.4)
        Diarrhea: Any
    7.4 (5.3 to 10.1)
    5.6 (2.1 to 11.8)
        Diarrhea: Mild
    7.0 (5.0 to 9.7)
    5.6 (2.1 to 11.8)
        Diarrhea: Moderate
    0.2 (0.0 to 1.1)
    0 (0.0 to 3.4)
        Diarrhea: Severe
    0.2 (0.0 to 1.1)
    0 (0.0 to 3.4)
        Diarrhea: Grade 4
    0 (0.0 to 0.7)
    0 (0.0 to 3.4)
        New or worsened muscle pain: Any
    14.7 (11.7 to 18.1)
    11.2 (5.9 to 18.8)
        New or worsened muscle pain: Mild
    9.3 (6.9 to 12.2)
    9.3 (4.6 to 16.5)
        New or worsened muscle pain: Moderate
    5.4 (3.6 to 7.8)
    1.9 (0.2 to 6.6)
        New or worsened muscle pain: Severe
    0 (0.0 to 0.7)
    0 (0.0 to 3.4)
        New or worsened muscle pain: Grade 4
    0 (0.0 to 0.7)
    0 (0.0 to 3.4)
        New or worsened joint pain: Any
    6.4 (4.4 to 9.0)
    6.5 (2.7 to 13.0)
        New or worsened joint pain: Mild
    4.2 (2.6 to 6.4)
    6.5 (2.7 to 13.0)
        New or worsened joint pain: Moderate
    2.2 (1.1 to 3.9)
    0 (0.0 to 3.4)
        New or worsened joint pain: Severe
    0 (0.0 to 0.7)
    0 (0.0 to 3.4)
        New or worsened joint pain: Grade 4
    0 (0.0 to 0.7)
    0 (0.0 to 3.4)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Troponin group: >=12 to <16 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Troponin group: >=12 to <16 Years of age [41]
    End point description
    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from upto Day 7 after Dose 2.Fever: oral temperature >= 38.0 deg C;categorised as >=38.0 to 38.4 deg C, >38.4 to 38.9 deg C,>38.9 to 40.0 deg C and >40.0 deg C.Fatigue,headache,chills,new or worsened muscle pain and new or worsened joint pain:mild (did not interfere with activity),moderate (some interference with activity),severe (prevented daily routine activity).Vomiting:mild:1-2 times in 24 hours,moderate: >2 times in 24 hours,severe: required intravenous hydration.Diarrhea:mild: 2-3 loose stools in 24 hours, moderate:4-5 loose stools in 24 hours,severe: 6 or more loose stools in 24 hours.Grade 4 for all events: ER visit/hospitalisation and were classified by investigator or medically qualified person.Events reported as AEs in the CRF within 7 days after vaccination were also included.Exact 95% CI based on Clopper and Pearson method.Safety population.'N'= participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 2
    Notes
    [41] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3:Troponin group:BNT162b2 (30 mcg):12 to <16 years
    Number of subjects analysed
    448
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever: >=38.0
    3.3 (1.9 to 5.5)
        Fever:38.0 to 38.4 deg C
    1.6 (0.6 to 3.2)
        Fever: >38.4 to 38.9 deg C
    1.3 (0.5 to 2.9)
        Fever: >38.9 to 40.0 deg C
    0.4 (0.1 to 1.6)
        Fever: >40.0 deg C
    0 (0.0 to 0.8)
        Fatigue: Any
    36.4 (31.9 to 41.0)
        Fatigue: Mild
    21.0 (17.3 to 25.1)
        Fatigue: Moderate
    15.0 (11.8 to 18.6)
        Fatigue: Severe
    0.4 (0.1 to 1.6)
        Fatigue: Grade 4
    0 (0.0 to 0.8)
        Headache: Any
    33.3 (28.9 to 37.8)
        Headache: Mild
    19.4 (15.9 to 23.4)
        Headache: Moderate
    13.2 (10.2 to 16.7)
        Headache: Severe
    0.7 (0.1 to 1.9)
        Headache: Grade 4
    0 (0.0 to 0.8)
        Chills: Any
    11.2 (8.4 to 14.4)
        Chills: Mild
    7.4 (5.1 to 10.2)
        Chills: Moderate
    3.8 (2.2 to 6.0)
        Chills: Severe
    0 (0.0 to 0.8)
        Chills: Grade 4
    0 (0.0 to 0.8)
        Vomiting: Any
    2.2 (1.1 to 4.1)
        Vomiting: Mild
    2.0 (0.9 to 3.8)
        Vomiting: Moderate
    0.2 (0.0 to 1.2)
        Vomiting: Severe
    0 (0.0 to 0.8)
        Vomiting: Grade 4
    0 (0.0 to 0.8)
        Diarrhea: Any
    7.1 (4.9 to 9.9)
        Diarrhea: Mild
    5.1 (3.3 to 7.6)
        Diarrhea: Moderate
    1.8 (0.8 to 3.5)
        Diarrhea: Severe
    0.2 (0.0 to 1.2)
        Diarrhea: Grade 4
    0 (0.0 to 0.8)
        New or worsened muscle pain: Any
    19.6 (16.1 to 23.6)
        New or worsened muscle pain: Mild
    12.5 (9.6 to 15.9)
        New or worsened muscle pain: Moderate
    6.9 (4.7 to 9.7)
        New or worsened muscle pain: Severe
    0.2 (0.0 to 1.2)
        New or worsened muscle pain: Grade 4
    0 (0.0 to 0.8)
        New or worsened joint pain: Any
    6.7 (4.6 to 9.4)
        New or worsened joint pain: Mild
    3.8 (2.2 to 6.0)
        New or worsened joint pain: Moderate
    2.7 (1.4 to 4.6)
        New or worsened joint pain: Severe
    0.2 (0.0 to 1.2)
        New or worsened joint pain: Grade 4
    0 (0.0 to 0.8)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Troponin Group: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Troponin Group: >=5 to <12 Years of age [42]
    End point description
    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from upto Day 7 after Dose 3.Fever: oral temperature >= 38.0 deg C;categorised as >=38.0 to 38.4 deg C, >38.4 to 38.9 deg C,>38.9 to 40.0 deg C and >40.0 deg C.Fatigue,headache,chills,new or worsened muscle pain and new or worsened joint pain:mild (did not interfere with activity),moderate (some interference with activity),severe (prevented daily routine activity).Vomiting:mild:1-2 times in 24 hours,moderate: >2 times in 24 hours,severe: required intravenous hydration.Diarrhea:mild: 2-3 loose stools in 24 hours, moderate:4-5 loose stools in 24 hours,severe: 6 or more loose stools in 24 hours.Grade 4 for all events: ER visit/hospitalisation and were classified by investigator or medically qualified person.Events reported as AEs in the CRF within 7 days after vaccination were also included.Exact 95% CI based on Clopper and Pearson method.Safety population.'N'= participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 3
    Notes
    [42] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3:Troponin group:BNT162b2 (10 mcg):5 to <12 years Phase 2/3:Troponin group:Placebo:5 to <12 years
    Number of subjects analysed
    394
    0 [43]
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever: >=38.0
    4.6 (2.7 to 7.1)
    ( to )
        Fever:38.0 to 38.4 deg C
    2.5 (1.2 to 4.6)
    ( to )
        Fever: >38.4 to 38.9 deg C
    1.0 (0.3 to 2.6)
    ( to )
        Fever: >38.9 to 40.0 deg C
    1.0 (0.3 to 2.6)
    ( to )
        Fever: >40.0 deg C
    0 (0.0 to 0.9)
    ( to )
        Fatigue: Any
    38.8 (34.0 to 43.8)
    ( to )
        Fatigue: Mild
    26.4 (22.1 to 31.0)
    ( to )
        Fatigue: Moderate
    11.9 (8.9 to 15.5)
    ( to )
        Fatigue: Severe
    0.5 (0.1 to 1.8)
    ( to )
        Fatigue: Grade 4
    0 (0.0 to 0.9)
    ( to )
        Headache: Any
    23.6 (19.5 to 28.1)
    ( to )
        Headache: Mild
    16.2 (12.7 to 20.3)
    ( to )
        Headache: Moderate
    6.9 (4.6 to 9.8)
    ( to )
        Headache: Severe
    0.5 (0.1 to 1.8)
    ( to )
        Headache: Grade 4
    0 (0.0 to 0.9)
    ( to )
        Chills: Any
    8.9 (6.3 to 12.1)
    ( to )
        Chills: Mild
    5.8 (3.7 to 8.6)
    ( to )
        Chills: Moderate
    2.8 (1.4 to 4.9)
    ( to )
        Chills: Severe
    0.3 (0.0 to 1.4)
    ( to )
        Chills: Grade 4
    0 (0.0 to 0.9)
    ( to )
        Vomiting: Any
    1.8 (0.7 to 3.6)
    ( to )
        Vomiting: Mild
    1.5 (0.6 to 3.3)
    ( to )
        Vomiting: Moderate
    0.3 (0.0 to 1.4)
    ( to )
        Vomiting: Severe
    0 (0.0 to 0.9)
    ( to )
        Vomiting: Grade 4
    0 (0.0 to 0.9)
    ( to )
        Diarrhea: Any
    4.8 (2.9 to 7.4)
    ( to )
        Diarrhea: Mild
    4.6 (2.7 to 7.1)
    ( to )
        Diarrhea: Moderate
    0.3 (0.0 to 1.4)
    ( to )
        Diarrhea: Severe
    0 (0.0 to 0.9)
    ( to )
        Diarrhea: Grade 4
    0 (0.0 to 0.9)
    ( to )
        New or worsened muscle pain: Any
    18.5 (14.8 to 22.7)
    ( to )
        New or worsened muscle pain: Mild
    10.2 (7.4 to 13.6)
    ( to )
        New or worsened muscle pain: Moderate
    8.4 (5.8 to 11.6)
    ( to )
        New or worsened muscle pain: Severe
    0 (0.0 to 0.9)
    ( to )
        New or worsened muscle pain: Grade 4
    0 (0.0 to 0.9)
    ( to )
        New or worsened joint pain: Any
    5.8 (3.7 to 8.6)
    ( to )
        New or worsened joint pain: Mild
    4.1 (2.3 to 6.5)
    ( to )
        New or worsened joint pain: Moderate
    1.8 (0.7 to 3.6)
    ( to )
        New or worsened joint pain: Severe
    0 (0.0 to 0.9)
    ( to )
        New or worsened joint pain: Grade 4
    0 (0.0 to 0.9)
    ( to )
    Notes
    [43] - No participants received dose 3 from this cohort.
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Troponin Group: >=12 to <16 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Troponin Group: >=12 to <16 Years of age [44]
    End point description
    Systemic events were recorded in an e-diary and at unscheduled clinical assessments from upto Day 7 after Dose 3.Fever: oral temperature >= 38.0 deg C;categorised as >=38.0 to 38.4 deg C, >38.4 to 38.9 deg C,>38.9 to 40.0 deg C and >40.0 deg C.Fatigue,headache,chills,new or worsened muscle pain and new or worsened joint pain:mild (did not interfere with activity),moderate (some interference with activity),severe (prevented daily routine activity).Vomiting:mild:1-2 times in 24 hours,moderate: >2 times in 24 hours,severe: required intravenous hydration.Diarrhea:mild: 2-3 loose stools in 24 hours, moderate:4-5 loose stools in 24 hours,severe: 6 or more loose stools in 24 hours.Grade 4 for all events: ER visit/hospitalisation and were classified by investigator or medically qualified person.Events reported as AEs in the CRF within 7 days after vaccination were also included.Exact 95% CI based on Clopper and Pearson method.Safety population.'N'= participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 3
    Notes
    [44] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3:Troponin group:BNT162b2 (30 mcg):12 to <16 years
    Number of subjects analysed
    405
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever: >=38.0
    3.5 (1.9 to 5.7)
        Fever: 8.0 to 38.4 deg C
    1.7 (0.7 to 3.5)
        Fever: >38.4 to 38.9 deg C
    1.2 (0.4 to 2.9)
        Fever: >38.9 to 40.0 deg C
    0.5 (0.1 to 1.8)
        Fever: >40.0 deg C
    0 (0.0 to 0.9)
        Fatigue: Any
    36.8 (32.1 to 41.7)
        Fatigue: Mild
    21.7 (17.8 to 26.1)
        Fatigue: Moderate
    14.8 (11.5 to 18.7)
        Fatigue: Severe
    0.2 (0.0 to 1.4)
        Fatigue: Grade 4
    0 (0.0 to 0.9)
        Headache: Any
    35.3 (30.7 to 40.2)
        Headache: Mild
    23.0 (19.0 to 27.4)
        Headache: Moderate
    11.6 (8.7 to 15.1)
        Headache: Severe
    0.7 (0.2 to 2.1)
        Headache: Grade 4
    0 (0.0 to 0.9)
        Chills: Any
    12.8 (9.7 to 16.5)
        Chills: Mild
    8.4 (5.9 to 11.5)
        Chills: Moderate
    4.4 (2.7 to 6.9)
        Chills: Severe
    0 (0.0 to 0.9)
        Chills: Grade 4
    0 (0.0 to 0.9)
        Vomiting: Any
    2.7 (1.4 to 4.8)
        Vomiting: Mild
    2.2 (1.0 to 4.2)
        Vomiting: Moderate
    0.5 (0.1 to 1.8)
        Vomiting: Severe
    0 (0.0 to 0.9)
        Vomiting: Grade 4
    0 (0.0 to 0.9)
        Diarrhea: Any
    4.4 (2.7 to 6.9)
        Diarrhea: Mild
    4.0 (2.3 to 6.3)
        Diarrhea: Moderate
    0.5 (0.1 to 1.8)
        Diarrhea: Severe
    0 (0.0 to 0.9)
        Diarrhea: Grade 4
    0 (0.0 to 0.9)
        New or worsened muscle pain: Any
    18.8 (15.1 to 22.9)
        New or worsened muscle pain: Mild
    10.6 (7.8 to 14.0)
        New or worsened muscle pain: Moderate
    8.1 (5.7 to 11.3)
        New or worsened muscle pain: Severe
    0 (0.0 to 0.9)
        New or worsened muscle pain: Grade 4
    0 (0.0 to 0.9)
        New or worsened joint pain: Any
    6.4 (4.2 to 9.3)
        New or worsened joint pain: Mild
    4.0 (2.3 to 6.3)
        New or worsened joint pain: Moderate
    2.5 (1.2 to 4.5)
        New or worsened joint pain: Severe
    0 (0.0 to 0.9)
        New or worsened joint pain: Grade 4
    0 (0.0 to 0.9)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Troponin Group: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Troponin Group: >=5 to <12 Years of age [45]
    End point description
    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 1 to 1 month after dose 2 were reported in this endpoint. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this endpoint. Safety population included all participants who received at least 1 dose of the study intervention.
    End point type
    Primary
    End point timeframe
    From Dose 1 to 1 month after Dose 2
    Notes
    [45] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3:Troponin group:BNT162b2 (10 mcg):5 to <12 years Phase 2/3:Troponin group:Placebo:5 to <12 years
    Number of subjects analysed
    518
    260
    Units: Percentage of participants
        number (confidence interval 95%)
    7.1 (5.1 to 9.7)
    8.1 (5.1 to 12.1)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Troponin Group: >=12 to <16 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Troponin Group: >=12 to <16 Years of age [46]
    End point description
    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 1 to 1 month after dose 2 were reported in this endpoint. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this endpoint. Safety population included all participants who received at least 1 dose of the study intervention.
    End point type
    Primary
    End point timeframe
    From Dose 1 to 1 month after Dose 2
    Notes
    [46] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3:Troponin group:BNT162b2 (30 mcg):12 to <16 years
    Number of subjects analysed
    487
    Units: Percentage of participants
        number (confidence interval 95%)
    5.3 (3.5 to 7.7)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: Troponin Group: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: Troponin Group: >=5 to <12 Years of age [47]
    End point description
    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 3 to 1 month after dose 3 were reported in this endpoint. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this endpoint. Safety population included all participants who received at least 1 dose of the study intervention.
    End point type
    Primary
    End point timeframe
    From Dose 3 to 1 month after Dose 3
    Notes
    [47] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3:Troponin group:BNT162b2 (10 mcg):5 to <12 years Phase 2/3:Troponin group:Placebo:5 to <12 years
    Number of subjects analysed
    418
    202
    Units: Percentage of participants
        number (confidence interval 95%)
    11.5 (8.6 to 14.9)
    15.3 (10.7 to 21.1)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: Troponin Group:>=12 to <16 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: Troponin Group:>=12 to <16 Years of age [48]
    End point description
    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 3 to 1 month after dose 3 were reported in this endpoint. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this endpoint. Safety population included all participants who received at least 1 dose of the study intervention.
    End point type
    Primary
    End point timeframe
    From Dose 3 to 1 month after Dose 3
    Notes
    [48] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3:Troponin group:BNT162b2 (30 mcg):12 to <16 years
    Number of subjects analysed
    433
    Units: Percentage of participants
        number (confidence interval 95%)
    1.4 (0.5 to 3.0)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : Troponin Group: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : Troponin Group: >=5 to <12 Years of age [49]
    End point description
    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalisation or prolongation of existing hospitalisation, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Safety population included all participants who received at least 1 dose of the study intervention.
    End point type
    Primary
    End point timeframe
    From Dose 1 to 6 months after Dose 2
    Notes
    [49] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3:Troponin group:BNT162b2 (10 mcg):5 to <12 years Phase 2/3:Troponin group:Placebo:5 to <12 years
    Number of subjects analysed
    518
    260
    Units: Percentage of participants
        number (confidence interval 95%)
    0.2 (0.0 to 1.1)
    0 (0.0 to 1.4)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Troponin Group: >=12 to <16 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Troponin Group: >=12 to <16 Years of age [50]
    End point description
    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalisation or prolongation of existing hospitalisation, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Safety population included all participants who received at least 1 dose of the study intervention.
    End point type
    Primary
    End point timeframe
    From Dose 1 to 6 months after Dose 2
    Notes
    [50] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3:Troponin group:BNT162b2 (30 mcg):12 to <16 years
    Number of subjects analysed
    487
    Units: Percentage of participants
        number (confidence interval 95%)
    0.4 (0.0 to 1.5)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=5 to <12 Years of age [51]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild(>=0.5 to 2.0 cm),moderate(>2.0 to 7.0 cm),severe(>7.0 cm)& G4 (necrosis[redness and swelling]or exfoliative dermatitis[redness]).Pain at injection site was graded as mild(did not interfere with activity),moderate (interfered with activity),severe (prevented daily activity)&G4 ER visit or hospitalisation for severe pain at injection site).G4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included.Two-sided 95% CI was based on Clopper and Pearson method.Safety population=all participants who received at least 1 dose of study intervention.‘N’ signifies participants evaluable for this endpoint and ‘n’ signifies participants evaluable for the specified rows.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 1
    Notes
    [51] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age Phase 2/3: Placebo: 5 to <12 years of age
    Number of subjects analysed
    3096
    1532
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any (3096,1532)
    14.0 (12.8 to 15.3)
    5.9 (4.8 to 7.2)
        Redness: Mild (3096,1532)
    9.3 (8.3 to 10.3)
    5.1 (4.0 to 6.3)
        Redness: Moderate (3096,1532)
    4.7 (4.0 to 5.5)
    0.7 (0.4 to 1.3)
        Redness: Severe (3096,1532)
    0.0 (0.0 to 0.2)
    0.1 (0.0 to 0.5)
        Redness: Grade 4 (3096,1532)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
        Swelling: Any (3096,1532)
    10.3 (9.3 to 11.5)
    3.0 (2.2 to 4.0)
        Swelling: Mild (3096,1532)
    5.7 (4.9 to 6.6)
    1.8 (1.2 to 2.6)
        Swelling: Moderate (3096,1532)
    4.6 (3.9 to 5.4)
    1.2 (0.7 to 1.9)
        Swelling: Severe (3096,1532)
    0.0 (0.0 to 0.2)
    0 (0.0 to 0.2)
        Swelling: Grade 4 (3096,1532)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
        Pain at the injection site: Any (3096,1531)
    72.9 (71.3 to 74.5)
    31.5 (29.2 to 33.9)
        Pain at the injection site: Mild (3096,1531)
    58.5 (56.7 to 60.2)
    28.3 (26.1 to 30.7)
        Pain at the injection site: Moderate (3096,1531)
    14.3 (13.1 to 15.6)
    3.1 (2.3 to 4.1)
        Pain at the injection site: Severe (3096,1531)
    0.2 (0.1 to 0.4)
    0 (0.0 to 0.2)
        Pain at the injection site: Grade 4 (3096,1531)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3 : Troponin Group:>=12 to <16 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3 : Troponin Group:>=12 to <16 Years of age [52]
    End point description
    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalisation or prolongation of existing hospitalisation, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Safety population included all participants who received at least 1 dose of the study intervention.
    End point type
    Primary
    End point timeframe
    From Dose 3 to 6 months after Dose 3
    Notes
    [52] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3:Troponin group:BNT162b2 (30 mcg):12 to <16 years
    Number of subjects analysed
    433
    Units: Percentage of participants
        number (confidence interval 95%)
    1.4 (0.5 to 3.0)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: Troponin Group: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: Troponin Group: >=5 to <12 Years of age [53]
    End point description
    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalisation or prolongation of existing hospitalisation, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Safety population included all participants who received at least 1 dose of the study intervention.
    End point type
    Primary
    End point timeframe
    From Dose 3 to 6 months after Dose 3 (Approximately 6 months)
    Notes
    [53] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3:Troponin group:BNT162b2 (10 mcg):5 to <12 years Phase 2/3:Troponin group:Placebo:5 to <12 years
    Number of subjects analysed
    418
    202
    Units: Percentage of participants
        number (confidence interval 95%)
    0.5 (0.1 to 1.7)
    0 (0.0 to 1.8)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=5 to <12 Years of age [54]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild(>=0.5 to 2.0 cm),moderate(>2.0 to 7.0 cm),severe(>7.0 cm)& G4 (necrosis[redness and swelling]or exfoliative dermatitis[redness]).Pain at injection site was graded as mild(did not interfere with activity),moderate (interfered with activity),severe (prevented daily activity)&G4 ER visit or hospitalisation for severe pain at injection site).G4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included.Two-sided 95% CI was based on Clopper and Pearson method.Safety population=all participants who received at least 1 dose of study intervention.‘N’ signifies participants evaluable for this endpoint and ‘n’ signifies participants evaluable for the specified rows.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 2
    Notes
    [54] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age Phase 2/3: Placebo: 5 to <12 years of age
    Number of subjects analysed
    3064
    1522
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any (3064, 1522)
    18.8 (17.4 to 20.2)
    5.2 (4.1 to 6.4)
        Redness: Mild (3064, 1522)
    10.3 (9.2 to 11.4)
    3.7 (2.8 to 4.8)
        Redness: Moderate (3064, 1522)
    8.4 (7.4 to 9.4)
    1.3 (0.8 to 2.0)
        Redness: Severe (3064, 1522)
    0.1 (0.0 to 0.3)
    0.1 (0.0 to 0.5)
        Redness: Grade 4 (3064, 1522)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
        Swelling: Any (3064, 1522)
    14.7 (13.5 to 16.0)
    2.7 (1.9 to 3.6)
        Swelling: Mild (3064, 1522)
    8.1 (7.1 to 9.1)
    2.0 (1.3 to 2.8)
        Swelling: Moderate (3064, 1522)
    6.6 (5.8 to 7.6)
    0.7 (0.4 to 1.3)
        Swelling: Severe (3064, 1522)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
        Swelling: Grade 4 (3064, 1522)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
        Pain at the injection site: Any (3064, 1521)
    71.2 (69.5 to 72.8)
    28.5 (26.3 to 30.9)
        Pain at the injection site: Mild (3064, 1521)
    53.6 (51.8 to 55.4)
    25.6 (23.4 to 27.8)
        Pain at the injection site: Moderate (3064, 1521)
    17.4 (16.1 to 18.8)
    2.9 (2.1 to 3.9)
        Pain at the injection site: Severe (3064, 1521)
    0.2 (0.1 to 0.4)
    0.1 (0.0 to 0.4)
        Pain at the injection site: Grade 4 (3064, 1521)
    0 (0.0 to 0.1)
    0 (0.0 to 0.4)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=5 to <12 Years of age [55]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild(>=0.5 to 2.0 cm),moderate(>2.0 to 7.0 cm),severe(>7.0 cm)& G4 (necrosis[redness and swelling]or exfoliative dermatitis[redness]).Pain at injection site was graded as mild(did not interfere with activity),moderate (interfered with activity),severe (prevented daily activity)&G4 ER visit or hospitalisation for severe pain at injection site).G4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included.Two-sided 95% CI was based on Clopper and Pearson method.Safety population=all participants who received at least 1 dose of study intervention.‘N’ signifies participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 3
    Notes
    [55] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age
    Number of subjects analysed
    2265
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any
    15.6 (14.2 to 17.2)
        Redness: Mild
    9.4 (8.3 to 10.7)
        Redness: Moderate
    6.1 (5.1 to 7.2)
        Redness: Severe
    0.1 (0.0 to 0.3)
        Redness: Grade 4
    0 (0.0 to 0.2)
        Swelling: Any
    12.6 (11.3 to 14.1)
        Swelling: Mild
    6.5 (5.6 to 7.6)
        Swelling: Moderate
    6.1 (5.1 to 7.2)
        Swelling: Severe
    0 (0.0 to 0.2)
        Swelling: Grade 4
    0 (0.0 to 0.2)
        Pain at the injection site: Any
    69.2 (67.3 to 71.1)
        Pain at the injection site: Mild
    48.0 (46.0 to 50.1)
        Pain at the injection site: Moderate
    20.9 (19.3 to 22.7)
        Pain at the injection site: Severe
    0.3 (0.1 to 0.6)
        Pain at the injection site: Grade 4
    0 (0.0 to 0.2)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=5 to <12 Years of age [56]
    End point description
    Systemic events were recorded in an e-diary and at unscheduled clinical assessments upto Day 7 after Dose 1. Fever: oral temperature >= 38.0 deg C;categorised as >=38.0 to 38.4 deg C,>38.4 to 38.9 deg C,>38.9 to 40.0 deg C and >40.0 deg C.Fatigue,headache,chills,new or worsened muscle pain &joint pain: mild(did not interfere with activity),moderate(some interference with activity),severe(prevented daily routine activity).Vomiting:mild:1-2 times in 24 h,moderate:>2 times in 24 h, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24h,moderate:4-5 loose stools in 24h,severe:6 or more loose stools in 24h.G4 for all events: ER visit/hospitalisation & were classified by investigator or medically qualified person.Events reported as AEs in the CRF within 7 days after vaccination were also included.Exact 95%CI based on Clopper and Pearson method. Safety population was used. ‘N= participants evaluable for this endpoint & ‘n'= participants evaluable for specified rows.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 1
    Notes
    [56] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age Phase 2/3: Placebo: 5 to <12 years of age
    Number of subjects analysed
    3096
    1532
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever:>=38.0 (n=3096, 1532)
    2.1 (1.6 to 2.6)
    1.4 (0.9 to 2.1)
        Fever: 38.0 to 38.4 deg C (n=3096, 1532)
    1.2 (0.8 to 1.6)
    0.7 (0.3 to 1.2)
        Fever: >38.4 to 38.9 deg C (n=3096, 1532)
    0.7 (0.4 to 1.1)
    0.6 (0.3 to 1.1)
        Fever: >38.9 to 40.0 deg C (n=3096, 1532)
    0.1 (0.0 to 0.3)
    0.1 (0.0 to 0.5)
        Fever: >40.0 deg C (n=3096, 1532)
    0.0 (0.0 to 0.2)
    0 (0.0 to 0.2)
        Fatigue: Any (n=3096, 1531)
    34.5 (32.8 to 36.2)
    32.4 (30.1 to 34.8)
        Fatigue: Mild (n=3096, 1531)
    22.7 (21.2 to 24.2)
    21.1 (19.1 to 23.2)
        Fatigue: Moderate (n=3096, 1531)
    11.6 (10.5 to 12.8)
    11.2 (9.6 to 12.9)
        Fatigue: Severe (n=3096, 1531)
    0.2 (0.1 to 0.4)
    0.1 (0.0 to 0.5)
        Fatigue: Grade 4 (n=3096, 1531)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
        Headache: Any (n=3096, 1531)
    22.7 (21.2 to 24.2)
    24.3 (22.2 to 26.5)
        Headache: Mild (n=3096, 1531)
    17.1 (15.8 to 18.5)
    18.0 (16.1 to 20.0)
        Headache: Moderate (n=3096, 1531)
    5.5 (4.7 to 6.4)
    5.9 (4.8 to 7.2)
        Headache: Severe (n=3096, 1531)
    0.1 (0.0 to 0.3)
    0.4 (0.1 to 0.9)
        Headache: Grade 4 (n=3096, 1531)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
        Chills: Any (n=3096, 1531)
    5.6 (4.8 to 6.5)
    5.5 (4.4 to 6.7)
        Chills: Mild (n=3096, 1531)
    4.5 (3.8 to 5.2)
    4.5 (3.5 to 5.7)
        Chills: Moderate (n=3096, 1531)
    1.2 (0.8 to 1.6)
    1.0 (0.5 to 1.6)
        Chills: Severe (n=3096, 1531)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
        Chills: Grade 4 (n=3096, 1531)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
        Vomiting: Any (n=3096, 1531)
    2.0 (1.6 to 2.6)
    2.0 (1.3 to 2.8)
        Vomiting: Mild (n=3096, 1531)
    1.7 (1.3 to 2.2)
    1.8 (1.2 to 2.6)
        Vomiting: Moderate (n=3096, 1531)
    0.4 (0.2 to 0.6)
    0.1 (0.0 to 0.5)
        Vomiting: Severe (n=3096, 1531)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
        Vomiting: Grade 4 (n=3096, 1531)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
        Diarrhea: Any (n=3096, 1531)
    6.4 (5.6 to 7.3)
    4.9 (3.9 to 6.1)
        Diarrhea: Mild (n=3096, 1531)
    5.9 (5.1 to 6.8)
    4.7 (3.7 to 5.9)
        Diarrhea: Moderate (n=3096, 1531)
    0.5 (0.2 to 0.8)
    0.2 (0.0 to 0.6)
        Diarrhea: Severe (n=3096, 1531)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
        Diarrhea: Grade 4 (n=3096, 1531)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
        New or worsened muscle pain: Any(n=3096,1531)
    9.3 (8.3 to 10.4)
    8.2 (6.9 to 9.7)
        New or worsened muscle pain: Mild(n=3096,1531)
    6.7 (5.8 to 7.6)
    6.3 (5.1 to 7.6)
        New or worsened muscle pain: Moderate(n=3096,1531)
    2.6 (2.1 to 3.3)
    2.0 (1.3 to 2.8)
        New or worsened muscle pain: Severe(n=3096,1531)
    0.0 (0.0 to 0.2)
    0 (0.0 to 0.2)
        New or worsened muscle pain:G4 (n=3096,1531)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
        New or worsened joint pain:Any (n=3096,1531)
    3.4 (2.8 to 4.1)
    4.6 (3.6 to 5.7)
        New or worsened joint pain:Mild (n=3096,1531)
    2.3 (1.8 to 2.9)
    3.7 (2.8 to 4.7)
        New or worsened joint pain:Moderate(n=3096,1531)
    1.1 (0.8 to 1.6)
    0.9 (0.5 to 1.5)
        New or worsened joint pain:Severe (n=3096,1531)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
        New or worsened joint pain: G4 (n=3096,1531)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=5 to <12 Years of age [57]
    End point description
    Systemic events were recorded in an e-diary and at unscheduled clinical assessments upto Day 7 after Dose 2. Fever: oral temperature >= 38.0 deg C;categorised as >=38.0 to 38.4 deg C,>38.4 to 38.9 deg C,>38.9 to 40.0 deg C and >40.0 deg C.Fatigue,headache,chills,new or worsened muscle pain &joint pain: mild(did not interfere with activity),moderate(some interference with activity),severe(prevented daily routine activity).Vomiting:mild:1-2 times in 24 h,moderate:>2 times in 24 h, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24h,moderate:4-5 loose stools in 24h,severe:6 or more loose stools in 24h.G4 for all events: ER visit/hospitalisation & were classified by investigator or medically qualified person.Events reported as AEs in the CRF within 7 days after vaccination were also included.Exact 95%CI based on Clopper and Pearson method. Safety population was used. ‘N= participants evaluable for this endpoint & ‘n'= participants evaluable for specified rows.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 2
    Notes
    [57] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age Phase 2/3: Placebo: 5 to <12 years of age
    Number of subjects analysed
    3064
    1522
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever: Any (n=3064, 1522)
    6.3 (5.5 to 7.2)
    1.4 (0.9 to 2.1)
        Fever: >=38.0 to 38.4 deg C (n=3064, 1522)
    3.3 (2.7 to 4.0)
    0.9 (0.5 to 1.5)
        Fever: >38.4 to 38.9 deg C (n=3064, 1522)
    2.3 (1.8 to 2.9)
    0.3 (0.1 to 0.8)
        Fever: >38.9 to 40.0 deg C (n=3064,1522)
    0.7 (0.4 to 1.0)
    0.2 (0.0 to 0.6)
        Fever: >40.0 deg C (n=3064, 1522)
    0.0 (0.0 to 0.2)
    0 (0.0 to 0.2)
        Fatigue: Any (n=3064, 1521)
    39.2 (37.4 to 40.9)
    25.2 (23.0 to 27.4)
        Fatigue: Mild (n=3064, 1521)
    21.7 (20.3 to 23.2)
    15.1 (13.4 to 17.0)
        Fatigue: Moderate (n=3064, 1521)
    16.6 (15.3 to 17.9)
    9.8 (8.3 to 11.4)
        Fatigue: Severe (n=3064, 1521)
    0.9 (0.6 to 1.3)
    0.3 (0.1 to 0.7)
        Fatigue: Grade 4 (n=3064, 1521)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
        Headache: Any (n=3064, 1521)
    28.4 (26.8 to 30.0)
    18.7 (16.7 to 20.7)
        Headache: Mild (n=3064, 1521)
    18.8 (17.4 to 20.2)
    13.2 (11.6 to 15.0)
        Headache: Moderate (n=3064, 1521)
    9.3 (8.3 to 10.4)
    5.4 (4.3 to 6.6)
        Headache: Severe (n=3064, 1521)
    0.3 (0.1 to 0.5)
    0.1 (0.0 to 0.4)
        Headache: Grade 4 (n=3064, 1521)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
        Chills: Any (n=3064, 1521)
    9.8 (8.8 to 10.9)
    4.3 (3.4 to 5.5)
        Chills: Mild (n=3064, 1521)
    6.7 (5.8 to 7.6)
    3.4 (2.6 to 4.5)
        Chills: Moderate (n=3064, 1521)
    3.1 (2.5 to 3.7)
    0.9 (0.5 to 1.5)
        Chills: Severe (n=3064, 1521)
    0.1 (0.0 to 0.2)
    0.1 (0.0 to 0.4)
        Chills: Grade 4 (n=3064, 1521)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
        Vomiting: Any (n=3064, 1521)
    2.0 (1.6 to 2.6)
    1.8 (1.2 to 2.6)
        Vomiting: Mild (n=3064, 1521)
    1.8 (1.4 to 2.4)
    1.4 (0.9 to 2.2)
        Vomiting: Moderate (n=3064, 1521)
    0.2 (0.1 to 0.4)
    0.3 (0.1 to 0.8)
        Vomiting: Severe (n=3064, 1521)
    0.0 (0.0 to 0.2)
    0 (0.0 to 0.2)
        Vomiting: Grade 4 (n=3064, 1521)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
        Diarrhea: Any (n=3064, 1521)
    5.4 (4.6 to 6.3)
    5.0 (4.0 to 6.2)
        Diarrhea: Mild (n=3064, 1521)
    4.9 (4.1 to 5.7)
    4.6 (3.6 to 5.8)
        Diarrhea: Moderate (n=3064, 1521)
    0.5 (0.3 to 0.8)
    0.4 (0.1 to 0.9)
        Diarrhea: Severe (n=3064, 1521)
    0.1 (0.0 to 0.2)
    0 (0.0 to 0.2)
        Diarrhea: Grade 4 (n=3064, 1521)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
        New or worsened muscle pain:Any (n=3064,1521)
    12.0 (10.9 to 13.2)
    6.8 (5.6 to 8.2)
        New or worsened muscle pain:Mild (n=3064,1521)
    8.0 (7.1 to 9.0)
    4.5 (3.5 to 5.6)
        New or worsened muscle pain: Moderate(n=3064,1521)
    4.0 (3.3 to 4.7)
    2.4 (1.7 to 3.3)
        New or worsened muscle pain: Severe(n=3064,1521)
    0.0 (0.0 to 0.2)
    0 (0.0 to 0.2)
        New or worsened muscle pain:G4 (n=3064,1521)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
        New or worsened joint pain:Any (n=3064,1521)
    5.2 (4.4 to 6.0)
    3.7 (2.9 to 4.8)
        New or worsened joint pain:Mild (n=3064,1521)
    3.4 (2.8 to 4.1)
    2.8 (2.0 to 3.7)
        New or worsened joint pain: Moderate(n=3064,1521)
    1.8 (1.4 to 2.4)
    1.0 (0.6 to 1.6)
        New or worsened joint pain: Severe (n=3064,1521)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
        New or worsened joint pain:G4 (n=3064,1521)
    0 (0.0 to 0.1)
    0 (0.0 to 0.2)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=5 to <12 Years of age [58]
    End point description
    Systemic events were recorded in an e-diary and at unscheduled clinical assessments upto Day 7 after Dose 3. Fever: oral temperature >= 38.0 deg C;categorised as >=38.0 to 38.4 deg C,>38.4 to 38.9 deg C,>38.9 to 40.0 deg C and >40.0 deg C.Fatigue,headache,chills,new or worsened muscle pain &joint pain: mild(did not interfere with activity),moderate(some interference with activity),severe(prevented daily routine activity).Vomiting:mild:1-2 times in 24 h,moderate:>2 times in 24 h, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24h,moderate:4-5 loose stools in 24h,severe:6 or more loose stools in 24h.G4 for all events: ER visit/hospitalisation & were classified by investigator or medically qualified person.Events reported as AEs in the CRF within 7 days after vaccination were also included.Exact 95%CI based on Clopper and Pearson method. Safety population was used. ‘N= participants evaluable for this endpoint & ‘n'= participants evaluable for specified rows.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 3
    Notes
    [58] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age
    Number of subjects analysed
    2265
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever: >=38.0
    6.8 (5.8 to 7.9)
        Fever:38.0 to 38.4 deg C
    4.1 (3.3 to 5.0)
        Fever: >38.4 to 38.9 deg C
    1.8 (1.3 to 2.4)
        Fever: >38.9 to 40.0 deg C
    0.9 (0.5 to 1.4)
        Fever: >40.0 deg C
    0.0 (0.0 to 0.2)
        Fatigue: Any
    39.6 (37.6 to 41.7)
        Fatigue: Mild
    21.0 (19.4 to 22.8)
        Fatigue: Moderate
    17.3 (15.8 to 18.9)
        Fatigue: Severe
    1.3 (0.9 to 1.8)
        Fatigue: Grade 4
    0 (0.0 to 0.2)
        Headache: Any
    26.9 (25.1 to 28.8)
        Headache: Mild
    16.2 (14.7 to 17.8)
        Headache: Moderate
    10.3 (9.1 to 11.7)
        Headache: Severe
    0.4 (0.2 to 0.8)
        Headache: Grade 4
    0 (0.0 to 0.2)
        Chills: Any
    10.2 (9.0 to 11.5)
        Chills: Mild
    6.2 (5.2 to 7.3)
        Chills: Moderate
    3.9 (3.1 to 4.8)
        Chills: Severe
    0.1 (0.0 to 0.4)
        Chills: Grade 4
    0 (0.0 to 0.2)
        Vomiting: Any
    2.7 (2.1 to 3.4)
        Vomiting: Mild
    2.2 (1.6 to 2.9)
        Vomiting: Moderate
    0.4 (0.2 to 0.8)
        Vomiting: Severe
    0.0 (0.0 to 0.2)
        Vomiting: Grade 4
    0 (0.0 to 0.2)
        Diarrhea: Any
    4.6 (3.8 to 5.5)
        Diarrhea: Mild
    4.3 (3.5 to 5.2)
        Diarrhea: Moderate
    0.3 (0.1 to 0.6)
        Diarrhea: Severe
    0.0 (0.0 to 0.2)
        Diarrhea: Grade 4
    0 (0.0 to 0.2)
        New or worsened muscle pain: Any
    15.5 (14.0 to 17.0)
        New or worsened muscle pain: Mild
    8.8 (7.7 to 10.0)
        New or worsened muscle pain: Moderate
    6.5 (5.6 to 7.6)
        New or worsened muscle pain: Severe
    0.1 (0.0 to 0.4)
        New or worsened muscle pain: Grade 4
    0 (0.0 to 0.2)
        New or worsened joint pain: Any
    5.7 (4.8 to 6.7)
        New or worsened joint pain: Mild
    3.5 (2.8 to 4.3)
        New or worsened joint pain: Moderate
    2.2 (1.6 to 2.9)
        New or worsened joint pain: Severe
    0.0 (0.0 to 0.2)
        New or worsened joint pain: Grade 4
    0 (0.0 to 0.2)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=2 to <5 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=2 to <5 Years of age [59]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild(>=0.5 to 2.0 cm),moderate(>2.0 to 7.0 cm),severe(>7.0 cm)& G4 (necrosis[redness and swelling]or exfoliative dermatitis[redness]).Pain at injection site was graded as mild(did not interfere with activity),moderate (interfered with activity),severe (prevented daily activity)&G4 ER visit or hospitalisation.G4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included.Two-sided 95% CI was based on Clopper and Pearson method.Safety population=all participants who received at least 1 dose of study intervention.‘N’ signifies participants evaluable for this endpoint and ‘n’ signifies participants evaluable for the specified rows.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 1
    Notes
    [59] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age Phase 2/3: Placebo: 2 to <5 years of age
    Number of subjects analysed
    2327
    1164
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any (2327, 1164)
    9.0 (7.9 to 10.3)
    8.4 (6.9 to 10.2)
        Redness: Mild (2327, 1164)
    7.7 (6.7 to 8.9)
    7.5 (6.0 to 9.1)
        Redness: Moderate (2327, 1164)
    1.2 (0.8 to 1.8)
    0.9 (0.4 to 1.6)
        Redness: Severe (2327, 1164)
    0.0 (0.0 to 0.2)
    0.1 (0.0 to 0.5)
        Redness: Grade 4 (2327, 1164)
    0 (0.0 to 0.2)
    0 (0.0 to 0.3)
        Swelling: Any (2327, 1164)
    3.9 (3.2 to 4.8)
    3.1 (2.2 to 4.3)
        Swelling: Mild (2327, 1164)
    3.4 (2.7 to 4.3)
    2.5 (1.7 to 3.6)
        Swelling: Moderate (2327, 1164)
    0.5 (0.2 to 0.8)
    0.6 (0.2 to 1.2)
        Swelling: Severe (2327, 1164)
    0 (0.0 to 0.2)
    0 (0.0 to 0.3)
        Swelling: Grade 4 (2327, 1164)
    0 (0.0 to 0.2)
    0 (0.0 to 0.3)
        Pain at the injection site: Any (2305, 1159)
    30.3 (28.4 to 32.2)
    20.6 (18.3 to 23.1)
        Pain at the injection site: Mild (2305, 1159)
    28.1 (26.3 to 30.0)
    19.4 (17.2 to 21.8)
        Pain at the injection site: Moderate (2305, 1159)
    2.2 (1.6 to 2.8)
    1.1 (0.6 to 1.9)
        Pain at the injection site: Severe (2305, 1159)
    0 (0.0 to 0.2)
    0.1 (0.0 to 0.5)
        Pain at the injection site: Grade 4 (2305, 1159)
    0 (0.0 to 0.2)
    0 (0.0 to 0.5)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=2 to <5 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=2 to <5 Years of age [60]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild(>=0.5 to 2.0 cm),moderate(>2.0 to 7.0 cm),severe(>7.0 cm)& G4 (necrosis[redness and swelling]or exfoliative dermatitis[redness]).Pain at injection site was graded as mild(did not interfere with activity),moderate (interfered with activity),severe (prevented daily activity)&G4 ER visit or hospitalisation.G4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included.Two-sided 95% CI was based on Clopper and Pearson method.Safety population=all participants who received at least 1 dose of study intervention.‘N’ signifies participants evaluable for this endpoint and ‘n’ signifies participants evaluable for the specified rows.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 2
    Notes
    [60] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age Phase 2/3: Placebo: 2 to <5 years of age
    Number of subjects analysed
    2094
    1038
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any (2094, 1038)
    11.2 (9.9 to 12.7)
    5.4 (4.1 to 6.9)
        Redness: Mild (2094, 1038)
    9.6 (8.3 to 10.9)
    4.6 (3.4 to 6.1)
        Redness: Moderate (2094, 1038)
    1.6 (1.1 to 2.3)
    0.8 (0.3 to 1.5)
        Redness: Severe (2094, 1038)
    0.0 (0.0 to 0.3)
    0 (0.0 to 0.4)
        Redness: Grade 4 (2094, 1038)
    0.0 (0.0 to 0.2)
    0 (0.0 to 0.4)
        Swelling: Any (2094, 1038)
    5.6 (4.7 to 6.7)
    2.0 (1.3 to 3.1)
        Swelling: Mild (2094, 1038)
    4.4 (3.6 to 5.4)
    1.8 (1.1 to 2.8)
        Swelling: Moderate (2094, 1038)
    1.2 (0.8 to 1.8)
    0.2 (0.0 to 0.7)
        Swelling: Severe (2094, 1038)
    0 (0.0 to 0.2)
    0 (0.0 to 0.4)
        Swelling: Grade 4 (2094, 1038)
    0 (0.0 to 0.2)
    0 (0.0 to 0.4)
        Pain at the injection site: Any (2082, 1037)
    30.5 (28.5 to 32.5)
    20.3 (17.9 to 22.9)
        Pain at the injection site: Mild (2082, 1037)
    28.2 (26.3 to 30.2)
    19.4 (17.0 to 21.9)
        Pain at the injection site: Moderate (2082, 1037)
    2.2 (1.6 to 2.9)
    0.9 (0.4 to 1.6)
        Pain at the injection site: Severe (2082, 1037)
    0 (0.0 to 0.2)
    0.1 (0.0 to 0.5)
        Pain at the injection site: Grade 4 (2082, 1037)
    0 (0.0 to 0.2)
    0 (0.0 to 0.4)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=2 to <5 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=2 to <5 Years of age [61]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild(>=0.5 to 2.0 cm),moderate(>2.0 to 7.0 cm),severe(>7.0 cm)& G4 (necrosis[redness and swelling]or exfoliative dermatitis[redness]).Pain at injection site was graded as mild(did not interfere with activity),moderate (interfered with activity),severe (prevented daily activity)&G4 ER visit or hospitalisation.G4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included.Two-sided 95% CI was based on Clopper and Pearson method.Safety population=all participants who received at least 1 dose of study intervention.‘N’ signifies participants evaluable for this endpoint and ‘n’ signifies participants evaluable for the specified rows.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 3
    Notes
    [61] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age Phase 2/3: Placebo: 2 to <5 years of age
    Number of subjects analysed
    799
    376
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any (799, 376)
    10.4 (8.4 to 12.7)
    4.8 (2.9 to 7.5)
        Redness: Mild (799, 376)
    9.0 (7.1 to 11.2)
    4.0 (2.2 to 6.5)
        Redness: Moderate (799, 376)
    1.4 (0.7 to 2.4)
    0.8 (0.2 to 2.3)
        Redness: Severe (799, 376)
    0 (0.0 to 0.5)
    0 (0.0 to 1.0)
        Redness: Grade 4 (799, 376)
    0 (0.0 to 0.5)
    0 (0.0 to 1.0)
        Swelling: Any (799, 376)
    3.1 (2.0 to 4.6)
    1.6 (0.6 to 3.4)
        Swelling: Mild (799, 376)
    2.9 (1.8 to 4.3)
    1.6 (0.6 to 3.4)
        Swelling: Moderate (799, 376)
    0.3 (0.0 to 0.9)
    0 (0.0 to 1.0)
        Swelling: Severe (799, 376)
    0 (0.0 to 0.5)
    0 (0.0 to 1.0)
        Swelling: Grade 4 (799, 376)
    0 (0.0 to 0.5)
    0 (0.0 to 1.0)
        Pain at the injection site: Any (793, 375)
    28.0 (24.9 to 31.3)
    12.8 (9.6 to 16.6)
        Pain at the injection site: Mild (793, 375)
    26.0 (23.0 to 29.2)
    12.0 (8.9 to 15.7)
        Pain at the injection site: Moderate (793, 375)
    2.0 (1.2 to 3.3)
    0.8 (0.2 to 2.3)
        Pain at the injection site: Severe (793, 375)
    0 (0.0 to 0.5)
    0 (0.0 to 1.0)
        Pain at the injection site: Grade 4 (793, 375)
    0 (0.0 to 0.5)
    0 (0.0 to 1.0)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=2 to <5 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=2 to <5 Years of age [62]
    End point description
    Systemic events were recorded in an e-diary & at unscheduled clinical assessments from Day 1 to Day 7 after Dose 1.Fever:oral temperature>= 38.0 deg C;categorised as >=38.0 to 38.4 deg C,>38.4 to 38.9 deg C, >38.9 to 40.0 deg C & >40.0 deg C. Fatigue,headache,chills,new or worsened muscle pain and joint pain: mild(did not interfere with activity),moderate(some interference with activity),severe(prevented daily routine activity).Vomiting:mild: 1-2 times in 24 h,moderate:>2 times in 24 h, severe:required intravenous hydration.Diarrhea:mild:2-3 loose stools in 24 h,moderate:4-5 loose stools in 24 h,severe:6 or more loose stools in 24 h.G4 for all events: ER visit or hospitalisation& were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included.Exact 95%CI based on Clopper and Pearson method. Safety population.N=participants evaluable for endpoint & n=participants evaluable for specified rows.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 1
    Notes
    [62] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age Phase 2/3: Placebo: 2 to <5 years of age
    Number of subjects analysed
    2325
    1164
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever:>=38.0(n=2325, 1164)
    5.5 (4.6 to 6.5)
    5.7 (4.4 to 7.2)
        Fever: 38.0 to 38.4 deg C (n=2325, 1164)
    3.1 (2.4 to 3.8)
    2.6 (1.7 to 3.7)
        Fever: >38.4 to 38.9 deg C (n=2325, 1164)
    1.5 (1.0 to 2.0)
    2.1 (1.3 to 3.1)
        Fever: >38.9 to 40.0 deg C (n=2325, 1164)
    0.9 (0.6 to 1.4)
    1.0 (0.5 to 1.8)
        Fever: >40.0 deg C (n=2325, 1164)
    0.1 (0.0 to 0.3)
    0 (0.0 to 0.3)
        Fatigue: Any (n=2304, 1159)
    30.6 (28.7 to 32.5)
    31.9 (29.2 to 34.7)
        Fatigue: Mild (n=2304, 1159)
    18.8 (17.2 to 20.4)
    19.5 (17.3 to 21.9)
        Fatigue: Moderate (n=2304, 1159)
    11.5 (10.2 to 12.8)
    11.6 (9.9 to 13.6)
        Fatigue: Severe (n=2304, 1159)
    0.4 (0.2 to 0.7)
    0.8 (0.4 to 1.5)
        Fatigue: Grade 4 (n=2304, 1159)
    0 (0.0 to 0.2)
    0 (0.0 to 0.3)
        Headache: Any (n=2304, 1159)
    5.1 (4.2 to 6.1)
    4.8 (3.7 to 6.2)
        Headache: Mild (n=2304, 1159)
    3.9 (3.2 to 4.8)
    3.7 (2.7 to 5.0)
        Headache: Moderate (n=2304, 1159)
    1.1 (0.7 to 1.6)
    1.0 (0.5 to 1.8)
        Headache: Severe (n=2304, 1159)
    0 (0.0 to 0.2)
    0.1 (0.0 to 0.5)
        Headache: Grade 4 (n=2304, 1159)
    0 (0.0 to 0.2)
    0 (0.0 to 0.3)
        Chills: Any (n=2304, 1159)
    2.8 (2.1 to 3.5)
    2.9 (2.0 to 4.1)
        Chills: Mild (n=2304, 1159)
    1.8 (1.3 to 2.4)
    2.0 (1.3 to 3.0)
        Chills: Moderate (n=2304, 1159)
    0.9 (0.5 to 1.3)
    0.9 (0.4 to 1.6)
        Chills: Severe (n=2304, 1159)
    0.1 (0.0 to 0.4)
    0.1 (0.0 to 0.5)
        Chills: Grade 4 (n=2304, 1159)
    0 (0.0 to 0.2)
    0 (0.0 to 0.3)
        Vomiting: Any (n=2304, 1159)
    3.5 (2.8 to 4.4)
    2.9 (2.0 to 4.1)
        Vomiting: Mild (n=2304, 1159)
    2.9 (2.2 to 3.6)
    2.1 (1.3 to 3.1)
        Vomiting: Moderate (n=2304, 1159)
    0.7 (0.4 to 1.1)
    0.9 (0.4 to 1.6)
        Vomiting: Severe (n=2304, 1159)
    0 (0.0 to 0.2)
    0 (0.0 to 0.3)
        Vomiting: Grade 4 (n=2304, 1159)
    0 (0.0 to 0.2)
    0 (0.0 to 0.3)
        Diarrhea: Any (n=2304, 1159)
    8.6 (7.4 to 9.8)
    8.3 (6.8 to 10.0)
        Diarrhea: Mild (n=2304, 1159)
    7.9 (6.8 to 9.0)
    7.4 (6.0 to 9.1)
        Diarrhea: Moderate (n=2304, 1159)
    0.7 (0.4 to 1.1)
    0.9 (0.4 to 1.6)
        Diarrhea: Severe (n=2304, 1159)
    0 (0.0 to 0.2)
    0 (0.0 to 0.3)
        Diarrhea: Grade 4 (n=2304, 1159)
    0 (0.0 to 0.2)
    0 (0.0 to 0.3)
        New or worsened muscle pain:Any (n=2304,1159)
    2.6 (2.0 to 3.3)
    2.3 (1.5 to 3.4)
        New or worsened muscle pain: Mild (n=2304,1159)
    1.9 (1.4 to 2.6)
    1.7 (1.1 to 2.7)
        New or worsened muscle pain: Moderate(n=2304,1159)
    0.7 (0.4 to 1.1)
    0.5 (0.2 to 1.1)
        New or worsened muscle pain: Severe(n=2304,1159)
    0.0 (0.0 to 0.2)
    0.1 (0.0 to 0.5)
        New or worsened muscle pain: G4(n=2304,1159)
    0 (0.0 to 0.2)
    0 (0.0 to 0.3)
        New or worsened joint pain: Any (n=2304,1159)
    1.2 (0.8 to 1.7)
    1.8 (1.1 to 2.8)
        New or worsened joint pain:Mild (n=2304,1159)
    0.9 (0.6 to 1.4)
    1.4 (0.8 to 2.2)
        New or worsened joint pain: Moderate(n=2304,1159)
    0.2 (0.1 to 0.5)
    0.4 (0.1 to 1.0)
        New or worsened joint pain:Severe (n=2304,1159)
    0.0 (0.0 to 0.2)
    0 (0.0 to 0.3)
        New or worsened joint pain: G4 (n=2304,1159)
    0 (0.0 to 0.2)
    0 (0.0 to 0.3)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=2 to <5 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=2 to <5 Years of age [63]
    End point description
    Systemic events were recorded in an e-diary & at unscheduled clinical assessments from Day 1 to Day 7 after Dose 2.Fever:oral temperature>= 38.0 deg C;categorised as >=38.0 to 38.4 deg C,>38.4 to 38.9 deg C, >38.9 to 40.0 deg C & >40.0 deg C. Fatigue,headache,chills,new or worsened muscle pain and joint pain: mild(did not interfere with activity),moderate(some interference with activity),severe(prevented daily routine activity).Vomiting:mild: 1-2 times in 24 h,moderate:>2 times in 24 h, severe:required intravenous hydration.Diarrhea:mild:2-3 loose stools in 24 h,moderate:4-5 loose stools in 24 h,severe:6 or more loose stools in 24 h.G4 for all events: ER visit or hospitalisation& were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included.Exact 95%CI based on Clopper and Pearson method. Safety population.N=participants evaluable for endpoint & n=participants evaluable for specified rows.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 2
    Notes
    [63] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age Phase 2/3: Placebo: 2 to <5 years of age
    Number of subjects analysed
    2094
    1038
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever: >=38.0 (n=2094, 1038)
    5.2 (4.3 to 6.2)
    5.8 (4.4 to 7.4)
        Fever:38.0 to 38.4 deg C (n=2094, 1038)
    2.4 (1.8 to 3.2)
    2.2 (1.4 to 3.3)
        Fever: >38.4 to 38.9 deg C (n=2094, 1038)
    1.5 (1.0 to 2.2)
    2.6 (1.7 to 3.8)
        Fever: >38.9 to 40.0 deg C (n=2094, 1038)
    1.1 (0.7 to 1.6)
    0.9 (0.4 to 1.6)
        Fever: >40.0 deg C (n=2094, 1038)
    0.1 (0.0 to 0.4)
    0.1 (0.0 to 0.5)
        Fatigue: Any (n=2082, 1037)
    26.1 (24.2 to 28.0)
    24.3 (21.7 to 27.0)
        Fatigue: Mild (n=2082, 1037)
    15.5 (13.9 to 17.1)
    14.7 (12.6 to 17.0)
        Fatigue: Moderate (n=2082, 1037)
    10.2 (9.0 to 11.6)
    9.3 (7.6 to 11.2)
        Fatigue: Severe (n=2082, 1037)
    0.4 (0.2 to 0.8)
    0.4 (0.1 to 1.0)
        Fatigue: Grade 4 (n=2082, 1037)
    0 (0.0 to 0.2)
    0 (0.0 to 0.4)
        Headache: Any (n=2082, 1037)
    4.6 (3.8 to 5.6)
    4.1 (3.0 to 5.5)
        Headache: Mild (n=2082, 1037)
    3.5 (2.7 to 4.3)
    2.6 (1.7 to 3.8)
        Headache: Moderate (n=2082, 1037)
    1.2 (0.7 to 1.7)
    1.4 (0.8 to 2.4)
        Headache: Severe (n=2082, 1037)
    0 (0.0 to 0.2)
    0.1 (0.0 to 0.5)
        Headache: Grade 4 (n=2082, 1037)
    0 (0.0 to 0.2)
    0 (0.0 to 0.4)
        Chills: Any (n=2082, 1037)
    3.2 (2.5 to 4.0)
    2.8 (1.9 to 4.0)
        Chills: Mild (n=2082, 1037)
    2.2 (1.6 to 2.9)
    2.2 (1.4 to 3.3)
        Chills: Moderate (n=2082, 1037)
    1.0 (0.6 to 1.5)
    0.6 (0.2 to 1.3)
        Chills: Severe (n=2082, 1037)
    0 (0.0 to 0.2)
    0 (0.0 to 0.4)
        Chills: Grade 4 (n=2082, 1037)
    0 (0.0 to 0.2)
    0 (0.0 to 0.4)
        Vomiting: Any (n=2082, 1037)
    3.4 (2.6 to 4.2)
    3.4 (2.4 to 4.7)
        Vomiting: Mild (n=2082, 1037)
    3.0 (2.3 to 3.8)
    2.9 (2.0 to 4.1)
        Vomiting: Moderate (n=2082, 1037)
    0.4 (0.2 to 0.8)
    0.5 (0.2 to 1.1)
        Vomiting: Severe (n=2082, 1037)
    0 (0.0 to 0.2)
    0 (0.0 to 0.4)
        Vomiting: Grade 4 (n=2082, 1037)
    0 (0.0 to 0.2)
    0 (0.0 to 0.4)
        Diarrhea: Any (n=2082, 1037)
    6.8 (5.7 to 7.9)
    8.0 (6.4 to 9.8)
        Diarrhea: Mild (n=2082, 1037)
    5.9 (4.9 to 7.0)
    7.1 (5.6 to 8.9)
        Diarrhea: Moderate (n=2082, 1037)
    0.8 (0.5 to 1.3)
    0.8 (0.3 to 1.5)
        Diarrhea: Severe (n=2082, 1037)
    0.1 (0.0 to 0.3)
    0.1 (0.0 to 0.5)
        Diarrhea: Grade 4 (n=2082, 1037)
    0 (0.0 to 0.2)
    0 (0.0 to 0.4)
        New or worsened muscle pain: Any (n=2082, 1037)
    2.6 (2.0 to 3.4)
    2.6 (1.7 to 3.8)
        New or worsened muscle pain:Mild (n=2082,1037)
    1.9 (1.3 to 2.6)
    2.0 (1.3 to 3.1)
        New or worsened muscle pain: Moderate(n=2082,1037)
    0.8 (0.4 to 1.2)
    0.6 (0.2 to 1.3)
        New or worsened muscle pain: Severe(n=2082,1037)
    0 (0.0 to 0.2)
    0 (0.0 to 0.4)
        New or worsened muscle pain: G4 (n=2082,1037)
    0 (0.0 to 0.2)
    0 (0.0 to 0.4)
        New or worsened joint pain:Any (n=2082,1037)
    1.2 (0.8 to 1.8)
    1.2 (0.6 to 2.0)
        New or worsened joint pain:Mild (n=2082,1037)
    0.9 (0.6 to 1.4)
    0.9 (0.4 to 1.6)
        New or worsened joint pain: Moderate(n=2082,1037)
    0.3 (0.1 to 0.7)
    0.3 (0.1 to 0.8)
        New or worsened joint pain:Severe (n=2082,1037)
    0 (0.0 to 0.2)
    0 (0.0 to 0.4)
        New or worsened joint pain:G4 (n=2082,1037)
    0 (0.0 to 0.2)
    0 (0.0 to 0.4)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=2 to <5 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=2 to <5 Years of age [64]
    End point description
    Systemic events were recorded in an e-diary & at unscheduled clinical assessments from Day 1 to Day 7 after Dose 3.Fever:oral temperature>= 38.0 deg C;categorised as >=38.0 to 38.4 deg C,>38.4 to 38.9 deg C, >38.9 to 40.0 deg C & >40.0 deg C. Fatigue,headache,chills,new or worsened muscle pain and joint pain: mild(did not interfere with activity),moderate(some interference with activity),severe(prevented daily routine activity).Vomiting:mild: 1-2 times in 24 h,moderate:>2 times in 24 h, severe:required intravenous hydration.Diarrhea:mild:2-3 loose stools in 24 h,moderate:4-5 loose stools in 24 h,severe:6 or more loose stools in 24 h.G4 for all events: ER visit or hospitalisation& were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included.Exact 95%CI based on Clopper and Pearson method. Safety population.N=participants evaluable for endpoint & n=participants evaluable for specified rows.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 3
    Notes
    [64] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age Phase 2/3: Placebo: 2 to <5 years of age
    Number of subjects analysed
    799
    376
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever: >=38.0 (n=799, 376)
    5.1 (3.7 to 6.9)
    5.6 (3.5 to 8.4)
        Fever:38.0 to 38.4 deg C (n=799, 376)
    2.5 (1.5 to 3.8)
    2.1 (0.9 to 4.1)
        Fever: >38.4 to 38.9 deg C (n=799, 376)
    1.8 (1.0 to 2.9)
    1.9 (0.8 to 3.8)
        Fever: >38.9 to 40.0 deg C (n=799, 376)
    0.9 (0.4 to 1.8)
    1.6 (0.6 to 3.4)
        Fever: >40.0 deg C (n=799, 376)
    0 (0.0 to 0.5)
    0 (0.0 to 1.0)
        Fatigue: Any (n=793, 375)
    25.5 (22.5 to 28.7)
    24.3 (20.0 to 28.9)
        Fatigue: Mild (n=793, 375)
    16.0 (13.5 to 18.8)
    14.7 (11.2 to 18.7)
        Fatigue: Moderate (n=793, 375)
    9.2 (7.3 to 11.4)
    9.3 (6.6 to 12.7)
        Fatigue: Severe (n=793, 375)
    0.3 (0.0 to 0.9)
    0.3 (0.0 to 1.5)
        Fatigue: Grade 4 (n=793, 375)
    0 (0.0 to 0.5)
    0 (0.0 to 1.0)
        Headache: Any (n=793, 375)
    4.5 (3.2 to 6.2)
    4.0 (2.3 to 6.5)
        Headache: Mild (n=793, 375)
    2.9 (1.8 to 4.3)
    2.9 (1.5 to 5.2)
        Headache: Moderate (n=793, 375)
    1.6 (0.9 to 2.8)
    1.1 (0.3 to 2.7)
        Headache: Severe (n=793, 375)
    0 (0.0 to 0.5)
    0 (0.0 to 1.0)
        Headache: Grade 4 (n=793, 375)
    0 (0.0 to 0.5)
    0 (0.0 to 1.0)
        Chills: Any (n=793, 375)
    2.8 (1.7 to 4.2)
    2.7 (1.3 to 4.8)
        Chills: Mild (n=793, 375)
    2.1 (1.3 to 3.4)
    2.4 (1.1 to 4.5)
        Chills: Moderate (n=793, 375)
    0.5 (0.1 to 1.3)
    0.3 (0.0 to 1.5)
        Chills: Severe (n=793, 375)
    0.1 (0.0 to 0.7)
    0 (0.0 to 1.0)
        Chills: Grade 4 (n=793, 375)
    0 (0.0 to 0.5)
    0 (0.0 to 1.0)
        Vomiting: Any (n=793, 375)
    2.0 (1.2 to 3.3)
    4.3 (2.5 to 6.8)
        Vomiting: Mild (n=793, 375)
    1.5 (0.8 to 2.6)
    2.9 (1.5 to 5.2)
        Vomiting: Moderate (n=793, 375)
    0.5 (0.1 to 1.3)
    1.3 (0.4 to 3.1)
        Vomiting: Severe (n=793, 375)
    0 (0.0 to 0.5)
    0 (0.0 to 1.0)
        Vomiting: Grade 4 (n=793, 375)
    0 (0.0 to 0.5)
    0 (0.0 to 1.0)
        Diarrhea: Any (n=793, 375)
    4.9 (3.5 to 6.7)
    5.6 (3.5 to 8.4)
        Diarrhea: Mild (n=793, 375)
    3.8 (2.6 to 5.4)
    4.5 (2.7 to 7.2)
        Diarrhea: Moderate (n=793, 375)
    1.1 (0.5 to 2.1)
    1.1 (0.3 to 2.7)
        Diarrhea: Severe (n=793, 375)
    0 (0.0 to 0.5)
    0 (0.0 to 1.0)
        Diarrhea: Grade 4 (n=793, 375)
    0 (0.0 to 0.5)
    0 (0.0 to 1.0)
        New or worsened muscle pain: Any (n=793, 375)
    1.9 (1.1 to 3.1)
    1.6 (0.6 to 3.4)
        New or worsened muscle pain: Mild (n=793, 375)
    1.5 (0.8 to 2.6)
    1.3 (0.4 to 3.1)
        New or worsened muscle pain: Moderate (n=793, 375)
    0.4 (0.1 to 1.1)
    0.3 (0.0 to 1.5)
        New or worsened muscle pain: Severe (n=793, 375)
    0 (0.0 to 0.5)
    0 (0.0 to 1.0)
        New or worsened muscle pain: Grade 4 (n=793, 375)
    0 (0.0 to 0.5)
    0 (0.0 to 1.0)
        New or worsened joint pain: Any (n=793, 375)
    1.1 (0.5 to 2.1)
    1.1 (0.3 to 2.7)
        New or worsened joint pain: Mild (n=793, 375)
    0.9 (0.4 to 1.8)
    1.1 (0.3 to 2.7)
        New or worsened joint pain: Moderate (n=793, 375)
    0.1 (0.0 to 0.7)
    0 (0.0 to 1.0)
        New or worsened joint pain: Severe (n=793, 375)
    0.1 (0.0 to 0.7)
    0 (0.0 to 1.0)
        New or worsened joint pain: Grade 4 (n=793, 375)
    0 (0.0 to 0.5)
    0 (0.0 to 1.0)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=6 Months to <2 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=6 Months to <2 Years of age [65]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where,1 mdu =0.5 cm and were graded as mild (>=0.5 to 2.0 cm), moderate (>2.0 to 7.0 cm), severe (>7.0 cm) & G4 (necrosis [redness and swelling] or exfoliative dermatitis [redness]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate(hurts if gently touched with crying), severe (causes limitation of limb movement) & G4 (ER visit or hospitalisation).G4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method. Safety population was used. ‘N=participants evaluable for this endpoint and ‘n=participants evaluable for the specified rows.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 1
    Notes
    [65] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age Phase 2/3: Placebo: 6 months to <2 years
    Number of subjects analysed
    1439
    712
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any (n=1439, 712)
    10.7 (9.2 to 12.4)
    7.6 (5.7 to 9.8)
        Redness: Mild (n=1439, 712)
    9.8 (8.3 to 11.5)
    7.2 (5.4 to 9.3)
        Redness: Moderate (n=1439, 712)
    0.9 (0.5 to 1.5)
    0.4 (0.1 to 1.2)
        Redness: Severe (n=1439, 712)
    0 (0.0 to 0.3)
    0 (0.0 to 0.5)
        Redness: Grade 4 (n=1439, 712)
    0 (0.0 to 0.3)
    0 (0.0 to 0.5)
        Swelling: Any (n=1439, 712)
    3.8 (2.8 to 4.9)
    2.5 (1.5 to 4.0)
        Swelling: Mild (n=1439, 712)
    3.3 (2.5 to 4.4)
    2.2 (1.3 to 3.6)
        Swelling: Moderate (n=1439, 712)
    0.4 (0.2 to 0.9)
    0.3 (0.0 to 1.0)
        Swelling: Severe (n=1439, 712)
    0 (0.0 to 0.3)
    0 (0.0 to 0.5)
        Swelling: Grade 4 (n=1439, 712)
    0 (0.0 to 0.3)
    0 (0.0 to 0.5)
        Tenderness at injection site: Any (n=1425, 706)
    17.2 (15.3 to 19.3)
    12.6 (10.2 to 15.3)
        Tenderness at injection site: Mild (n=1425, 706)
    16.3 (14.4 to 18.3)
    11.5 (9.2 to 14.1)
        Tenderness at injection site:Moderate (n=1425,706)
    0.8 (0.4 to 1.5)
    1.1 (0.5 to 2.2)
        Tenderness at injection site:Severe(n=1425,706)
    0.1 (0.0 to 0.4)
    0 (0.0 to 0.5)
        Tenderness at injection site: G4 (n=1425, 706)
    0 (0.0 to 0.3)
    0 (0.0 to 0.5)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=6 Months to <2 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=6 Months to <2 Years of age [66]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where,1 mdu =0.5 cm and were graded as mild (>=0.5 to 2.0 cm), moderate (>2.0 to 7.0 cm), severe (>7.0 cm) & G4 (necrosis [redness and swelling] or exfoliative dermatitis [redness]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate(hurts if gently touched with crying), severe (causes limitation of limb movement) & G4 (ER visit or hospitalisation).G4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method. Safety population was used. ‘N=participants evaluable for this endpoint and ‘n=participants evaluable for the specified rows.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 2
    Notes
    [66] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age Phase 2/3: Placebo: 6 months to <2 years
    Number of subjects analysed
    1323
    666
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any (n= 1323,666)
    9.9 (8.3 to 11.6)
    6.3 (4.6 to 8.4)
        Redness: Mild (n= 1323,666)
    9.1 (7.6 to 10.7)
    5.9 (4.2 to 7.9)
        Redness: Moderate (n= 1323,666)
    0.8 (0.4 to 1.5)
    0.5 (0.1 to 1.3)
        Redness: Severe (n= 1323,666)
    0 (0.0 to 0.3)
    0 (0.0 to 0.6)
        Redness: Grade 4 (n= 1323,666)
    0 (0.0 to 0.3)
    0 (0.0 to 0.6)
        Swelling: Any (n= 1323,666)
    4.1 (3.1 to 5.3)
    1.5 (0.7 to 2.7)
        Swelling: Mild (n= 1323,666)
    3.5 (2.6 to 4.6)
    1.4 (0.6 to 2.5)
        Swelling: Moderate (n= 1323,666)
    0.6 (0.3 to 1.2)
    0.2 (0.0 to 0.8)
        Swelling: Severe (n= 1323,666)
    0 (0.0 to 0.3)
    0 (0.0 to 0.6)
        Swelling: Grade 4 (n= 1323,666)
    0 (0.0 to 0.3)
    0 (0.0 to 0.6)
        Tenderness at injection site: Any(n= 1314,664)
    15.4 (13.5 to 17.5)
    9.3 (7.2 to 11.8)
        Tenderness at injection site:Mild (n= 1314,664)
    13.8 (12.0 to 15.8)
    7.7 (5.8 to 10.0)
        Tenderness at injection site:Moderate(n=1314,664)
    1.6 (1.0 to 2.4)
    1.7 (0.8 to 2.9)
        Tenderness at injection site:Severe (n= 1314,664)
    0.1 (0.0 to 0.4)
    0 (0.0 to 0.6)
        Tenderness at injection site: G4 (n= 1314,664)
    0 (0.0 to 0.3)
    0 (0.0 to 0.6)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=6 Months to <2 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=6 Months to <2 Years of age [67]
    End point description
    Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where,1 mdu =0.5 cm and were graded as mild (>=0.5 to 2.0 cm), moderate (>2.0 to 7.0 cm), severe (>7.0 cm) & G4 (necrosis [redness and swelling] or exfoliative dermatitis [redness]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate(hurts if gently touched with crying), severe (causes limitation of limb movement) & G4 (ER visit or hospitalisation).G4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method. Safety population was used. ‘N=participants evaluable for this endpoint and ‘n=participants evaluable for the specified rows.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 3
    Notes
    [67] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age Phase 2/3: Placebo: 6 months to <2 years
    Number of subjects analysed
    459
    222
    Units: Percentage of participants
    number (confidence interval 95%)
        Redness: Any (n=459,222)
    7.2 (5.0 to 9.9)
    5.0 (2.5 to 8.7)
        Redness: Mild (n=459,222)
    5.0 (3.2 to 7.4)
    4.5 (2.2 to 8.1)
        Redness: Moderate (n=459,222)
    2.0 (0.9 to 3.7)
    0.5 (0.0 to 2.5)
        Redness: Severe (n=459,222)
    0.2 (0.0 to 1.2)
    0 (0.0 to 1.6)
        Redness: Grade 4 (n=459,222)
    0 (0.0 to 0.8)
    0 (0.0 to 1.6)
        Swelling: Any (n=459,222)
    3.3 (1.8 to 5.3)
    2.3 (0.7 to 5.2)
        Swelling: Mild (n=459,222)
    2.0 (0.9 to 3.7)
    2.3 (0.7 to 5.2)
        Swelling: Moderate (n=459,222)
    1.3 (0.5 to 2.8)
    0 (0.0 to 1.6)
        Swelling: Severe (n=459,222)
    0 (0.0 to 0.8)
    0 (0.0 to 1.6)
        Swelling: Grade 4 (n=459,222)
    0 (0.0 to 0.8)
    0 (0.0 to 1.6)
        Tenderness at injection site:Any (n=455,222)
    14.7 (11.6 to 18.3)
    9.9 (6.3 to 14.6)
        Tenderness at injection site:Mild (n=455,222)
    13.0 (10.0 to 16.4)
    8.6 (5.2 to 13.0)
        Tenderness at injection site: Moderate(n=455,222)
    1.8 (0.8 to 3.4)
    1.4 (0.3 to 3.9)
        Tenderness at injection site:Severe (n=455,222)
    0 (0.0 to 0.8)
    0 (0.0 to 1.6)
        Tenderness at injection site: G4 (n=455,222)
    0 (0.0 to 0.8)
    0 (0.0 to 1.6)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=6 Months to <2 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=6 Months to <2 Years of age [68]
    End point description
    Systemic events recorded in an e-diary & at unscheduled clinical assessments up to Day 7 after Dose 1. Fever: oral temperature >= 38.0 deg C; categorised as >=38.0 to 38.4 deg C,>38.4 to 38.9 deg C, >38.9 to 40.0 deg C & >40.0 deg C. Decreased appetite: mild (decreased interest in eating),moderate(decreased oral intake),severe(refusal to feed). Drowsiness: mild(increased or prolonged sleeping bouts),moderate(slightly subdued interfering with daily activity),severe(disabling;not interested in usual daily activity).Irritability:mild(easily consolable),moderate(requiring increased attention),severe(Inconsolable; crying cannot be comforted).G4 for all events: ER visit or hospitalisation & were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method. Safety population. N=participants evaluable for this endpoint & n=participants evaluable for specified rows.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 1
    Notes
    [68] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age Phase 2/3: Placebo: 6 months to <2 years
    Number of subjects analysed
    1439
    712
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever: >=38.0 (n=1439,712)
    7.2 (5.9 to 8.7)
    7.4 (5.6 to 9.6)
        Fever: 38.0 to 38.4 deg C (n=1439,712)
    3.4 (2.5 to 4.5)
    3.5 (2.3 to 5.1)
        Fever: >38.4 to 38.9 deg C (n=1439,712)
    2.2 (1.5 to 3.1)
    2.5 (1.5 to 4.0)
        Fever: >38.9 to 40.0 deg C (n=1439,712)
    1.5 (1.0 to 2.3)
    1.3 (0.6 to 2.4)
        Fever: >40.0 deg C (n=1439,712)
    0.1 (0.0 to 0.4)
    0.1 (0.0 to 0.8)
        Decreased appetite: Any (n=1425,706)
    22.7 (20.5 to 24.9)
    21.2 (18.3 to 24.5)
        Decreased appetite: Mild (n=1425,706)
    12.4 (10.7 to 14.2)
    12.0 (9.7 to 14.7)
        Decreased appetite: Moderate (n=1425,706)
    10.1 (8.6 to 11.8)
    8.9 (6.9 to 11.3)
        Decreased appetite: Severe (n=1425,706)
    0.2 (0.0 to 0.6)
    0.3 (0.0 to 1.0)
        Decreased appetite: Grade 4 (n=1425,706)
    0 (0.0 to 0.3)
    0 (0.0 to 0.5)
        Drowsiness: Any (n=1425,706)
    27.8 (25.5 to 30.2)
    30.0 (26.7 to 33.6)
        Drowsiness: Mild (n=1425,706)
    22.0 (19.8 to 24.2)
    22.7 (19.6 to 25.9)
        Drowsiness: Moderate (n=1425,706)
    5.6 (4.5 to 6.9)
    6.9 (5.2 to 9.1)
        Drowsiness: Severe (n=1425,706)
    0.2 (0.0 to 0.6)
    0.4 (0.1 to 1.2)
        Drowsiness: Grade 4 (n=1425,706)
    0 (0.0 to 0.3)
    0 (0.0 to 0.5)
        Irritability: Any (n=1425,706)
    51.0 (48.4 to 53.6)
    48.2 (44.4 to 51.9)
        Irritability: Mild (n=1425,706)
    20.6 (18.6 to 22.8)
    18.3 (15.5 to 21.3)
        Irritability: Moderate (n=1425,706)
    29.7 (27.3 to 32.1)
    29.6 (26.3 to 33.1)
        Irritability: Severe (n=1425,706)
    0.7 (0.3 to 1.3)
    0.3 (0.0 to 1.0)
        Irritability: Grade 4 (n=1425,706)
    0 (0.0 to 0.3)
    0 (0.0 to 0.5)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=6 Months to <2 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=6 Months to <2 Years of age [69]
    End point description
    Systemic events recorded in an e-diary & at unscheduled clinical assessments up to Day 7 after Dose 2. Fever: oral temperature >= 38.0 deg C; categorised as >=38.0 to 38.4 deg C,>38.4 to 38.9 deg C, >38.9 to 40.0 deg C & >40.0 deg C. Decreased appetite: mild (decreased interest in eating),moderate(decreased oral intake),severe(refusal to feed). Drowsiness: mild(increased or prolonged sleeping bouts),moderate(slightly subdued interfering with daily activity),severe(disabling;not interested in usual daily activity).Irritability:mild(easily consolable),moderate(requiring increased attention),severe(Inconsolable; crying cannot be comforted).G4 for all events: ER visit or hospitalisation & were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method. Safety population. N=participants evaluable for this endpoint & n=participants evaluable for specified rows.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 2
    Notes
    [69] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age Phase 2/3: Placebo: 6 months to <2 years
    Number of subjects analysed
    1322
    666
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever: >=38.0 (n=1322,666)
    7.6 (6.3 to 9.2)
    6.5 (4.7 to 8.6)
        Fever: 38.0 to 38.4 deg C (n=1322,666)
    3.6 (2.7 to 4.8)
    3.6 (2.3 to 5.3)
        Fever: >38.4 to 38.9 deg C (n=1322,666)
    2.0 (1.4 to 3.0)
    1.7 (0.8 to 2.9)
        Fever: >38.9 to 40.0 deg C (n=1322,666)
    1.9 (1.2 to 2.8)
    1.2 (0.5 to 2.4)
        Fever: >40.0 deg C (n=1322,666)
    0.1 (0.0 to 0.4)
    0 (0.0 to 0.6)
        Decreased appetite: Any (n=1314,664)
    22.5 (20.3 to 24.9)
    19.4 (16.5 to 22.6)
        Decreased appetite: Mild (n=1314,664)
    13.9 (12.1 to 15.9)
    11.3 (9.0 to 14.0)
        Decreased appetite: Moderate (n=1314,664)
    8.1 (6.7 to 9.8)
    8.0 (6.0 to 10.3)
        Decreased appetite: Severe (n=1314,664)
    0.5 (0.2 to 1.0)
    0.2 (0.0 to 0.8)
        Decreased appetite: Grade 4 (n=1314,664)
    0 (0.0 to 0.3)
    0 (0.0 to 0.6)
        Drowsiness: Any (n=1314,664)
    24.1 (21.8 to 26.5)
    21.4 (18.3 to 24.7)
        Drowsiness: Mild (n=1314,664)
    17.8 (15.8 to 20.0)
    16.9 (14.1 to 19.9)
        Drowsiness: Moderate (n=1314,664)
    6.0 (4.8 to 7.4)
    4.4 (2.9 to 6.2)
        Drowsiness: Severe (n=1314,664)
    0.3 (0.1 to 0.8)
    0.2 (0.0 to 0.8)
        Drowsiness: Grade 4 (n=1314,664)
    0 (0.0 to 0.3)
    0 (0.0 to 0.6)
        Irritability: Any (n=1314,664)
    46.9 (44.2 to 49.6)
    41.4 (37.6 to 45.3)
        Irritability: Mild (n=1314,664)
    18.5 (16.4 to 20.7)
    15.8 (13.1 to 18.8)
        Irritability: Moderate (n=1314,664)
    27.8 (25.4 to 30.3)
    24.7 (21.5 to 28.2)
        Irritability: Severe (n=1314,664)
    0.6 (0.3 to 1.2)
    0.9 (0.3 to 2.0)
        Irritability: Grade 4 (n=1314,664)
    0 (0.0 to 0.3)
    0 (0.0 to 0.6)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=6 Months to <2 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=6 Months to <2 Years of age [70]
    End point description
    Systemic events recorded in an e-diary & at unscheduled clinical assessments up to Day 7 after Dose 3. Fever: oral temperature >= 38.0 deg C; categorised as >=38.0 to 38.4 deg C,>38.4 to 38.9 deg C, >38.9 to 40.0 deg C & >40.0 deg C. Decreased appetite: mild (decreased interest in eating),moderate(decreased oral intake),severe(refusal to feed). Drowsiness: mild(increased or prolonged sleeping bouts),moderate(slightly subdued interfering with daily activity),severe(disabling;not interested in usual daily activity).Irritability:mild(easily consolable),moderate(requiring increased attention),severe(Inconsolable; crying cannot be comforted).G4 for all events: ER visit or hospitalisation & were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method. Safety population. N=participants evaluable for this endpoint & n=participants evaluable for specified rows.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 7 after Dose 3
    Notes
    [70] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age Phase 2/3: Placebo: 6 months to <2 years
    Number of subjects analysed
    459
    222
    Units: Percentage of participants
    number (confidence interval 95%)
        Fever:>=38.0 (n=459,222)
    6.1 (4.1 to 8.7)
    5.9 (3.2 to 9.8)
        Fever:38.0 to 38.4 deg C (n=459,222)
    3.3 (1.8 to 5.3)
    3.2 (1.3 to 6.4)
        Fever: >38.4 to 38.9 deg C (n=459,222)
    1.3 (0.5 to 2.8)
    1.8 (0.5 to 4.5)
        Fever: >38.9 to 40.0 deg C (n=459,222)
    1.1 (0.4 to 2.5)
    0.9 (0.1 to 3.2)
        Fever: >40.0 deg C (n=459,222)
    0.4 (0.1 to 1.6)
    0 (0.0 to 1.6)
        Decreased appetite: Any (n=455,222)
    19.6 (16.0 to 23.5)
    13.1 (8.9 to 18.2)
        Decreased appetite: Mild (n=455,222)
    11.2 (8.5 to 14.5)
    7.2 (4.2 to 11.4)
        Decreased appetite: Moderate (n=455,222)
    7.5 (5.2 to 10.3)
    5.9 (3.2 to 9.8)
        Decreased appetite: Severe (n=455,222)
    0.9 (0.2 to 2.2)
    0 (0.0 to 1.6)
        Decreased appetite: Grade 4 (n=455,222)
    0 (0.0 to 0.8)
    0 (0.0 to 1.6)
        Drowsiness: Any (n=455,222)
    21.5 (17.8 to 25.6)
    12.2 (8.2 to 17.2)
        Drowsiness: Mild (n=455,222)
    15.8 (12.6 to 19.5)
    9.0 (5.6 to 13.6)
        Drowsiness: Moderate (n=455,222)
    5.3 (3.4 to 7.7)
    2.7 (1.0 to 5.8)
        Drowsiness: Severe (n=455,222)
    0.4 (0.1 to 1.6)
    0.5 (0.0 to 2.5)
        Drowsiness: Grade 4 (n=455,222)
    0 (0.0 to 0.8)
    0 (0.0 to 1.6)
        Irritability: Any (n=455,222)
    42.0 (37.4 to 46.7)
    36.9 (30.6 to 43.7)
        Irritability: Mild (n=455,222)
    15.8 (12.6 to 19.5)
    15.3 (10.8 to 20.7)
        Irritability: Moderate (n=455,222)
    25.7 (21.8 to 30.0)
    21.6 (16.4 to 27.6)
        Irritability: Severe (n=455,222)
    0.4 (0.1 to 1.6)
    0 (0.0 to 1.6)
        Irritability: Grade 4 (n=455,222)
    0 (0.0 to 0.8)
    0 (0.0 to 1.6)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=5 to <12 Years of age [71]
    End point description
    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 1 to 1 month after dose 2 were reported in this endpoint. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this endpoint. Safety population included all participants who received at least 1 dose of the study intervention.
    End point type
    Primary
    End point timeframe
    From Dose 1 to 1 month after Dose 2
    Notes
    [71] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age Phase 2/3: Placebo: 5 to <12 years of age
    Number of subjects analysed
    3109
    1538
    Units: Percentage of participants
        number (confidence interval 95%)
    10.7 (9.6 to 11.9)
    9.8 (8.3 to 11.3)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=5 to <12 Years of age [72]
    End point description
    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 3 to 1 month after dose 3 were reported in this endpoint. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this endpoint. Safety population included all participants who received at least 1 dose of the study intervention.‘N’ signifies participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    From Dose 3 to 1 month after Dose 3
    Notes
    [72] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age
    Number of subjects analysed
    2408
    Units: Percentage of participants
        number (confidence interval 95%)
    8.0 (7.0 to 9.2)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : >=5 to <12 Years of age [73]
    End point description
    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalisation or prolongation of existing hospitalisation, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Safety population included all participants who received at least 1 dose of the study intervention. ‘N’ signifies participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    From Dose 1 to 6 months after Dose 2
    Notes
    [73] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age Phase 2/3: Placebo: 5 to <12 years of age
    Number of subjects analysed
    3109
    1538
    Units: Percentage of participants
        number (confidence interval 95%)
    0.3 (0.1 to 0.5)
    0.1 (0.0 to 0.5)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=5 to <12 Years of age [74]
    End point description
    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalisation or prolongation of existing hospitalisation, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Safety population included all participants who received at least 1 dose of the study intervention.‘N’ signifies participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    From Dose 3 to 6 months after Dose 3 (Approximately 6 months)
    Notes
    [74] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age
    Number of subjects analysed
    2408
    Units: Percentage of participants
        number (confidence interval 95%)
    0.4 (0.2 to 0.8)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=2 to <5 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=2 to <5 Years of age [75]
    End point description
    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 1 to 1 month after dose 2 were reported in this endpoint. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this endpoint. Safety population included all participants who received at least 1 dose of the study intervention.‘N’ signifies participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    From Dose 1 to 1 month after Dose 2
    Notes
    [75] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age Phase 2/3: Placebo: 2 to <5 years of age
    Number of subjects analysed
    2350
    1173
    Units: Percentage of participants
        number (confidence interval 95%)
    13.1 (11.8 to 14.6)
    13.0 (11.1 to 15.0)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3:>=2 to <5 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3:>=2 to <5 Years of age [76]
    End point description
    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 3 to 1 month after dose 3 were reported in this endpoint. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this endpoint. Safety population included all participants who received at least 1 dose of the study intervention.‘N’ signifies participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    From Dose 3 to 1 month after Dose 3
    Notes
    [76] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age Phase 2/3: Placebo: 2 to <5 years of age
    Number of subjects analysed
    863
    405
    Units: Percentage of participants
        number (confidence interval 95%)
    4.5 (3.2 to 6.1)
    6.4 (4.2 to 9.3)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=2 to <5 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=2 to <5 Years of age [77]
    End point description
    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalisation or prolongation of existing hospitalisation, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Safety population included all participants who received at least 1 dose of the study intervention. ‘N’ signifies participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    From Dose 1 to 6 months after Dose 2
    Notes
    [77] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age Phase 2/3: Placebo: 2 to <5 years of age
    Number of subjects analysed
    2350
    1173
    Units: Percentage of participants
        number (confidence interval 95%)
    0.5 (0.2 to 0.8)
    0.9 (0.4 to 1.6)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3:>=2 to <5 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3:>=2 to <5 Years of age [78]
    End point description
    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalisation or prolongation of existing hospitalisation, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Safety population included all participants who received at least 1 dose of the study intervention. ‘N’ signifies participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    From Dose 3 to 6 months after Dose 3 (Approximately 6 months)
    Notes
    [78] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age Phase 2/3: Placebo: 2 to <5 years of age
    Number of subjects analysed
    863
    405
    Units: Percentage of participants
        number (confidence interval 95%)
    0.3 (0.1 to 1.0)
    0 (0.0 to 0.9)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2 : >=6 Months to <2 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2 : >=6 Months to <2 Years of age [79]
    End point description
    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 1 to 1 month after dose 2 were reported in this endpoint. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this endpoint. Safety population included all participants who received at least 1 dose of the study intervention.‘N’ signifies participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    From Dose 1 to 1 month after Dose 2
    Notes
    [79] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age Phase 2/3: Placebo: 6 months to <2 years
    Number of subjects analysed
    1447
    718
    Units: Percentage of participants
        number (confidence interval 95%)
    21.5 (19.4 to 23.7)
    19.9 (17.1 to 23.0)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3 : >=6 Months to <2 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3 : >=6 Months to <2 Years of age [80]
    End point description
    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 3 to 1 month after dose 3 were reported in this endpoint. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this endpoint. Safety population included all participants who received at least 1 dose of the study intervention.‘N’ signifies participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    From Dose 3 to 1 month after Dose 3
    Notes
    [80] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age Phase 2/3: Placebo: 6 months to <2 years
    Number of subjects analysed
    483
    237
    Units: Percentage of participants
        number (confidence interval 95%)
    10.4 (7.8 to 13.4)
    7.6 (4.6 to 11.7)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : >=6 Months to <2 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : >=6 Months to <2 Years of age [81]
    End point description
    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalisation or prolongation of existing hospitalisation, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Safety population included all participants who received at least 1 dose of the study intervention. ‘N’ signifies participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    From Dose 1 to 6 months after Dose 2
    Notes
    [81] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age Phase 2/3: Placebo: 6 months to <2 years
    Number of subjects analysed
    1447
    718
    Units: Percentage of participants
        number (confidence interval 95%)
    1.7 (1.1 to 2.5)
    2.4 (1.4 to 3.8)
    No statistical analyses for this end point

    Primary: Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3 : >=6 Months to <2 Years of age

    Close Top of page
    End point title
    Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3 : >=6 Months to <2 Years of age [82]
    End point description
    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalisation or prolongation of existing hospitalisation, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Safety population included all participants who received at least 1 dose of the study intervention. ‘N’ signifies participants evaluable for this endpoint.
    End point type
    Primary
    End point timeframe
    From Dose 3 to 6 months after Dose 3 (Approximately 6 months)
    Notes
    [82] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was planned to be analysed only for the specified reporting arms.
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age Phase 2/3: Placebo: 6 months to <2 years
    Number of subjects analysed
    483
    237
    Units: Percentage of participants
        number (confidence interval 95%)
    0.2 (0.0 to 1.1)
    0 (0.0 to 1.5)
    No statistical analyses for this end point

    Primary: Phase 2/3: Geometric Mean Ratio (GMR) for SARS-CoV-2 Neutralizing Titers in Participants >=5 to <12 Years of age to Participants 16 to 25 Years of age From Phase 2/3 of the C4591001 Study:1 Month After Dose 2:Participants Without Evidence of Infection

    Close Top of page
    End point title
    Phase 2/3: Geometric Mean Ratio (GMR) for SARS-CoV-2 Neutralizing Titers in Participants >=5 to <12 Years of age to Participants 16 to 25 Years of age From Phase 2/3 of the C4591001 Study:1 Month After Dose 2:Participants Without Evidence of Infection
    End point description
    GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of the logarithm of the titers and the corresponding CIs(based on student t distribution).Assay results below the lower limit of quantitation(LLOQ))were set to 0.5*LLOQ.Results include those from a comparator group of C4591001(NCT04368728)Phase 2/3 participants of the age 16 to 25 years who received 2 doses of original BNT162b2 30 mcg who had no serological or virological evidence of past SARS-CoV-2 infection and had no medical history of COVID-19 were also included.Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised,had a valid and determinate immunogenicity result within 28-42 days after the study vaccination,and had no other important protocol deviations as determined by the clinician.N=participants evaluable.GMT is reported in descriptive analysis & GMR is reported under statistical analysis.
    End point type
    Primary
    End point timeframe
    C4591007 (>=5 to <12 years):1 month after Dose 2 and C4591001 control arm (16-25 years):1 month after Dose 2
    End point values
    Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age Historical cohort:C4591001 BNT162b2(30 mcg)16 Through 25 Years
    Number of subjects analysed
    264
    253
    Units: Titers
        geometric mean (confidence interval 95%)
    1197.6 (1106.1 to 1296.6)
    1146.5 (1045.5 to 1257.2)
    Statistical analysis title
    Geometric Mean Ratio
    Statistical analysis description
    Phase 2/3: Geometric Mean Ratio for SARS-CoV-2 Neutralizing Titers in Participants >=5 to <12 Years of age to Participants 16 to 25 Years of age from Phase 2/3 of the C4591001 Study : 1 Month after Dose 2
    Comparison groups
    Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age v Historical cohort:C4591001 BNT162b2(30 mcg)16 Through 25 Years
    Number of subjects included in analysis
    517
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Geometric mean ratio
    Point estimate
    1.04
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.93
         upper limit
    1.18

    Primary: Phase 2/3: Difference in Percentage of Participants who Achieved Seroresponse in >=5 to <12 Years of age and 16 to 25 Years of age From Phase 2/3 of the C4591001 Study : 1 Month After Dose 2: Participants Without Evidence of Infection

    Close Top of page
    End point title
    Phase 2/3: Difference in Percentage of Participants who Achieved Seroresponse in >=5 to <12 Years of age and 16 to 25 Years of age From Phase 2/3 of the C4591001 Study : 1 Month After Dose 2: Participants Without Evidence of Infection
    End point description
    Seroresponse is defined as achieving a >=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination >=4*LLOQ is considered a seroresponse.Results include those from a comparator group of C4591001(NCT04368728)Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.'N'=participants evaluable for this endpoint. Percentage of participants with seroresponse is reported in descriptive analysis and the difference in percentage of participants is reported under statistical analysis.
    End point type
    Primary
    End point timeframe
    C4591007 (>=5 to <12 years):1 month after Dose 2 and C4591001 control arm (16-25 years):1 month after Dose 2
    End point values
    Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age Historical cohort:C4591001 BNT162b2(30 mcg)16 Through 25 Years
    Number of subjects analysed
    264
    253
    Units: Percentage of participants
        number (confidence interval 95%)
    99.2 (97.3 to 99.9)
    99.2 (97.2 to 99.9)
    Statistical analysis title
    Difference in Percentages
    Statistical analysis description
    Difference in Percentages of Participants With Seroresponse – Participants Without Evidence of Infection up to 1 Month After Dose 2 – Immunobridging Subset – Phase 2/3 – Comparison of 5 to <12 Years of Age to Study C4591001 Phase 2/3 – 16 Through 25 Years of Age
    Comparison groups
    Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age v Historical cohort:C4591001 BNT162b2(30 mcg)16 Through 25 Years
    Number of subjects included in analysis
    517
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Difference in percentage
    Point estimate
    0
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -2
         upper limit
    2.2

    Primary: Phase 2/3: GMR for SARS-CoV-2 Neutralizing Titers in Participants >=2 to <5 Years of age to Participants 16 to 25 Years of age From Phase 2/3 of the C4591001 Study : 1 Month After Dose 2: Participants Without Evidence of Infection

    Close Top of page
    End point title
    Phase 2/3: GMR for SARS-CoV-2 Neutralizing Titers in Participants >=2 to <5 Years of age to Participants 16 to 25 Years of age From Phase 2/3 of the C4591001 Study : 1 Month After Dose 2: Participants Without Evidence of Infection
    End point description
    GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of the logarithm of the titers and the corresponding CIs(based on student t distribution).Assay results below the lower limit of quantitation(LLOQ))were set to 0.5*LLOQ.Results include those from a comparator group of C4591001(NCT04368728)Phase 2/3 participants of the age 16 to 25 years who received 2 doses of original BNT162b2 30 mcg who had no serological or virological evidence of past SARS-CoV-2 infection and had no medical history of COVID-19 were also included.Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised,had a valid and determinate immunogenicity result within 28-42 days after the study vaccination,and had no other important protocol deviations as determined by the clinician.N=participants evaluable.GMT is reported in descriptive analysis & GMR is reported under statistical analysis.
    End point type
    Primary
    End point timeframe
    C4591007 (>=2 to <5 years):1 month after Dose 2 and C4591001 control arm (16-25 years):1 month after Dose 2
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age Historical cohort:C4591001 BNT162b2(30 mcg)16 Through 25 Years
    Number of subjects analysed
    243
    252
    Units: Titers
        geometric mean (confidence interval 95%)
    763.9 (688.5 to 847.5)
    1255.4 (1131.2 to 1393.3)
    Statistical analysis title
    Geometric Mean Ratio
    Statistical analysis description
    Geometric Mean Ratio for SARS-CoV-2 Neutralizing Titers in Participants >=2 to <5 Years of age to Participants 16 to 25 Years of age from Phase 2/3 of the C4591001 study : at 1 Month after Dose- 2 Phase 2/3
    Comparison groups
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age v Historical cohort:C4591001 BNT162b2(30 mcg)16 Through 25 Years
    Number of subjects included in analysis
    495
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Geometric mean ratio
    Point estimate
    0.61
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.53
         upper limit
    0.7

    Primary: Phase 2/3: Difference in Percentage of Participants who Achieved Seroresponse in >=2 to <5 Years of age and 16 to 25 Years of age From Phase 2/3 of the C4591001 Study : 1 Month After Dose 2: Participants Without Evidence of Infection

    Close Top of page
    End point title
    Phase 2/3: Difference in Percentage of Participants who Achieved Seroresponse in >=2 to <5 Years of age and 16 to 25 Years of age From Phase 2/3 of the C4591001 Study : 1 Month After Dose 2: Participants Without Evidence of Infection
    End point description
    Seroresponse is defined as achieving a >=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination >=4*LLOQ is considered a seroresponse.Results include those from a comparator group of C4591001(NCT04368728)Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.'N'=participants evaluable for this endpoint. Percentage of participants with seroresponse is reported in descriptive analysis and the difference in percentage of participants is reported under statistical analysis.
    End point type
    Primary
    End point timeframe
    C4591007 (>=2 to <5 years):1 month after Dose 2 and C4591001 control arm (16-25 years):1 month after Dose 2
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age Historical cohort:C4591001 BNT162b2(30 mcg)16 Through 25 Years
    Number of subjects analysed
    243
    251
    Units: Percentage of Participants
        number (confidence interval 95%)
    96.7 (93.6 to 98.6)
    97.6 (94.9 to 99.1)
    Statistical analysis title
    Difference in Percentage
    Statistical analysis description
    Phase 2/3: Difference in Percentage of Participants who Achieved Seroresponse in >=2 to <5 Years of age and 16 to 25 Years of age from Phase 2/3 of the C4591001 study : 1 Month after Dose 2
    Comparison groups
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age v Historical cohort:C4591001 BNT162b2(30 mcg)16 Through 25 Years
    Number of subjects included in analysis
    494
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Difference in Percentage
    Point estimate
    -0.9
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -4.3
         upper limit
    2.3

    Primary: Phase 2/3: GMR for SARS-CoV-2 Neutralizing Titers in Participants >=6 Months to <2 Years of age to Participants 16 to 25 Years of age From Phase 2/3 of the C4591001 Study : 1 Month After Dose 2: Participants Without Evidence of Infection

    Close Top of page
    End point title
    Phase 2/3: GMR for SARS-CoV-2 Neutralizing Titers in Participants >=6 Months to <2 Years of age to Participants 16 to 25 Years of age From Phase 2/3 of the C4591001 Study : 1 Month After Dose 2: Participants Without Evidence of Infection
    End point description
    GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of the logarithm of the titers and the corresponding CIs(based on student t distribution).Assay results below the lower limit of quantitation(LLOQ))were set to 0.5*LLOQ.Results include those from a comparator group of C4591001(NCT04368728)Phase 2/3 participants of the age 16 to 25 years who received 2 doses of original BNT162b2 30 mcg who had no serological or virological evidence of past SARS-CoV-2 infection and had no medical history of COVID-19 were also included.Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised,had a valid and determinate immunogenicity result within 28-42 days after the study vaccination,and had no other important protocol deviations as determined by the clinician.N=participants evaluable.GMT is reported in descriptive analysis & GMR is reported under statistical analysis.
    End point type
    Primary
    End point timeframe
    C4591007 (>=6 months to <2 years):1 month after Dose 2 and C4591001 control arm (16-25 years):1 month after Dose 2
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age Historical cohort:C4591001 BNT162b2(30 mcg)16 Through 25 Years
    Number of subjects analysed
    245
    238
    Units: Titers
        geometric mean (confidence interval 95%)
    979.7 (893.2 to 1074.6)
    946.8 (850.8 to 1053.7)
    Statistical analysis title
    Geometric Mean Ratio
    Statistical analysis description
    Phase 2/3: Geometric Mean Ratio for SARS-CoV-2 Neutralizing Titers in Participants >=6 Months to <2 Years of age to Participants 16 to 25 Years of age from Phase 2/3 of the C4591001 study : at 1 Month after Dose 2
    Comparison groups
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age v Historical cohort:C4591001 BNT162b2(30 mcg)16 Through 25 Years
    Number of subjects included in analysis
    483
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Geometric Mean Ratio
    Point estimate
    1.03
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.9
         upper limit
    1.19

    Primary: Phase 2/3: Difference in Percentage of Participants who Achieved Seroresponse in >=6 Months to <2 Years of age and 16 to 25 Years of age From Phase 2/3 of the C4591001 Study: 1 Month After Dose 2: Participants Without Evidence of Infection

    Close Top of page
    End point title
    Phase 2/3: Difference in Percentage of Participants who Achieved Seroresponse in >=6 Months to <2 Years of age and 16 to 25 Years of age From Phase 2/3 of the C4591001 Study: 1 Month After Dose 2: Participants Without Evidence of Infection
    End point description
    Seroresponse is defined as achieving a >=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination >=4*LLOQ is considered a seroresponse.Results include those from a comparator group of C4591001(NCT04368728)Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.'N'=participants evaluable for this endpoint. Percentage of participants with seroresponse is reported in descriptive analysis and the difference in percentage of participants is reported under statistical analysis.
    End point type
    Primary
    End point timeframe
    C4591007 (>=6 months to <2 years):1 month after Dose 2 and C4591001 control arm (16-25 years):1 month after Dose 2
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age Historical cohort:C4591001 BNT162b2(30 mcg)16 Through 25 Years
    Number of subjects analysed
    245
    238
    Units: Percentage of Participants
        number (confidence interval 95%)
    98.0 (95.3 to 99.3)
    96.2 (92.9 to 98.3)
    Statistical analysis title
    Difference in Percentage
    Statistical analysis description
    Phase 2/3: Difference in Percentage of Participants who Achieved Seroresponse in >=6 Months to <2 Years of age and 16 to 25 Years of age from Phase 2/3 of the C4591001 study : 1 Month after Dose 2
    Comparison groups
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age v Historical cohort:C4591001 BNT162b2(30 mcg)16 Through 25 Years
    Number of subjects included in analysis
    483
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Difference in Percentage
    Point estimate
    1.7
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.4
         upper limit
    5.2

    Primary: Phase 2/3:GMR for SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 3 in Participants Aged >=2 to <5 Years to Those at 1 Month After Dose 2 in Participants Aged 16 to 25 Years From Phase 2/3 of C4591001 Study:Participants Without Evidence of Infection

    Close Top of page
    End point title
    Phase 2/3:GMR for SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 3 in Participants Aged >=2 to <5 Years to Those at 1 Month After Dose 2 in Participants Aged 16 to 25 Years From Phase 2/3 of C4591001 Study:Participants Without Evidence of Infection
    End point description
    GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of the logarithm of the titers and the corresponding CIs(based on student t distribution).Assay results below the lower limit of quantitation(LLOQ))were set to 0.5*LLOQ.Results include those from a comparator group of C4591001(NCT04368728)Phase 2/3 participants of the age 16 to 25 years who received 2 doses of original BNT162b2 30 mcg who had no serological or virological evidence of past SARS-CoV-2 infection and had no medical history of COVID-19 were also included.Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised,had a valid and determinate immunogenicity result within 28-42 days after the study vaccination,and had no other important protocol deviations as determined by the clinician.N=participants evaluable.GMT is reported in descriptive analysis & GMR is reported under statistical analysis.
    End point type
    Primary
    End point timeframe
    C4591007 (>=2 to <5 years):1 month after Dose 2 and C4591001 control arm (16-25 years):1 month after Dose 2
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age Historical cohort:C4591001 BNT162b2(30 mcg)16 Through 25 Years
    Number of subjects analysed
    143
    170
    Units: Titers
        geometric mean (confidence interval 95%)
    1535.2 (1388.2 to 1697.8)
    1180.0 (1066.6 to 1305.4)
    Statistical analysis title
    Geometric Mean Ratio
    Statistical analysis description
    Phase 2/3: Geometric Mean Ratio for SARS-CoV-2 Neutralizing Titers at 1 Month after dose 3 in Participants >=2 to <5 Years of age to those at 1 month after Dose 2 in participants 16 to 25 years of age from Phase 2/3 of the C4591001 study
    Comparison groups
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age v Historical cohort:C4591001 BNT162b2(30 mcg)16 Through 25 Years
    Number of subjects included in analysis
    313
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Geometric Mean Ratio
    Point estimate
    1.3
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    1.13
         upper limit
    1.5

    Primary: Phase 2/3:Difference in Percentage of Participants With Seroresponse in 2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 Through 25 Years of Age: Participants Without Evidence of Infection

    Close Top of page
    End point title
    Phase 2/3:Difference in Percentage of Participants With Seroresponse in 2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 Through 25 Years of Age: Participants Without Evidence of Infection
    End point description
    Seroresponse is defined as achieving a >=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination >=4*LLOQ is considered a seroresponse.Results include those from a comparator group of C4591001(NCT04368728)Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.'N'=participants evaluable for this endpoint. Percentage of participants with seroresponse is reported in descriptive analysis and the difference in percentage of participants is reported under statistical analysis.
    End point type
    Primary
    End point timeframe
    C4591007 (>=2 to <5 years):1 month after Dose 3 and C4591001 control arm (16-25 years):1 month after Dose 2
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age Historical cohort:C4591001 BNT162b2(30 mcg)16 Through 25 Years
    Number of subjects analysed
    141
    170
    Units: Percentage of participants
        number (confidence interval 95%)
    100.0 (97.4 to 100.0)
    98.8 (95.8 to 99.9)
    Statistical analysis title
    Difference in Percentages
    Statistical analysis description
    Phase 2/3: Difference in Percentages of Participants With Seroresponse – Participants Without Evidence of Infection – Immunobridging Subset – Comparison of Study C4591007 Phase 2/3 2 to <5 Years of Age (1 Month After Dose 3) and Study C4591001 Phase 2/3 16 Through 25 Years of Age (1 Month After Dose 2)
    Comparison groups
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age v Historical cohort:C4591001 BNT162b2(30 mcg)16 Through 25 Years
    Number of subjects included in analysis
    311
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Difference in Percentages
    Point estimate
    1.2
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.5
         upper limit
    4.2

    Primary: Phase 2/3:GMR for SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 3 in Participants Aged 6 Months to 2 Years to Those at 1 Month After Dose 3 in Participants Aged 16 to 25 Years From Phase 2/3 of C4591001:Participants Without Evidence of Infection

    Close Top of page
    End point title
    Phase 2/3:GMR for SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 3 in Participants Aged 6 Months to 2 Years to Those at 1 Month After Dose 3 in Participants Aged 16 to 25 Years From Phase 2/3 of C4591001:Participants Without Evidence of Infection
    End point description
    GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of the logarithm of the titers and the corresponding CIs(based on student t distribution).Assay results below the lower limit of quantitation(LLOQ))were set to 0.5*LLOQ.Results include those from a comparator group of C4591001(NCT04368728)Phase 2/3 participants of the age 16 to 25 years who received 2 doses of original BNT162b2 30 mcg who had no serological or virological evidence of past SARS-CoV-2 infection and had no medical history of COVID-19 were also included.Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised,had a valid and determinate immunogenicity result within 28-42 days after the study vaccination,and had no other important protocol deviations as determined by the clinician.N=participants evaluable.GMT is reported in descriptive analysis & GMR is reported under statistical analysis.
    End point type
    Primary
    End point timeframe
    C4591007 (>=2 to <5 years):1 month after Dose 3 and C4591001 control arm (16-25 years):1 month after Dose 2
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age Historical cohort:C4591001 BNT162b2(30 mcg)16 Through 25 Years
    Number of subjects analysed
    82
    170
    Units: Titers
        geometric mean (confidence interval 95%)
    1406.5 (1211.3 to 1633.1)
    1180.0 (1066.6 to 1305.4)
    Statistical analysis title
    Geometric Mean Ratio
    Statistical analysis description
    Phase 2/3: Geometric Mean Ratio for SARS-CoV-2 Neutralizing Titers at 1 Month after dose 3 in Participants 6 Months to <2 Years of age to those at 1 month after Dose 3 in participants 16 to 25 years of age from Phase 2/3 of the C4591001 study
    Comparison groups
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age v Historical cohort:C4591001 BNT162b2(30 mcg)16 Through 25 Years
    Number of subjects included in analysis
    252
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Geometric mean ratio
    Point estimate
    1.19
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    1
         upper limit
    1.42

    Primary: Phase 2/3:Difference in Percentage of Participants With Seroresponse in 6 Months to <2 Years (1 Month After Dose 3) Compared With Study C4591001 Phase 2/3 16 Through 25 Years (1 Month After Dose 2): Participants Without Evidence of Infection

    Close Top of page
    End point title
    Phase 2/3:Difference in Percentage of Participants With Seroresponse in 6 Months to <2 Years (1 Month After Dose 3) Compared With Study C4591001 Phase 2/3 16 Through 25 Years (1 Month After Dose 2): Participants Without Evidence of Infection
    End point description
    Seroresponse is defined as achieving a >=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination >=4*LLOQ is considered a seroresponse.Results include those from a comparator group of C4591001(NCT04368728)Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.'N'=participants evaluable for this endpoint. Percentage of participants with seroresponse is reported in descriptive analysis and the difference in percentage of participants is reported under statistical analysis.
    End point type
    Primary
    End point timeframe
    C4591007 (>=6 months to <2 years):1 month after Dose 3 and C4591001 control arm (16-25 years):1 month after Dose 2
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age Historical cohort:C4591001 BNT162b2(30 mcg)16 Through 25 Years
    Number of subjects analysed
    80
    170
    Units: Percentage of participants
        number (confidence interval 95%)
    100.0 (95.5 to 100.0)
    98.8 (95.8 to 99.9)
    Statistical analysis title
    Difference in Percentages
    Statistical analysis description
    Phase 2/3: Difference in Percentages of Participants With Seroresponse – Participants Without Evidence of Infection – Immunobridging Subset – Comparison of Study C4591007 Phase 2/3 6 Months to <2 Years of Age (1 Month After Dose 3) and Study C4591001 Phase 2/3 16 Through 25 Years of Age (1 Month After Dose 2) – Evaluable Immunogenicity Population
    Comparison groups
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age v Historical cohort:C4591001 BNT162b2(30 mcg)16 Through 25 Years
    Number of subjects included in analysis
    250
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Difference in percentage
    Point estimate
    1.2
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3.4
         upper limit
    4.2

    Secondary: Phase 1: GMTs of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titers at 7 Days After Dose 2: >=2 to <5 Years of age: Participants Without Evidence of Infection

    Close Top of page
    End point title
    Phase 1: GMTs of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titers at 7 Days After Dose 2: >=2 to <5 Years of age: Participants Without Evidence of Infection
    End point description
    GMT of SARS-CoV-2 neutralizing titers after the study vaccination was reported in this endpoint. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs(based on Student's t distribution).Assay results below the LLOQ were set to 0.5*LLOQ. Evaluable Immunogenicity Population consisted of all eligible randomized participants who received 2 doses with the same dose level to which they were randomized, with Dose 2 received within the predefined window, had at least 1 valid and determinate immunogenicity result after Dose 2 from the blood sample collected within an appropriate window after Dose 2(within 6-8 days after Dose 2 for Phase 1), and had no other important protocol deviations as determined by the clinician.Participants without evidence of prior infection were included in the analysis.'N'=participants evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    Day 7 post Dose 2
    End point values
    Phase 1: BNT162b2 (3 mcg): 2 to <5 years of age Phase 1: BNT162b2 (10 mcg): 2 to <5 years of age
    Number of subjects analysed
    13
    29
    Units: Titers
        geometric mean (confidence interval 95%)
    1350.4 (973.1 to 1873.9)
    2059.5 (1679.1 to 2526.0)
    No statistical analyses for this end point

    Secondary: Phase 1: Geometric Mean Titers (GMTs) of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titers at 7 Days After Dose 2: >=6 Months to <2 Years of age: Participants Without Evidence of Infection

    Close Top of page
    End point title
    Phase 1: Geometric Mean Titers (GMTs) of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titers at 7 Days After Dose 2: >=6 Months to <2 Years of age: Participants Without Evidence of Infection
    End point description
    GMT of SARS-CoV-2 neutralizing titers after the study vaccination was reported in this endpoint. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs(based on Student's t distribution).Assay results below the LLOQ were set to 0.5*LLOQ. Evaluable Immunogenicity Population consisted of all eligible randomized participants who received 2 doses with the same dose level to which they were randomized, with Dose 2 received within the predefined window, had at least 1 valid and determinate immunogenicity result after Dose 2 from the blood sample collected within an appropriate window after Dose 2(within 6-8 days after Dose 2 for Phase 1), and had no other important protocol deviations as determined by the clinician.Participants without evidence of prior infection were included in the analysis.'N'=participants evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    Day 7 post Dose 2
    End point values
    Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 years of age
    Number of subjects analysed
    13
    Units: Titers
        geometric mean (confidence interval 95%)
    1643.8 (1151.3 to 2347.1)
    No statistical analyses for this end point

    Secondary: Phase 1: GMTs of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titers at 7 Days After Dose 2: >=5 to <12 Years of age: Participants Without Evidence of Infection

    Close Top of page
    End point title
    Phase 1: GMTs of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titers at 7 Days After Dose 2: >=5 to <12 Years of age: Participants Without Evidence of Infection
    End point description
    GMT of SARS-CoV-2 neutralizing titers after the study vaccination was reported in this endpoint. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs(based on Student's t distribution).Assay results below the LLOQ were set to 0.5*LLOQ. Evaluable Immunogenicity Population consisted of all eligible randomized participants who received 2 doses with the same dose level to which they were randomized, with Dose 2 received within the predefined window, had at least 1 valid and determinate immunogenicity result after Dose 2 from the blood sample collected within an appropriate window after Dose 2(within 6-8 days after Dose 2 for Phase 1), and had no other important protocol deviations as determined by the clinician.Participants without evidence of prior infection were included in the analysis.'N'=participants evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    Day 7 post Dose 2
    End point values
    Phase 1: BNT162b2 (10 mcg): 5 to <12 years of age Phase 1: BNT162b2 (20 mcg): 5 to <12 years of age
    Number of subjects analysed
    15
    15
    Units: Titers
        geometric mean (confidence interval 95%)
    4162.6 (2584.7 to 6704.0)
    4583.4 (2802.9 to 7494.8)
    No statistical analyses for this end point

    Secondary: Phase 2/3: Geometric Mean Titers – NT50: Immunogenicity Set – 5 to <12 Years of Age: Dose 1 to 1 Month After Dose 2:Participants Without Evidence of Infection

    Close Top of page
    End point title
    Phase 2/3: Geometric Mean Titers – NT50: Immunogenicity Set – 5 to <12 Years of Age: Dose 1 to 1 Month After Dose 2:Participants Without Evidence of Infection
    End point description
    GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.'N'=participants evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    Pre-dose 1 and 1 month after Dose 2
    End point values
    Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age Phase 2/3: Placebo: 5 to <12 years of age
    Number of subjects analysed
    264
    130
    Units: Titers
    geometric mean (confidence interval 95%)
        Pre-dose 1
    10.1 (9.9 to 10.3)
    10.0 (10.0 to 10.0)
        1 month after Dose 2
    1197.6 (1106.1 to 1296.6)
    10.7 (9.7 to 11.8)
    No statistical analyses for this end point

    Secondary: Phase 2/3: Geometric Mean Titers – NT50: Immunogenicity Set – 5 to <12 Years of Age:Dose 3 and 1 Month After Dose 3 :Participants Without Evidence of Infection

    Close Top of page
    End point title
    Phase 2/3: Geometric Mean Titers – NT50: Immunogenicity Set – 5 to <12 Years of Age:Dose 3 and 1 Month After Dose 3 :Participants Without Evidence of Infection
    End point description
    GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5*LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.'N'=participants evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    Dose 3 set: Pre-dose 3 and 1 month after Dose 3
    End point values
    Phase 2/3: BNT162b2 (10 mcg) 3-Dose Set
    Number of subjects analysed
    67
    Units: Titers
    number (confidence interval 95%)
        Pre-dose 3
    271.0 (229.1 to 320.6)
        1 month after dose 3
    2720.9 (2280.1 to 3247.0)
    No statistical analyses for this end point

    Secondary: Phase 2/3: Geometric Mean Titers – NT50:2 to <5 Years of Age: Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3: Participants Without Evidence of Infection

    Close Top of page
    End point title
    Phase 2/3: Geometric Mean Titers – NT50:2 to <5 Years of Age: Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3: Participants Without Evidence of Infection
    End point description
    GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 *LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. 'N'=participants evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age Phase 2/3: Placebo: 2 to <5 years of age
    Number of subjects analysed
    143
    59
    Units: Titers
    number (confidence interval 95%)
        Pre-dose 1 (n=141, 57)
    20.7 (20.3 to 21.2)
    20.5 (20.5 to 20.5)
        Pre-dose 3 (n=143, 59)
    401.1 (361.7 to 444.7)
    20.9 (20.1 to 21.8)
        1 month after dose 3 (n=143, 59)
    1535.2 (1388.2 to 1697.8)
    22.9 (19.5 to 26.8)
    No statistical analyses for this end point

    Secondary: Phase 2/3: Geometric Mean Titers- NT50:6 Months to <2 Years of Age: Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3: Participants Without Evidence of Infection

    Close Top of page
    End point title
    Phase 2/3: Geometric Mean Titers- NT50:6 Months to <2 Years of Age: Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3: Participants Without Evidence of Infection
    End point description
    GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5*LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. 'N'=participants evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age Phase 2/3: Placebo: 6 months to <2 years
    Number of subjects analysed
    82
    49
    Units: Titer
    number (confidence interval 95%)
        Pre- dose 1 (80, 48)
    20.8 (20.2 to 21.5)
    20.5 (20.5 to 20.5)
        Pre-dose 3 (81, 49)
    317.0 (268.8 to 373.9)
    24.2 (19.7 to 29.8)
        1 Month After Dose 3 (82, 49)
    1406.5 (1211.3 to 1633.1)
    22.3 (18.8 to 26.4)
    No statistical analyses for this end point

    Secondary: Phase 2/3: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Titers From Dose 1 to 1 Month After Dose 2: >=5 to 12 Years of age: Participants Without Evidence of Infection

    Close Top of page
    End point title
    Phase 2/3: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Titers From Dose 1 to 1 Month After Dose 2: >=5 to 12 Years of age: Participants Without Evidence of Infection
    End point description
    GMFR of SARS-CoV-2 neutralizing titers from dose 1 to 1 month after dose 2 were reported in this endpoint. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Assay results below the LLOQ were set to 0.5* LLOQ in the analysis. Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.'N'=participants evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    From Dose 1 to 1 month after Dose 2
    End point values
    Phase 2/3: BNT162b2 (10 mcg): 5 to <12 years of age Phase 2/3: Placebo: 5 to <12 years of age
    Number of subjects analysed
    264
    130
    Units: Fold rise
        geometric mean (confidence interval 95%)
    118.2 (109.2 to 127.9)
    1.1 (1.0 to 1.2)
    No statistical analyses for this end point

    Secondary: Phase 2/3: GMFR of SARS-CoV-2 Neutralizing Titers From Before Dose 1 to Each Subsequent Time Point After Dose 3: >=2 to 5 Years of age: Participants Without Evidence of Infection

    Close Top of page
    End point title
    Phase 2/3: GMFR of SARS-CoV-2 Neutralizing Titers From Before Dose 1 to Each Subsequent Time Point After Dose 3: >=2 to 5 Years of age: Participants Without Evidence of Infection
    End point description
    GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs(based on the Student t distribution). Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection and had no medical history of COVID-19 infection.Assay results below the LLOQ were set to 0.5*LLOQ in the analysis.Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised,had a valid and determinate immunogenicity result within 28-42 days after the study vaccination,and had no other important protocol deviations as determined by the clinician.'N'=participants evaluable in this endpoint.
    End point type
    Secondary
    End point timeframe
    Pre-dose 3, 1 Month After Dose 3
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 2 to <5 years of age Phase 2/3: Placebo: 2 to <5 years of age
    Number of subjects analysed
    141
    57
    Units: Fold rise
    geometric mean (confidence interval 95%)
        Pre-dose 3
    19.2 (17.4 to 21.3)
    1.0 (1.0 to 1.0)
        1 month after Dose 3
    73.3 (66.3 to 81.1)
    1.1 (0.9 to 1.3)
    No statistical analyses for this end point

    Secondary: Phase 2/3:GMFR of SARS-CoV-2 Neutralizing Titers From Dose 3 to 1 Month After Dose 3: >=5 to 12 Years of age: Participants Without Evidence of Infection

    Close Top of page
    End point title
    Phase 2/3:GMFR of SARS-CoV-2 Neutralizing Titers From Dose 3 to 1 Month After Dose 3: >=5 to 12 Years of age: Participants Without Evidence of Infection
    End point description
    GMFR of SARS-CoV-2 neutralizing titers from before Dose 3 to 1 month after Dose were reported in this endpoint. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ in the analysis. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population included all eligible randomized participants who received the study interventions to which they were randomized, had a valid and determined immunogenicity result within 28-42 days after Dose 3, and had no other important protocol deviations as determined by the clinicians. 'N' = participants evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    Before dose 1 to 1 month after dose 2, pre-dose 3 and 1 month after dose 3
    End point values
    Phase 2/3: BNT162b2 (10 mcg) 3-Dose Set
    Number of subjects analysed
    67
    Units: Fold rise
        geometric mean (confidence interval 95%)
    10.0 (8.1 to 12.4)
    No statistical analyses for this end point

    Secondary: Phase 2/3: GMFR of SARS-CoV-2 Neutralizing Titers From Before Dose 1 to Each Subsequent Time Point After Dose 3: >=6 Months to 2 Years of age: Participants Without Evidence of Infection

    Close Top of page
    End point title
    Phase 2/3: GMFR of SARS-CoV-2 Neutralizing Titers From Before Dose 1 to Each Subsequent Time Point After Dose 3: >=6 Months to 2 Years of age: Participants Without Evidence of Infection
    End point description
    GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ in the analysis. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection prior to the 1-month post–Dose 2. Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. 'N'=participants evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    Pre-dose 3, 1 Month After Dose 3
    End point values
    Phase 2/3: BNT162b2 (3 mcg): 6 months to <2 years of age Phase 2/3: Placebo: 6 months to <2 years
    Number of subjects analysed
    80
    48
    Units: Fold rise
    geometric mean (confidence interval 95%)
        Pre-dose 3 (79,48)
    15.4 (12.9 to 18.3)
    1.2 (1.0 to 1.5)
        1 month after Dose 3 (80,48)
    68.4 (58.2 to 80.4)
    1.1 (0.9 to 1.3)
    No statistical analyses for this end point

    Secondary: Phase 2/3: Confirmed COVID-19 Cases From 7 Days After Dose 2 to Prior to Dose 3 per 1000 Person-Years of Blinded Follow-up in Participants Without Serological or Virological Evidence: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 2/3: Confirmed COVID-19 Cases From 7 Days After Dose 2 to Prior to Dose 3 per 1000 Person-Years of Blinded Follow-up in Participants Without Serological or Virological Evidence: >=5 to <12 Years of age
    End point description
    Number of confirmed COVID-19 cases from 7 days after dose 2 to prior to dose 3 without the evidence of infection were reported in this endpoint. Evaluable efficacy population included all eligible randomised subjects who received all vaccination(s) as randomized, with Dose 2 received within the predefined window (within 19-42 days after Dose 1) and have no other important protocol deviations as determined by the clinician on or before 7 days after Dose 2.
    End point type
    Secondary
    End point timeframe
    From 7 days after Dose 2 to prior to dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.591; Placebo - 0.292)
    End point values
    Ph2/3:BNT162b2 3 mcg 5-<12Y:WoEI:evaluable efficacy(3-dose)set Phase 2/3:Placebo 5 to <12Y:WoEI:evaluable efficacy(3-dose)set
    Number of subjects analysed
    2703
    1348
    Units: Cases
        number (not applicable)
    10
    42
    No statistical analyses for this end point

    Secondary: Phase 2/3: Confirmed COVID-19 Cases From 7 Days After Dose 3 per 1000 Person-Years of Blinded Follow-up in Participants Without Serological or Virological Evidence: >=6 Months to <5 Years of Age

    Close Top of page
    End point title
    Phase 2/3: Confirmed COVID-19 Cases From 7 Days After Dose 3 per 1000 Person-Years of Blinded Follow-up in Participants Without Serological or Virological Evidence: >=6 Months to <5 Years of Age
    End point description
    Number of confirmed COVID-19 cases from 7 days after dose 3 without the evidence of infection were reported in this endpoint. Evaluable efficacy population included all eligible randomised subjects who received all vaccination(s) as randomized, with Dose 3 received within the predefined window (within 19-42 days after Dose 2) and have no other important protocol deviations as determined by the clinician on or before 7 days after Dose 2. N'=participants evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    From 7 Days After Dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.124; Placebo - 0.054)
    End point values
    Ph2/3:BNT162b2 3mcg:6M-<5Y:WoEI:evaluable efficacy(3dose)set Phase2/3:Placebo:6M-<5Y):WoEI:evaluable efficacy(3-dose)set
    Number of subjects analysed
    873
    381
    Units: Cases
        number (not applicable)
    13
    21
    No statistical analyses for this end point

    Secondary: Phase 2/3: Confirmed COVID-19 Cases From 7 Days After Dose 2 to prior to Dose 3 per 1000 Person-Years of Blinded Follow-up in Participants With or Without Serological or Virological Evidence: >=5 to <12 Years of age

    Close Top of page
    End point title
    Phase 2/3: Confirmed COVID-19 Cases From 7 Days After Dose 2 to prior to Dose 3 per 1000 Person-Years of Blinded Follow-up in Participants With or Without Serological or Virological Evidence: >=5 to <12 Years of age
    End point description
    Number of confirmed COVID-19 cases from 7 days after dose 2 to prior to dose 3 with or without the evidence of infection were reported in this endpoint. Evaluable efficacy population included all eligible randomised subjects who received all vaccination(s) as randomized, with Dose 2 received within the predefined window (within 19-42 days after Dose 1) and have no other important protocol deviations as determined by the clinician on or before 7 days after Dose 2.
    End point type
    Secondary
    End point timeframe
    From 7 Days After Dose 2 to prior to dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.653; Placebo - 0.326)
    End point values
    Phase 2/3:BNT162b2 3 mcg 5-<12Y:evaluable efficacy(3-dose)set Phase 2/3:Placebo 5-<12Y:evaluable efficacy(3-dose)set
    Number of subjects analysed
    3108
    1511
    Units: Cases
        number (not applicable)
    12
    42
    No statistical analyses for this end point

    Secondary: Phase 2/3: Confirmed COVID-19 Cases From 7 Days After Dose 3 per 1000 Person-Years of Blinded Follow-up in Participants With or Without Serological or Virological Evidence: >=6 Months to <5 Years of age

    Close Top of page
    End point title
    Phase 2/3: Confirmed COVID-19 Cases From 7 Days After Dose 3 per 1000 Person-Years of Blinded Follow-up in Participants With or Without Serological or Virological Evidence: >=6 Months to <5 Years of age
    End point description
    Number of confirmed COVID-19 cases from 7 days after dose 3 without the evidence of infection were reported in this endpoint. Evaluable efficacy population included all eligible randomised subjects who received all vaccination(s) as randomized, with Dose 3 received within the predefined window (within 19-42 days after Dose 2) and have no other important protocol deviations as determined by the clinician on or before 7 days after Dose 2. N'=participants evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    From 7 Days After Dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.149; Placebo - 0.067)
    End point values
    Phase 2/3:BNT162b2 3 mcg 6M<5Y:evaluable efficacy(3-dose)set Phase 2/3:Placebo 6M-<5Y:evaluable efficacy(3-dose)set
    Number of subjects analysed
    1294
    612
    Units: Cases
        number (not applicable)
    14
    23
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Local/systemic events: Day 1 to 7 after each dose. Non SAE: Treatment emergent adverse events are reported from time of first dose of study treatment up to 1 month after last dose. SAE: From first dose to 6 months after last dose of study treatment
    Adverse event reporting additional description
    Same event may appear as both non-SAE and SAE but are distinct events. An event may be categorised as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE.
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.1
    Reporting groups
    Reporting group title
    Ph2/3:BlPCFup:6M-<2Y:D1-6M After D2or Prior D3/BNT162b2 3mcg
    Reporting group description
    Phase 2/3: Participants aged 6 months to <2 years were randomised to receive dose 1 of BNT162b2 3 mcg intramuscularly in Blinded Placebo-Controlled Follow-Up Period were followed up to 6 month after dose 2 or prior to dose 3.

    Reporting group title
    Ph2/3:Bl PCFup:6 M -<2Y:D1-1M After D2/BNT162b2 3 mcg‌
    Reporting group description
    Phase 2/3 (Ph2/3): Participants aged 6 months to <2 years (6 M -<2 Yrs) were randomised to receive dose 1 (D1) of BNT162b2 3 mcg intramuscularly in Blinded Placebo-Controlled Follow-Up Period (Bl PCFup) and were followed up to 1 month after dose 2 (1M After D2).

    Reporting group title
    Ph2/3:Bl PCFup:6 M-<2Y:D1-1M After D2/Pb
    Reporting group description
    Phase 2/3: Participants aged 6 months to <2 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly (Placebo)(Pb) in Blinded Placebo-Controlled Follow-Up Period and were followed up to 1 month after dose 2.

    Reporting group title
    Ph2/3:Bl PCFup:6M-<2Y:D3-6M After D3/Pb
    Reporting group description
    Phase 2/3:Participants aged 6 months to <2 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly (Placebo) in Blinded Placebo-Controlled Follow-Up Period and were followed up to 6 month after dose 3.

    Reporting group title
    Ph2/3:Bl PCFup:6M-<2Y:D3-6M After D3/BNT162b2 3mcg
    Reporting group description
    Phase 2/3: Participants aged 6 months to <2 years were randomised to receive dose 3 of BNT162b2 3 mcg intramuscularly in Blinded Placebo-Controlled Follow-Up Period and were followed up to 6 month after dose 3.

    Reporting group title
    Ph2/3:Bl PCFup:6M-<2Y:D3-1M After D3/Pb
    Reporting group description
    Phase 2/3:Participants aged 6 months to <2 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly (Placebo) in Blinded Placebo-Controlled Follow-Up Period and were followed up to 1 month after dose 3.

    Reporting group title
    Ph2/3:Bl PCFup:6M-<2Y:D3-1M After D3/BNT162b2 3mcg
    Reporting group description
    Phase 2/3: Participants aged 6 months to <2 years were randomised to receive dose 3 of BNT162b2 3 mcg intramuscularly in Blinded Placebo-Controlled Follow-Up Period and were followed up to 1 month after dose 3.

    Reporting group title
    Ph2/3:BlPCFup:6M-<2Y:D1-6M After D2 or Prior D3/Pb
    Reporting group description
    Phase 2/3: Participants aged 6 months to <2 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly (Placebo) in Blinded Placebo-Controlled Follow-Up Period and were followed up to 6 month after dose 2 or prior to dose 3.

    Reporting group title
    Ph2/3:Bl PCFup:5-<12Y:D1-1M After D2/ BNT162b2 10mcg
    Reporting group description
    Phase 2/3:Participants aged 5 to <12 years were randomised to receive dose 1 of BNT162b2 10 mcg intramuscularly in Blinded Placebo-Controlled Follow-Up Period and were followed up to 1 month after dose 2.

    Reporting group title
    Ph2/3:Bl PCFup:5-<12Y:TPG:D1-6M After D2/BNT162b2 10 mcg
    Reporting group description
    Phase 2/3: Participants aged 5 to <12 years were randomised to receive dose 1 of BNT162b2 10 mcg intramuscularly in Blinded Placebo-Controlled Follow-Up Period in Troponin group and were followed up to 6 month after dose 2.

    Reporting group title
    Ph2/3:BlPCFup:5-<12Y:TPG:D1-6MAfterD2 orPriorD3/BNT162b210mcg
    Reporting group description
    Phase 2/3: Participants aged 5 to <12 years were randomised to receive dose 1 of BNT162b2 10 mcg intramuscularly in Blinded Placebo-Controlled Follow-Up Period in Troponin group (TPG) and were followed up to 6 month after dose 2 or prior to dose 3.

    Reporting group title
    Ph2/3:Bl PCFup:2-<5Y:D3-6M After D3/Pb
    Reporting group description
    Phase 2/3: Participants aged 2 to <5 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly (Placebo) in Blinded Placebo-Controlled Follow-Up Period and were followed up to 6 month after dose 3.

    Reporting group title
    Ph2/3:Bl PCFup:2-<5Y:D3-6M After D3/BNT162b2 3mcg
    Reporting group description
    Phase 2/3: Participants aged 2 to <5 years were randomised to receive dose 3 of BNT162b2 3 mcg intramuscularly in Blinded Placebo-Controlled Follow-Up Period and were followed up to 6 month after dose 3.

    Reporting group title
    Ph2/3:Bl PCFup:2-<5Y:D3-1M After D3/Pb
    Reporting group description
    Phase 2/3:Participants aged 2 to <5 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly (Placebo) in Blinded Placebo-Controlled Follow-Up Period and were followed up to 1 month after dose 3.

    Reporting group title
    Ph2/3:Bl PCFup:2-<5Y:D3-1M After D3/BNT162b2 3mcg
    Reporting group description
    Phase 2/3: Participants aged 2 to <5 years were randomised to receive dose 3 of BNT162b2 3 mcg intramuscularly in Blinded Placebo-Controlled Follow-Up Period and were followed up to 1 month after dose 3.

    Reporting group title
    Ph2/3:BlPCFup:2-<5Y:D1-6M After D2 or Prior D3/Pb
    Reporting group description
    Phase 2/3:Participants aged 2 to <5 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly (Placebo) in Blinded Placebo-Controlled Follow-Up Period and were followed up to 6 month after dose 2 or Prior to Dose 3.

    Reporting group title
    Ph2/3:BlPCFup:2-<5Y:D1-6M After D2 or Prior D3/BNT162b2 3mcg
    Reporting group description
    Phase 2/3:Participants aged 2 to <5 years were randomised to receive dose 1 of BNT162b2 3 mcg intramuscularly in Blinded Placebo-Controlled Follow-Up Period and were followed up to 6 month after dose 2 or Prior to Dose 3.

    Reporting group title
    Ph2/3:Bl PCFup:5-<12Y:TPG:D1-6M After D2 or Prior D3/Pb
    Reporting group description
    Phase 2/3: Participants aged 5 to <12 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly (Placebo) in Blinded Placebo-Controlled Follow-Up Period in Troponin group and were followed up to 6 month after dose 2 or prior to dose 3.

    Reporting group title
    Ph2/3:BlPCFup:2-<5Y:D1-1M After D2/ BNT162b2 3mcg
    Reporting group description
    Phase 2/3:Participants aged 2 to <5 years were randomised to receive dose 3 of BNT162b2 3 mcg intramuscularly in blinded placebo-controlled follow up period and were followed up from dose 1 to 1 month after dose 2.

    Reporting group title
    Ph2/3:Bl PCFup:2-<5Y:D1-1M After D2/Pb
    Reporting group description
    Phase 2/3:Participants aged 2 to <5 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly (Placebo) in blinded placebo controlled follow up period and were followed from Dose 1 to 1 month after dose 2.

    Reporting group title
    Ph2/3:5-<12Y:TPG:D3-1M After D3/BNT162b2 10 mcg
    Reporting group description
    Phase 2/3: Participants aged 5 to <12 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly (Placebo) intramuscularly in Blinded Placebo and had the opportunity to receive dose 3 as BNT162b2 10 mcg in Open Label Period in Troponin group and were followed up to 1 month after dose 3.

    Reporting group title
    Ph2/3:5-<12Y:TPG:D3-1M After D3/BNT162b2 10 mcg
    Reporting group description
    Phase 2/3: Participants aged 5 to <12 years were randomised to receive dose 3 of BNT162b2 10 mcg intramuscularly in Blinded and Open Label Period (OLP) in Troponin group and were followed up to 1 month after dose 3.

    Reporting group title
    Ph2/3:Bl OLP:5-<12Y:TPG:D3-6M After D3/BNT162b2 10 mcg
    Reporting group description
    Participants aged 5 to <12 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly (Placebo) intramuscularly in Blinded Placebo and had the opportunity to receive dose 3 as BNT162b2 10 mcg in Open Label Period in Troponin group and were followed up to 6 month after dose 3.

    Reporting group title
    Ph1:2-<5Y:D1-1M After D2/BNT162b2 3 mcg
    Reporting group description
    Phase 1: Participants aged 2 to <5 years received dose 1 of BNT162b2 3 mcg intramuscularly and were followed up to 1 month after dose 2.

    Reporting group title
    Ph1:6M-<2Y:D3-1M After D3/BNT162b2 3 mcg
    Reporting group description
    Phase 1: Participants aged 6 months to <2 years received dose 3 of BNT162b2 3 mcg intramuscularly and were followed up to 1 month after dose 3.

    Reporting group title
    Ph1:6M-<2Y:D1-6M After D2/BNT162b2 3 mcg
    Reporting group description
    Phase 1: Participants aged 6 months to <2 years received dose 1 of BNT162b2 3 mcg intramuscularly and were followed up to 6 month after dose 2.

    Reporting group title
    Ph2/3:OLP:12-<16Y:TPG:D3-1M After D3/BNT162b2 30 mcg
    Reporting group description
    Phase 2/3: Participants aged 12 to <16 years were randomised to receive dose 3 of BNT162b2 30 mcg intramuscularly in open label in Troponin group and were followed up to 1 month after dose 3.

    Reporting group title
    Ph2/3:OLP:12-<16Y:TPG:D1-6M After D2or priorD3/BNT162b2 30mcg
    Reporting group description
    Phase 2/3: Participants aged 12 to <16 years were randomised to receive dose 1 of BNT162b2 30 mcg intramuscularly in open label in Troponin group and were followed up to 6 month after dose 2 or prior to dose 3.

    Reporting group title
    Ph2/3:OLP:12-<16Y:TPG:D1-1M After D2/BNT162b2 30 mcg
    Reporting group description
    Phase 2/3: Participants aged 12 to <16 years were randomised to receive dose 1 of BNT162b2 30 mcg intramuscularly in Open label in Troponin group and were followed up to 1 month after dose 2.

    Reporting group title
    Ph1:2-<5Y:D1-1M After D2/BNT162b2 10 mcg
    Reporting group description
    Phase 1: Participants aged 2 to <5 years received dose 1 of BNT162b2 10 mcg intramuscularly and were followed up to 1 month after dose 2.

    Reporting group title
    Ph1:2-<5Y:D3-1M After D3/BNT162b2 3 mcg
    Reporting group description
    Phase 1: Participants aged 2 to <5 years received dose 3 of BNT162b2 3 mcg intramuscularly and were followed up to 1 month after dose 3.

    Reporting group title
    Ph2/3:BlPCFup:5 -<12Y:D1-1M After D2 or PTD3/Pb
    Reporting group description
    Phase 2/3:Participants aged 5 to <12 years received 0.9% sodium chloride solution for Injection intramuscularly (Placebo) in Blinded Placebo-Controlled Follow-Up Period and were followed up to 1 month after dose 2 or prior to dose 3.

    Reporting group title
    Ph2/3:BlOLP:5-<12Y:D3-1M After D3/BNT162b2 10 mcg
    Reporting group description
    Participants aged 5 to <12 years were randomised to receive dose 3 as BNT162b2 10 mcg in Blinded and Open Label Period and were followed up to 1 month after dose 3.

    Reporting group title
    Ph2/3:BlOLP:5-<12Y:D3-1M After D3/BNT162b2 10 mcg
    Reporting group description
    Participants aged 5 to <12 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly (Placebo) intramuscularly in Blinded Placebo and had the opportunity to receive dose 3 as BNT162b2 10 mcg in Open Label Period in Troponin group and were followed up to 1 month after dose 3.

    Reporting group title
    Ph1:5-<12Y:D1-6M After D2/BNT162b2 10 mcg
    Reporting group description
    Phase 1: Participants aged 5 to <12 years received dose 1 of BNT162b2 10 mcg intramuscularly and were followed up to 6 month after dose 2.

    Reporting group title
    Ph1:5-<12Y:D1-6M After D2/BNT162b2 10 mcg
    Reporting group description
    Phase 1: Participants aged 5 to <12 years received dose 1 of BNT162b2 10 mcg intramuscularly and were followed up to 6 month after dose 2.

    Reporting group title
    Ph1:5-<12Y:D1-1M After D2/BNT162b2 (30/30 mcg)
    Reporting group description
    Phase 1: Participants aged 5 to <12 years of age received dose 1 of 30 mcg BNT162b2 and received third dose of 10 mcg BNT162b2 were followed up to 1 month after dose 2.

    Reporting group title
    Ph1:5-<12Y:D1-1M After D2/BNT162b2 (30/10 mcg)
    Reporting group description
    Phase 1: Participants aged 5 to <12 years of age received dose 1 of 30 mcg, followed by dose 2 of 10 mcg BNT162b2 and received third dose of 10 mcg BNT162b2 were followed up to 1 month after dose 2.

    Reporting group title
    Ph1:5-<12Y:D3-1M After D3/BNT162b2 10 mcg
    Reporting group description
    Phase 1: Participants aged 5 to <12 years received dose 3 of BNT162b2 10 mcg intramuscularly and were followed up to 1 month after dose 3.

    Reporting group title
    Ph2/3:Bl PCFup:6M-<2Y:D1-1M After D2/Placebo
    Reporting group description
    Phase 2/3:Participants aged 6 months to <2 years were received 0.9% sodium chloride solution for Injection intramuscularly (Placebo) in Blinded Placebo-Controlled Follow-Up Period and were followed up to 1 month after dose 2.

    Reporting group title
    Ph2/3:BlPCFup:5 -<12Y:D1-1M After D2 or PTD3/BNT162b2 10 mcg
    Reporting group description
    Phase 2/3:Participants aged 5 to <12 years received dose 1 of BNT162b2 10 mcg intramuscularly in Blinded Placebo-Controlled Follow-Up Period and were followed up to 1 month after dose 2 or prior to dose 3.

    Reporting group title
    Ph2/3:Bl OLP:5-<12Y:D3-6M After D3/Org BNT162b2 10 mcg
    Reporting group description
    Participants aged 5 to <12 years received dose 3 as Original (Org) BNT162b2 10 mcg in Blinded and Open Label Period were followed up to 6 month after dose 3.

    Reporting group title
    Ph2/3:Bl PCFup:5-<12Y:TPG:D1-1M After D2/Pb BNT162b2 10 mcg
    Reporting group description
    Participants aged 5 to <12 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly (Placebo) intramuscularly in Blinded Placebo-Controlled Follow-Up Period and were followed up to 1 month after dose 2.

    Reporting group title
    Ph2/3:Bl OLP:5-<12Y:D3-6M After D3/BNT162b2 10 mcg
    Reporting group description
    Participants aged 5 to <12 years were randomised to receive dose 3 as BNT162b2 10 mcg in Blinded and Open Label Period and were followed up to 6 month after dose 3.

    Reporting group title
    Ph2/3:Bl OLP:5-<12Y:TPG:D3-1M After D3/Org BNT162b2 10 mcg
    Reporting group description
    Participants aged 5 to <12 years were randomised to receive 0.9% sodium chloride solution for Injection intramuscularly (Placebo) intramuscularly in Blinded and Open Label period and had the opportunity to receive dose 3 as BNT162b2 10 mcg in Open Label Period in Troponin group and were followed up to 6 month after dose 3.

    Serious adverse events
    Ph2/3:BlPCFup:6M-<2Y:D1-6M After D2or Prior D3/BNT162b2 3mcg Ph2/3:Bl PCFup:6 M -<2Y:D1-1M After D2/BNT162b2 3 mcg‌ Ph2/3:Bl PCFup:6 M-<2Y:D1-1M After D2/Pb Ph2/3:Bl PCFup:6M-<2Y:D3-6M After D3/Pb Ph2/3:Bl PCFup:6M-<2Y:D3-6M After D3/BNT162b2 3mcg Ph2/3:Bl PCFup:6M-<2Y:D3-1M After D3/Pb Ph2/3:Bl PCFup:6M-<2Y:D3-1M After D3/BNT162b2 3mcg Ph2/3:BlPCFup:6M-<2Y:D1-6M After D2 or Prior D3/Pb Ph2/3:Bl PCFup:5-<12Y:D1-1M After D2/ BNT162b2 10mcg Ph2/3:Bl PCFup:5-<12Y:TPG:D1-6M After D2/BNT162b2 10 mcg Ph2/3:BlPCFup:5-<12Y:TPG:D1-6MAfterD2 orPriorD3/BNT162b210mcg Ph2/3:Bl PCFup:2-<5Y:D3-6M After D3/Pb Ph2/3:Bl PCFup:2-<5Y:D3-6M After D3/BNT162b2 3mcg Ph2/3:Bl PCFup:2-<5Y:D3-1M After D3/Pb Ph2/3:Bl PCFup:2-<5Y:D3-1M After D3/BNT162b2 3mcg Ph2/3:BlPCFup:2-<5Y:D1-6M After D2 or Prior D3/Pb Ph2/3:BlPCFup:2-<5Y:D1-6M After D2 or Prior D3/BNT162b2 3mcg Ph2/3:Bl PCFup:5-<12Y:TPG:D1-6M After D2 or Prior D3/Pb Ph2/3:BlPCFup:2-<5Y:D1-1M After D2/ BNT162b2 3mcg Ph2/3:Bl PCFup:2-<5Y:D1-1M After D2/Pb Ph2/3:5-<12Y:TPG:D3-1M After D3/BNT162b2 10 mcg Ph2/3:5-<12Y:TPG:D3-1M After D3/BNT162b2 10 mcg Ph2/3:Bl OLP:5-<12Y:TPG:D3-6M After D3/BNT162b2 10 mcg Ph1:2-<5Y:D1-1M After D2/BNT162b2 3 mcg Ph1:6M-<2Y:D3-1M After D3/BNT162b2 3 mcg Ph1:6M-<2Y:D1-6M After D2/BNT162b2 3 mcg Ph2/3:OLP:12-<16Y:TPG:D3-1M After D3/BNT162b2 30 mcg Ph2/3:OLP:12-<16Y:TPG:D1-6M After D2or priorD3/BNT162b2 30mcg Ph2/3:OLP:12-<16Y:TPG:D1-1M After D2/BNT162b2 30 mcg Ph1:2-<5Y:D1-1M After D2/BNT162b2 10 mcg Ph1:2-<5Y:D3-1M After D3/BNT162b2 3 mcg Ph2/3:BlPCFup:5 -<12Y:D1-1M After D2 or PTD3/Pb Ph2/3:BlOLP:5-<12Y:D3-1M After D3/BNT162b2 10 mcg Ph2/3:BlOLP:5-<12Y:D3-1M After D3/BNT162b2 10 mcg Ph1:5-<12Y:D1-6M After D2/BNT162b2 10 mcg Ph1:5-<12Y:D1-6M After D2/BNT162b2 10 mcg Ph1:5-<12Y:D1-1M After D2/BNT162b2 (30/30 mcg) Ph1:5-<12Y:D1-1M After D2/BNT162b2 (30/10 mcg) Ph1:5-<12Y:D3-1M After D3/BNT162b2 10 mcg Ph2/3:Bl PCFup:6M-<2Y:D1-1M After D2/Placebo Ph2/3:BlPCFup:5 -<12Y:D1-1M After D2 or PTD3/BNT162b2 10 mcg Ph2/3:Bl OLP:5-<12Y:D3-6M After D3/Org BNT162b2 10 mcg Ph2/3:Bl PCFup:5-<12Y:TPG:D1-1M After D2/Pb BNT162b2 10 mcg Ph2/3:Bl OLP:5-<12Y:D3-6M After D3/BNT162b2 10 mcg Ph2/3:Bl OLP:5-<12Y:TPG:D3-1M After D3/Org BNT162b2 10 mcg
    Total subjects affected by serious adverse events
         subjects affected / exposed
    24 / 1458 (1.65%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    1 / 483 (0.21%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    17 / 718 (2.37%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    1 / 518 (0.19%)
    0 / 405 (0.00%)
    3 / 863 (0.35%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    10 / 1173 (0.85%)
    11 / 2368 (0.46%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    2 / 418 (0.48%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    2 / 487 (0.41%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    3 / 1538 (0.20%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    8 / 3109 (0.26%)
    3 / 957 (0.31%)
    0 / 260 (0.00%)
    10 / 2410 (0.41%)
    0 / 202 (0.00%)
         number of deaths (all causes)
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Vascular disorders
    Cyanosis
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    2 / 718 (0.28%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pregnancy, puerperium and perinatal conditions
    Abortion spontaneous
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    1 / 487 (0.21%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    1 / 2368 (0.04%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Immune system disorders
    Anaphylactic reaction
         subjects affected / exposed
    1 / 1458 (0.07%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    1 / 718 (0.14%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    1 / 2410 (0.04%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    Ovarian cyst
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    1 / 487 (0.21%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Testicular appendage torsion
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    1 / 3109 (0.03%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Acute respiratory failure
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    1 / 718 (0.14%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Asthma
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    1 / 518 (0.19%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    1 / 957 (0.10%)
    0 / 260 (0.00%)
    1 / 2410 (0.04%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bronchial hyperreactivity
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    1 / 1173 (0.09%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumomediastinum
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    1 / 718 (0.14%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory arrest
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    1 / 418 (0.24%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory distress
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    1 / 718 (0.14%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    Disruptive mood dysregulation disorder
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    1 / 2410 (0.04%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Suicidal ideation
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    1 / 2410 (0.04%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Accidental overdose
         subjects affected / exposed
    1 / 1458 (0.07%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Burns second degree
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    1 / 718 (0.14%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Concussion
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    1 / 718 (0.14%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Epiphyseal fracture
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    1 / 3109 (0.03%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Eyelid injury
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    1 / 2410 (0.04%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Fall
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    1 / 718 (0.14%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Femur fracture
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    1 / 2410 (0.04%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Foreign body
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    1 / 1173 (0.09%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Foreign body ingestion
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    1 / 3109 (0.03%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Head injury
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    1 / 718 (0.14%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Thermal burn
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    1 / 718 (0.14%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Upper limb fracture
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    1 / 3109 (0.03%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Epilepsy
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    1 / 1173 (0.09%)
    1 / 2368 (0.04%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Febrile convulsion
         subjects affected / exposed
    1 / 1458 (0.07%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    1 / 1173 (0.09%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Narcolepsy
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    1 / 1538 (0.07%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Seizure
         subjects affected / exposed
    1 / 1458 (0.07%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    1 / 2410 (0.04%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Status epilepticus
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    1 / 2368 (0.04%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Syncope
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    1 / 957 (0.10%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Transient ischaemic attack
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    1 / 3109 (0.03%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Sickle cell anaemia with crisis
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    1 / 418 (0.24%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Eye disorders
    Papilloedema
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    1 / 1173 (0.09%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    1 / 2368 (0.04%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal pain
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    1 / 1538 (0.07%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    1 / 2410 (0.04%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Colitis ulcerative
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    1 / 863 (0.12%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Constipation
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    1 / 1173 (0.09%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intestinal obstruction
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    1 / 2410 (0.04%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pancreatitis
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    1 / 1538 (0.07%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vomiting
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    1 / 718 (0.14%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Dermal cyst
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    1 / 863 (0.12%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Pain in extremity
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    1 / 2368 (0.04%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Abdominal abscess
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    1 / 957 (0.10%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acute sinusitis
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    1 / 2410 (0.04%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Anal abscess
         subjects affected / exposed
    1 / 1458 (0.07%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Appendicitis
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    2 / 2368 (0.08%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    1 / 957 (0.10%)
    0 / 260 (0.00%)
    1 / 2410 (0.04%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Arthritis bacterial
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    1 / 3109 (0.03%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bronchiolitis
         subjects affected / exposed
    3 / 1458 (0.21%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    3 / 718 (0.42%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    1 / 1173 (0.09%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cellulitis
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    1 / 3109 (0.03%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Complicated appendicitis
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    1 / 1538 (0.07%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Enterovirus infection
         subjects affected / exposed
    1 / 1458 (0.07%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Exanthema subitum
         subjects affected / exposed
    1 / 1458 (0.07%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Focal peritonitis
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    1 / 2368 (0.04%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    3 / 1458 (0.21%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    1 / 1173 (0.09%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis adenovirus
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    1 / 1173 (0.09%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis norovirus
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    1 / 718 (0.14%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis rotavirus
         subjects affected / exposed
    1 / 1458 (0.07%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    1 / 718 (0.14%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    1 / 1173 (0.09%)
    1 / 2368 (0.04%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis viral
         subjects affected / exposed
    2 / 1458 (0.14%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    1 / 2368 (0.04%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HCoV-NL63 infection
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    1 / 718 (0.14%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Large intestine infection
         subjects affected / exposed
    1 / 1458 (0.07%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lower respiratory tract infection
         subjects affected / exposed
    1 / 1458 (0.07%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lower respiratory tract infection viral
         subjects affected / exposed
    1 / 1458 (0.07%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metapneumovirus infection
         subjects affected / exposed
    1 / 1458 (0.07%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    1 / 1173 (0.09%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Otitis media
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    1 / 2368 (0.04%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Otitis media acute
         subjects affected / exposed
    1 / 1458 (0.07%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Parainfluenzae virus infection
         subjects affected / exposed
    1 / 1458 (0.07%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    2 / 1458 (0.14%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    1 / 863 (0.12%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia respiratory syncytial viral
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    1 / 3109 (0.03%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory syncytial virus bronchiolitis
         subjects affected / exposed
    5 / 1458 (0.34%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    1 / 483 (0.21%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    1 / 718 (0.14%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 6
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory syncytial virus infection
         subjects affected / exposed
    1 / 1458 (0.07%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rhinovirus infection
         subjects affected / exposed
    1 / 1458 (0.07%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    1 / 1173 (0.09%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tonsillitis
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    1 / 718 (0.14%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Upper respiratory tract infection
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    1 / 2368 (0.04%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Viral infection
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    1 / 718 (0.14%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Dehydration
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    2 / 2368 (0.08%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Feeding intolerance
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    1 / 718 (0.14%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypoglycaemia
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    1 / 718 (0.14%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 1%
    Non-serious adverse events
    Ph2/3:BlPCFup:6M-<2Y:D1-6M After D2or Prior D3/BNT162b2 3mcg Ph2/3:Bl PCFup:6 M -<2Y:D1-1M After D2/BNT162b2 3 mcg‌ Ph2/3:Bl PCFup:6 M-<2Y:D1-1M After D2/Pb Ph2/3:Bl PCFup:6M-<2Y:D3-6M After D3/Pb Ph2/3:Bl PCFup:6M-<2Y:D3-6M After D3/BNT162b2 3mcg Ph2/3:Bl PCFup:6M-<2Y:D3-1M After D3/Pb Ph2/3:Bl PCFup:6M-<2Y:D3-1M After D3/BNT162b2 3mcg Ph2/3:BlPCFup:6M-<2Y:D1-6M After D2 or Prior D3/Pb Ph2/3:Bl PCFup:5-<12Y:D1-1M After D2/ BNT162b2 10mcg Ph2/3:Bl PCFup:5-<12Y:TPG:D1-6M After D2/BNT162b2 10 mcg Ph2/3:BlPCFup:5-<12Y:TPG:D1-6MAfterD2 orPriorD3/BNT162b210mcg Ph2/3:Bl PCFup:2-<5Y:D3-6M After D3/Pb Ph2/3:Bl PCFup:2-<5Y:D3-6M After D3/BNT162b2 3mcg Ph2/3:Bl PCFup:2-<5Y:D3-1M After D3/Pb Ph2/3:Bl PCFup:2-<5Y:D3-1M After D3/BNT162b2 3mcg Ph2/3:BlPCFup:2-<5Y:D1-6M After D2 or Prior D3/Pb Ph2/3:BlPCFup:2-<5Y:D1-6M After D2 or Prior D3/BNT162b2 3mcg Ph2/3:Bl PCFup:5-<12Y:TPG:D1-6M After D2 or Prior D3/Pb Ph2/3:BlPCFup:2-<5Y:D1-1M After D2/ BNT162b2 3mcg Ph2/3:Bl PCFup:2-<5Y:D1-1M After D2/Pb Ph2/3:5-<12Y:TPG:D3-1M After D3/BNT162b2 10 mcg Ph2/3:5-<12Y:TPG:D3-1M After D3/BNT162b2 10 mcg Ph2/3:Bl OLP:5-<12Y:TPG:D3-6M After D3/BNT162b2 10 mcg Ph1:2-<5Y:D1-1M After D2/BNT162b2 3 mcg Ph1:6M-<2Y:D3-1M After D3/BNT162b2 3 mcg Ph1:6M-<2Y:D1-6M After D2/BNT162b2 3 mcg Ph2/3:OLP:12-<16Y:TPG:D3-1M After D3/BNT162b2 30 mcg Ph2/3:OLP:12-<16Y:TPG:D1-6M After D2or priorD3/BNT162b2 30mcg Ph2/3:OLP:12-<16Y:TPG:D1-1M After D2/BNT162b2 30 mcg Ph1:2-<5Y:D1-1M After D2/BNT162b2 10 mcg Ph1:2-<5Y:D3-1M After D3/BNT162b2 3 mcg Ph2/3:BlPCFup:5 -<12Y:D1-1M After D2 or PTD3/Pb Ph2/3:BlOLP:5-<12Y:D3-1M After D3/BNT162b2 10 mcg Ph2/3:BlOLP:5-<12Y:D3-1M After D3/BNT162b2 10 mcg Ph1:5-<12Y:D1-6M After D2/BNT162b2 10 mcg Ph1:5-<12Y:D1-6M After D2/BNT162b2 10 mcg Ph1:5-<12Y:D1-1M After D2/BNT162b2 (30/30 mcg) Ph1:5-<12Y:D1-1M After D2/BNT162b2 (30/10 mcg) Ph1:5-<12Y:D3-1M After D3/BNT162b2 10 mcg Ph2/3:Bl PCFup:6M-<2Y:D1-1M After D2/Placebo Ph2/3:BlPCFup:5 -<12Y:D1-1M After D2 or PTD3/BNT162b2 10 mcg Ph2/3:Bl OLP:5-<12Y:D3-6M After D3/Org BNT162b2 10 mcg Ph2/3:Bl PCFup:5-<12Y:TPG:D1-1M After D2/Pb BNT162b2 10 mcg Ph2/3:Bl OLP:5-<12Y:D3-6M After D3/BNT162b2 10 mcg Ph2/3:Bl OLP:5-<12Y:TPG:D3-1M After D3/Org BNT162b2 10 mcg
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    0 / 1458 (0.00%)
    1154 / 1458 (79.15%)
    550 / 718 (76.60%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    119 / 237 (50.21%)
    267 / 483 (55.28%)
    0 / 718 (0.00%)
    2821 / 3109 (90.74%)
    442 / 518 (85.33%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    152 / 405 (37.53%)
    398 / 863 (46.12%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    1661 / 2368 (70.14%)
    778 / 1173 (66.33%)
    22 / 202 (10.89%)
    319 / 418 (76.32%)
    0 / 418 (0.00%)
    10 / 16 (62.50%)
    7 / 15 (46.67%)
    10 / 16 (62.50%)
    285 / 433 (65.82%)
    0 / 487 (0.00%)
    414 / 487 (85.01%)
    32 / 32 (100.00%)
    17 / 27 (62.96%)
    0 / 1538 (0.00%)
    1794 / 2410 (74.44%)
    80 / 957 (8.36%)
    16 / 16 (100.00%)
    16 / 16 (100.00%)
    4 / 4 (100.00%)
    11 / 12 (91.67%)
    35 / 38 (92.11%)
    1083 / 1538 (70.42%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    163 / 260 (62.69%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
    General disorders and administration site conditions
    Axillary pain
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    5 / 418 (1.20%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    5
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Chills (CHILLS)
    alternative assessment type: Systematic
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    413 / 3109 (13.28%)
    50 / 518 (9.65%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    10 / 405 (2.47%)
    22 / 863 (2.55%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    125 / 2368 (5.28%)
    59 / 1173 (5.03%)
    0 / 202 (0.00%)
    35 / 418 (8.37%)
    0 / 418 (0.00%)
    1 / 16 (6.25%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    52 / 433 (12.01%)
    0 / 487 (0.00%)
    88 / 487 (18.07%)
    3 / 32 (9.38%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    231 / 2410 (9.59%)
    0 / 957 (0.00%)
    5 / 16 (31.25%)
    7 / 16 (43.75%)
    3 / 4 (75.00%)
    5 / 12 (41.67%)
    6 / 38 (15.79%)
    129 / 1538 (8.39%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    31 / 260 (11.92%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    475
    54
    0
    0
    0
    10
    22
    0
    0
    0
    129
    63
    0
    35
    0
    2
    0
    0
    52
    0
    104
    4
    0
    0
    231
    0
    5
    11
    5
    6
    6
    150
    0
    0
    33
    0
    0
    Fatigue
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    3 / 202 (1.49%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    14 / 2410 (0.58%)
    16 / 957 (1.67%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    1 / 38 (2.63%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    3
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    14
    16
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Fatigue (FATIGUE)
    alternative assessment type: Systematic
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    1614 / 3109 (51.91%)
    221 / 518 (42.66%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    91 / 405 (22.47%)
    202 / 863 (23.41%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    977 / 2368 (41.26%)
    487 / 1173 (41.52%)
    0 / 202 (0.00%)
    153 / 418 (36.60%)
    0 / 418 (0.00%)
    5 / 16 (31.25%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    149 / 433 (34.41%)
    0 / 487 (0.00%)
    255 / 487 (52.36%)
    23 / 32 (71.88%)
    8 / 27 (29.63%)
    0 / 1538 (0.00%)
    897 / 2410 (37.22%)
    0 / 957 (0.00%)
    14 / 16 (87.50%)
    13 / 16 (81.25%)
    4 / 4 (100.00%)
    10 / 12 (83.33%)
    15 / 38 (39.47%)
    641 / 1538 (41.68%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    105 / 260 (40.38%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    2267
    256
    0
    0
    0
    91
    202
    0
    0
    0
    1247
    622
    0
    153
    0
    8
    0
    0
    149
    0
    364
    34
    8
    0
    897
    0
    19
    21
    8
    15
    15
    879
    0
    0
    128
    0
    0
    Injection site bruising
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    1 / 32 (3.13%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Injection site discomfort
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    1 / 16 (6.25%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Injection site erythema
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    1 / 12 (8.33%)
    1 / 38 (2.63%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    1
    0
    0
    0
    0
    0
    0
    Injection site erythema (REDNESS)
    alternative assessment type: Systematic
         subjects affected / exposed
    0 / 1458 (0.00%)
    237 / 1458 (16.26%)
    83 / 718 (11.56%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    11 / 237 (4.64%)
    33 / 483 (6.83%)
    0 / 718 (0.00%)
    806 / 3109 (25.92%)
    92 / 518 (17.76%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    18 / 405 (4.44%)
    83 / 863 (9.62%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    379 / 2368 (16.01%)
    136 / 1173 (11.59%)
    0 / 202 (0.00%)
    67 / 418 (16.03%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    2 / 15 (13.33%)
    3 / 16 (18.75%)
    14 / 433 (3.23%)
    0 / 487 (0.00%)
    12 / 487 (2.46%)
    9 / 32 (28.13%)
    1 / 27 (3.70%)
    0 / 1538 (0.00%)
    354 / 2410 (14.69%)
    0 / 957 (0.00%)
    8 / 16 (50.00%)
    3 / 16 (18.75%)
    4 / 4 (100.00%)
    3 / 12 (25.00%)
    11 / 38 (28.95%)
    148 / 1538 (9.62%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    17 / 260 (6.54%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    285
    96
    0
    0
    11
    33
    0
    1009
    107
    0
    0
    0
    18
    83
    0
    0
    0
    444
    154
    0
    67
    0
    0
    2
    3
    14
    0
    14
    14
    1
    0
    354
    0
    8
    3
    7
    4
    11
    170
    0
    0
    18
    0
    0
    Injection site pain
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    17 / 202 (8.42%)
    7 / 418 (1.67%)
    0 / 418 (0.00%)
    2 / 16 (12.50%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    3 / 32 (9.38%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    34 / 2410 (1.41%)
    60 / 957 (6.27%)
    1 / 16 (6.25%)
    1 / 16 (6.25%)
    0 / 4 (0.00%)
    2 / 12 (16.67%)
    1 / 38 (2.63%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    18
    7
    0
    2
    0
    0
    0
    0
    0
    3
    0
    0
    34
    60
    1
    1
    0
    2
    1
    0
    0
    0
    0
    0
    0
    Injection site pain (PAIN)
    alternative assessment type: Systematic
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    2603 / 3109 (83.72%)
    397 / 518 (76.64%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    48 / 405 (11.85%)
    222 / 863 (25.72%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    998 / 2368 (42.15%)
    357 / 1173 (30.43%)
    0 / 202 (0.00%)
    273 / 418 (65.31%)
    0 / 418 (0.00%)
    7 / 16 (43.75%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    257 / 433 (59.35%)
    0 / 487 (0.00%)
    384 / 487 (78.85%)
    21 / 32 (65.63%)
    9 / 27 (33.33%)
    0 / 1538 (0.00%)
    1568 / 2410 (65.06%)
    0 / 957 (0.00%)
    14 / 16 (87.50%)
    15 / 16 (93.75%)
    4 / 4 (100.00%)
    11 / 12 (91.67%)
    33 / 38 (86.84%)
    661 / 1538 (42.98%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    79 / 260 (30.38%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    4439
    522
    0
    0
    0
    48
    222
    0
    0
    0
    1329
    449
    0
    273
    0
    11
    0
    0
    257
    0
    603
    37
    9
    0
    1568
    0
    28
    27
    8
    21
    33
    916
    0
    0
    98
    0
    0
    Injection site pain (TENDERNESS)
    alternative assessment type: Systematic
         subjects affected / exposed
    0 / 1458 (0.00%)
    353 / 1458 (24.21%)
    126 / 718 (17.55%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    22 / 237 (9.28%)
    67 / 483 (13.87%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    4 / 15 (26.67%)
    1 / 16 (6.25%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    448
    151
    0
    0
    22
    67
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    4
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Injection site swelling (SWELLING)
    alternative assessment type: Systematic
         subjects affected / exposed
    0 / 1458 (0.00%)
    94 / 1458 (6.45%)
    26 / 718 (3.62%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    5 / 237 (2.11%)
    15 / 483 (3.11%)
    0 / 718 (0.00%)
    622 / 3109 (20.01%)
    69 / 518 (13.32%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    6 / 405 (1.48%)
    25 / 863 (2.90%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    182 / 2368 (7.69%)
    53 / 1173 (4.52%)
    0 / 202 (0.00%)
    50 / 418 (11.96%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    1 / 15 (6.67%)
    1 / 16 (6.25%)
    12 / 433 (2.77%)
    0 / 487 (0.00%)
    27 / 487 (5.54%)
    4 / 32 (12.50%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    286 / 2410 (11.87%)
    0 / 957 (0.00%)
    8 / 16 (50.00%)
    3 / 16 (18.75%)
    3 / 4 (75.00%)
    1 / 12 (8.33%)
    5 / 38 (13.16%)
    78 / 1538 (5.07%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    14 / 260 (5.38%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    108
    28
    0
    0
    5
    15
    0
    770
    77
    0
    0
    0
    6
    25
    0
    0
    0
    209
    57
    0
    50
    0
    0
    1
    1
    12
    0
    29
    4
    0
    0
    286
    0
    8
    4
    4
    1
    5
    87
    0
    0
    17
    0
    0
    Malaise
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    1 / 16 (6.25%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Pyrexia
         subjects affected / exposed
    0 / 1458 (0.00%)
    43 / 1458 (2.95%)
    14 / 718 (1.95%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    2 / 237 (0.84%)
    12 / 483 (2.48%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    6 / 405 (1.48%)
    11 / 863 (1.27%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    37 / 2368 (1.56%)
    23 / 1173 (1.96%)
    4 / 202 (1.98%)
    2 / 418 (0.48%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    13 / 2410 (0.54%)
    10 / 957 (1.04%)
    0 / 16 (0.00%)
    1 / 16 (6.25%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    45
    14
    0
    0
    2
    13
    0
    0
    0
    0
    0
    0
    6
    11
    0
    0
    0
    37
    24
    4
    2
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    13
    10
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Pyrexia (FEVER)
    alternative assessment type: Systematic
         subjects affected / exposed
    0 / 1458 (0.00%)
    184 / 1458 (12.62%)
    87 / 718 (12.12%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    13 / 237 (5.49%)
    28 / 483 (5.80%)
    0 / 718 (0.00%)
    243 / 3109 (7.82%)
    16 / 518 (3.09%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    21 / 405 (5.19%)
    41 / 863 (4.75%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    224 / 2368 (9.46%)
    121 / 1173 (10.32%)
    0 / 202 (0.00%)
    18 / 418 (4.31%)
    0 / 418 (0.00%)
    1 / 16 (6.25%)
    1 / 15 (6.67%)
    2 / 16 (12.50%)
    14 / 433 (3.23%)
    0 / 487 (0.00%)
    33 / 487 (6.78%)
    9 / 32 (28.13%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    154 / 2410 (6.39%)
    0 / 957 (0.00%)
    3 / 16 (18.75%)
    4 / 16 (25.00%)
    4 / 4 (100.00%)
    4 / 12 (33.33%)
    1 / 38 (2.63%)
    40 / 1538 (2.60%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    8 / 260 (3.08%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    205
    96
    0
    0
    13
    28
    0
    257
    16
    0
    0
    0
    21
    41
    0
    0
    0
    237
    126
    0
    18
    0
    1
    1
    3
    14
    0
    35
    12
    0
    0
    154
    0
    3
    4
    4
    4
    1
    42
    0
    0
    8
    0
    0
    Immune system disorders
    Seasonal allergy
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    1 / 16 (6.25%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Social circumstances
    Menarche
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    1 / 16 (6.25%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Reproductive system and breast disorders
    Dysmenorrhoea
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    1 / 16 (6.25%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    0 / 1458 (0.00%)
    15 / 1458 (1.03%)
    5 / 718 (0.70%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    22 / 2368 (0.93%)
    14 / 1173 (1.19%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    18
    5
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    22
    14
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Rhinorrhoea
         subjects affected / exposed
    0 / 1458 (0.00%)
    20 / 1458 (1.37%)
    5 / 718 (0.70%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    1 / 16 (6.25%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    21
    5
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    1 / 16 (6.25%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Irritability
         subjects affected / exposed
    0 / 1458 (0.00%)
    15 / 1458 (1.03%)
    6 / 718 (0.84%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    16
    7
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Irritability (IRRITABILITY)
    alternative assessment type: Systematic
         subjects affected / exposed
    0 / 1458 (0.00%)
    932 / 1458 (63.92%)
    431 / 718 (60.03%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    82 / 237 (34.60%)
    191 / 483 (39.54%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    4 / 15 (26.67%)
    8 / 16 (50.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    1343
    615
    0
    0
    82
    191
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    4
    12
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Injury, poisoning and procedural complications
    Animal bite
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    1 / 16 (6.25%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Arthropod bite
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    1 / 16 (6.25%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Concussion
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    1 / 38 (2.63%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Contusion
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    1 / 16 (6.25%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    1 / 32 (3.13%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Fall
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    1 / 16 (6.25%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Foreign body ingestion
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    1 / 32 (3.13%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Fracture
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    1 / 38 (2.63%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Skin laceration
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    1 / 32 (3.13%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Nervous system disorders
    Headache
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    1 / 16 (6.25%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Headache (HEADACHE)
    alternative assessment type: Systematic
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    1193 / 3109 (38.37%)
    163 / 518 (31.47%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    15 / 405 (3.70%)
    36 / 863 (4.17%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    191 / 2368 (8.07%)
    86 / 1173 (7.33%)
    0 / 202 (0.00%)
    93 / 418 (22.25%)
    0 / 418 (0.00%)
    2 / 16 (12.50%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    143 / 433 (33.03%)
    0 / 487 (0.00%)
    228 / 487 (46.82%)
    8 / 32 (25.00%)
    1 / 27 (3.70%)
    0 / 1538 (0.00%)
    610 / 2410 (25.31%)
    0 / 957 (0.00%)
    10 / 16 (62.50%)
    11 / 16 (68.75%)
    3 / 4 (75.00%)
    6 / 12 (50.00%)
    13 / 38 (34.21%)
    506 / 1538 (32.90%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    77 / 260 (29.62%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1573
    185
    0
    0
    0
    15
    36
    0
    0
    0
    211
    99
    0
    93
    0
    4
    0
    0
    143
    0
    307
    8
    1
    0
    610
    0
    12
    14
    6
    8
    13
    656
    0
    0
    88
    0
    0
    Presyncope
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    1 / 16 (6.25%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Somnolence (DROWSINESS)
    alternative assessment type: Systematic
         subjects affected / exposed
    0 / 1458 (0.00%)
    560 / 1458 (38.41%)
    274 / 718 (38.16%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    27 / 237 (11.39%)
    98 / 483 (20.29%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    1 / 15 (6.67%)
    4 / 16 (25.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    713
    354
    0
    0
    27
    98
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    5
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Speech disorder developmental
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    1 / 15 (6.67%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Blood and lymphatic system disorders
    Lymphadenopathy
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    1 / 32 (3.13%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    40 / 2410 (1.66%)
    7 / 957 (0.73%)
    0 / 16 (0.00%)
    1 / 16 (6.25%)
    1 / 4 (25.00%)
    0 / 12 (0.00%)
    1 / 38 (2.63%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    40
    7
    0
    2
    1
    0
    1
    0
    0
    0
    0
    0
    0
    Gastrointestinal disorders
    Abdominal discomfort
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    1 / 32 (3.13%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Abdominal pain
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    2 / 32 (6.25%)
    1 / 27 (3.70%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    1 / 38 (2.63%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    1
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Diarrhea (DIARRHEA)
    alternative assessment type: Systematic
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    320 / 3109 (10.29%)
    40 / 518 (7.72%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    21 / 405 (5.19%)
    39 / 863 (4.52%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    305 / 2368 (12.88%)
    160 / 1173 (13.64%)
    0 / 202 (0.00%)
    19 / 418 (4.55%)
    0 / 418 (0.00%)
    1 / 16 (6.25%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    18 / 433 (4.16%)
    0 / 487 (0.00%)
    66 / 487 (13.55%)
    5 / 32 (15.63%)
    1 / 27 (3.70%)
    0 / 1538 (0.00%)
    104 / 2410 (4.32%)
    0 / 957 (0.00%)
    1 / 16 (6.25%)
    1 / 16 (6.25%)
    2 / 4 (50.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    138 / 1538 (8.97%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    26 / 260 (10.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    364
    46
    0
    0
    0
    21
    39
    0
    0
    0
    338
    179
    0
    19
    0
    2
    0
    0
    18
    0
    75
    6
    1
    0
    104
    0
    2
    1
    2
    0
    0
    151
    0
    0
    27
    0
    0
    Diarrhoea
         subjects affected / exposed
    0 / 1458 (0.00%)
    31 / 1458 (2.13%)
    17 / 718 (2.37%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    5 / 405 (1.23%)
    1 / 863 (0.12%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    22 / 2368 (0.93%)
    13 / 1173 (1.11%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    31
    17
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    5
    1
    0
    0
    0
    24
    13
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Nausea
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    1 / 27 (3.70%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Teething
         subjects affected / exposed
    0 / 1458 (0.00%)
    18 / 1458 (1.23%)
    7 / 718 (0.97%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    18
    7
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Vomiting
         subjects affected / exposed
    0 / 1458 (0.00%)
    27 / 1458 (1.85%)
    15 / 718 (2.09%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    7 / 237 (2.95%)
    6 / 483 (1.24%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    7 / 405 (1.73%)
    2 / 863 (0.23%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    41 / 2368 (1.73%)
    13 / 1173 (1.11%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    2 / 27 (7.41%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    1 / 12 (8.33%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    29
    17
    0
    0
    7
    6
    0
    0
    0
    0
    0
    0
    7
    2
    0
    0
    0
    42
    13
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Vomiting (VOMITING)
    alternative assessment type: Systematic
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    122 / 3109 (3.92%)
    13 / 518 (2.51%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    16 / 405 (3.95%)
    16 / 863 (1.85%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    144 / 2368 (6.08%)
    68 / 1173 (5.80%)
    0 / 202 (0.00%)
    7 / 418 (1.67%)
    0 / 418 (0.00%)
    1 / 16 (6.25%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    11 / 433 (2.54%)
    0 / 487 (0.00%)
    22 / 487 (4.52%)
    2 / 32 (6.25%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    61 / 2410 (2.53%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    1 / 16 (6.25%)
    1 / 4 (25.00%)
    2 / 12 (16.67%)
    1 / 38 (2.63%)
    55 / 1538 (3.58%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    8 / 260 (3.08%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    125
    14
    0
    0
    0
    16
    16
    0
    0
    0
    150
    69
    0
    7
    0
    1
    0
    0
    11
    0
    24
    3
    0
    0
    61
    0
    0
    1
    1
    2
    1
    57
    0
    0
    9
    0
    0
    Skin and subcutaneous tissue disorders
    Dermatitis diaper
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    1 / 32 (3.13%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Erythema
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    1 / 38 (2.63%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Pruritus
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    1 / 16 (6.25%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Rash
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    1 / 32 (3.13%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Rash macular
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    1 / 16 (6.25%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    1 / 38 (2.63%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Urticaria
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    1 / 16 (6.25%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    1 / 16 (6.25%)
    0 / 16 (0.00%)
    1 / 4 (25.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Arthralgia (JOINT PAIN)
    alternative assessment type: Systematic
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    235 / 3109 (7.56%)
    35 / 518 (6.76%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    4 / 405 (0.99%)
    9 / 863 (1.04%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    53 / 2368 (2.24%)
    30 / 1173 (2.56%)
    0 / 202 (0.00%)
    23 / 418 (5.50%)
    0 / 418 (0.00%)
    1 / 16 (6.25%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    26 / 433 (6.00%)
    0 / 487 (0.00%)
    69 / 487 (14.17%)
    1 / 32 (3.13%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    129 / 2410 (5.35%)
    0 / 957 (0.00%)
    1 / 16 (6.25%)
    1 / 16 (6.25%)
    1 / 4 (25.00%)
    1 / 12 (8.33%)
    1 / 38 (2.63%)
    110 / 1538 (7.15%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    22 / 260 (8.46%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    265
    39
    0
    0
    0
    4
    9
    0
    0
    0
    53
    33
    0
    23
    0
    1
    0
    0
    26
    0
    80
    1
    0
    0
    129
    0
    1
    1
    2
    1
    1
    127
    0
    0
    25
    0
    0
    Costochondritis
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    1 / 32 (3.13%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Myalgia
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    1 / 16 (6.25%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Myalgia (MUSCLE PAIN)
    alternative assessment type: Systematic
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    561 / 3109 (18.04%)
    81 / 518 (15.64%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    6 / 405 (1.48%)
    15 / 863 (1.74%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    106 / 2368 (4.48%)
    50 / 1173 (4.26%)
    0 / 202 (0.00%)
    73 / 418 (17.46%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    76 / 433 (17.55%)
    0 / 487 (0.00%)
    167 / 487 (34.29%)
    4 / 32 (12.50%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    350 / 2410 (14.52%)
    0 / 957 (0.00%)
    2 / 16 (12.50%)
    5 / 16 (31.25%)
    4 / 4 (100.00%)
    1 / 12 (8.33%)
    3 / 38 (7.89%)
    192 / 1538 (12.48%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    31 / 260 (11.92%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    657
    92
    0
    0
    0
    6
    15
    0
    0
    0
    114
    54
    0
    73
    0
    0
    0
    0
    76
    0
    213
    5
    0
    0
    350
    0
    2
    7
    6
    1
    3
    230
    0
    0
    38
    0
    0
    Neck pain
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    1 / 16 (6.25%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Infections and infestations
    COVID-19
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    2 / 202 (0.99%)
    8 / 418 (1.91%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    6 / 487 (1.23%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    8
    0
    0
    0
    0
    0
    0
    6
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Ear infection
         subjects affected / exposed
    0 / 1458 (0.00%)
    10 / 1458 (0.69%)
    8 / 718 (1.11%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    10
    8
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Enterobiasis
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    2 / 16 (12.50%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Hand-foot-and-mouth disease
         subjects affected / exposed
    0 / 1458 (0.00%)
    16 / 1458 (1.10%)
    11 / 718 (1.53%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    16
    11
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Otitis media
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    4 / 237 (1.69%)
    4 / 483 (0.83%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    4
    4
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Periorbital cellulitis
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    1 / 27 (3.70%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Rhinitis
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    14 / 2368 (0.59%)
    12 / 1173 (1.02%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    14
    12
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Upper respiratory tract infection
         subjects affected / exposed
    0 / 1458 (0.00%)
    0 / 1458 (0.00%)
    0 / 718 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    4 / 518 (0.77%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    3 / 260 (1.15%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    4
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    3
    0
    0
    Metabolism and nutrition disorders
    Decreased appetite (DECREASED APPETITE)
    alternative assessment type: Systematic
         subjects affected / exposed
    0 / 1458 (0.00%)
    511 / 1458 (35.05%)
    236 / 718 (32.87%)
    0 / 237 (0.00%)
    0 / 483 (0.00%)
    29 / 237 (12.24%)
    89 / 483 (18.43%)
    0 / 718 (0.00%)
    0 / 3109 (0.00%)
    0 / 518 (0.00%)
    0 / 518 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 405 (0.00%)
    0 / 863 (0.00%)
    0 / 1173 (0.00%)
    0 / 2368 (0.00%)
    0 / 260 (0.00%)
    0 / 2368 (0.00%)
    0 / 1173 (0.00%)
    0 / 202 (0.00%)
    0 / 418 (0.00%)
    0 / 418 (0.00%)
    0 / 16 (0.00%)
    2 / 15 (13.33%)
    2 / 16 (12.50%)
    0 / 433 (0.00%)
    0 / 487 (0.00%)
    0 / 487 (0.00%)
    0 / 32 (0.00%)
    0 / 27 (0.00%)
    0 / 1538 (0.00%)
    0 / 2410 (0.00%)
    0 / 957 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 4 (0.00%)
    0 / 12 (0.00%)
    0 / 38 (0.00%)
    0 / 1538 (0.00%)
    0 / 3109 (0.00%)
    0 / 957 (0.00%)
    0 / 260 (0.00%)
    0 / 2410 (0.00%)
    0 / 202 (0.00%)
         occurrences all number
    0
    619
    279
    0
    0
    29
    89
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    3
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    10 Sep 2019
    Amendment 3: Updated to allow an additional 2250 Phase 2/3 selected-dose Participants 5 years of age, to enlarge the size of the pediatric safety database. This has resulted in the total number of participants in this portion of the study increasing to approximately 9000 participants. Included blood draws, procedures, and objectives for potential troponin I testing in participants ≥5 to 12 and ≥12 to 16 years. Added the rationale for collecting serum samples for potential troponin I testing.Revised an objective and corresponding endpoint to describe severe COVID-19 cases in participants in the selected-dose portion of the study. Clarified the process for participants who become eligible for receipt of BNT162b2 or another COVID-19 vaccine prior to Visit 5 (6-month follow-up visit). Added a second definition of symptoms of severe COVID-19 disease per the CDC definition. Clarified instructions on how to unblind participants at the 6-month follow-up visit. Updated information on the recording of nonstudy vaccination and concomitant medications.
    05 Mar 2021
    Amendment 1: Added 2 age groups to the study: participants ≥2 to <5 years and ≥6 months to <2 years of age, to also study safety and immunogenicity in these age groups. Updated efficacy objectives to apply across ages in which immunobridging has been successful, if 22 cases are accrued. Made updates to match Pfizer’s response to 04 February 2021 CBER comments regarding this study, ie: Exclusion criterion 3 applied to all study participants rather than just to Phase 1 participants. References to “noninferiority” updated to “immunobridging.” Made additions to the exclusion criteria for previous or current diagnosis of MIS-C. Added to the exclusion criteria receipt of any passive antibody therapy specific to COVID-19 within 90 days prior to enrollment. Specified that placebo recipients who decline BNT162b2 will be followed for 24 months (Visits X and Y). Temporary delay of study intervention criteria regarding nonstudy vaccination updated to be most permissive, ie, to allow easier scheduling around childhood routine vaccinations. Added the following symptoms as prompts to complete the COVID-19/MIS-C illness e-diary: Inability to eat/poor feeding in participants <5 years of age; Abdominal pain; Hospitalization due to confirmed COVID-19 infection. Following updates made to the first confirmed COVID-19 case definition to accommodate inclusion of participants 5 years of age: Definition of diarrhea added. Inability to eat/poor feeding in participants 5 years of age added as an additional symptom. Definition of SARS-CoV-2–related hospitalization added. RR and HR required to meet the SARS-CoV-2–related severe case definition specified by participant age. Table 4 inserted. Added that cell-mediated immune responses will be described following isolation of PBMCs in a subset of Phase 2/3 participants ≥10 years of age. Corresponding visit (Visit 3) added approximately 7 days after Dose 2.
    06 Aug 2021
    Amendment 2: Made the following updates in response to commitments made to CBER concerning myocarditis and pericarditis: Insertion of additional row in risk assessment table in risk assessment section. Addition of myocarditis and pericarditis in Adverse Events of Special Interest section. Addition of a procedure to any visit that occurs sooner than 1 month after any vaccination. Addition of an unplanned visit to capture data pertaining to myocarditis and pericarditis. Revised protocol title to reflect the changes in age and dose evaluation.Updated to allow an additional 2250 Phase 2/3 selected-dose participants to enlarge the size of the pediatric safety database. Added Phase 1/2/3 evaluation of lower dose levels for children and young adults with corresponding objectives. Revised the order of Visit 1 activities to clarify when procedures should be conducted in relation to study intervention administration when the visit occurs over 2 consecutive days. Added updates and reformatted activities in the SoA. Removed the requirement to conduct a potential COVID-19 convalescent visit following each potential COVID-19 illness visit. The collection of the blood sample was to support an exploratory endpoint, which will be addressed with external data and thereby reduce burden to participants and caregivers. Added a country-specific appendix that allows flexibility to conduct scheduled follow-up visits in the participant’s home, ie, site-arranged home health visits, as permitted per local guidelines (applicable to Poland only).
    29 Sep 2021
    Amendment 4: Revised the success criterion for the efficacy hypotheses to the lower limit of 95% CI 30, in response to regulatory feedback. Added Section 1.1.1, requiring the avoidance of strenuous or endurance exercise 4 days prior to Visit 1 through Visit 1 and from Visit 2 through Visit 3 for the potential troponin I testing subset. Clarified that Phase 2/3 selected-dose participants who originally received active vaccine and are unblinded before Visit 5 will complete the original SoA (Section 1.3.3) before transitioning to the SoA in Section 1.3.3.1.
    15 Nov 2021
    Amendment 5: Based on the 10-μg immunobridging data in the ≥5- to 12-year age group, revised Phase 1/2/3 evaluation of lower dose schedules for children and adolescents. Revised age range for the oldest age group. Revised corresponding objectives, estimands, and endpoints. Revised corresponding SoA and procedures. Revised details in the statistical methods sections. Added flexibility for Visit 5 to be conducted as a telephone visit for the 4500 participants included to enlarge the size of the pediatric safety database, reducing the burden on the participant or participant’s parent(s)/legal guardian. Included an exploratory objective to describe the immune response to emerging VOCs. Added the instruction that participants who receive COVID-19 vaccines outside of the study from protocol amendment 5 onwards should be withdrawn to maintain the appropriate assessment of the study intervention. Removed the lifestyle consideration related to strenuous or endurance exercise (potential troponin I testing group only) following regulatory feedback. Updated the appendix for SAE reporting to include guidance on how to report SAEs to Pfizer Safety via an electronic data collection tool.
    04 Jan 2022
    Amendment 6: The primary immunogenicity analysis demonstrated that the immune response elicited by BNT162b2 in participants ≥2 to 5 years of age (2 doses at 3 μg) did not meet immunobridging criteria when compared to participants 16 to 25 years of age from the C4591001 study. As a result, and given the emerging data in individuals 16 years of age and older, an additional (third) dose of BNT162b2 will be administered to all Phase 1 dose-finding and Phase 2/3 selected-dose participants: Added corresponding objectives, estimands, and endpoints. Added corresponding SoA and procedures. Added details in the statistical methods sections. Cell-mediated immune responses will also be described following isolations of PBMCs in a subset of Phase 2/3 participants who receive a third dose. An additional 4500 Phase 2/3 selected-dose participants ≥6 months to 2 years and ≥2 to 5 years of age are permitted to enroll to enlarge the size of the pediatric safety database. Clarified that participants who decline the opportunity to receive third dose should be withdrawn. Clarified that the interval between the second and third doses will be based on the participant’s age at the time of enrollment. Clarified that the dose level of BNT162b2 will be based on age at the time of vaccination. As the asymptomatic efficacy objective is now restricted to participants ≥5 to 12 years of age, in the Phase 2/3 selected-dose portion, participants ≥6 months to 5 years of age who enrolled before protocol amendment 6 will no longer have a blood sample for immunogenicity testing at Visit 5 (6-month follow-up). Time frames for prohibited nonstudy vaccines were simplified. For the option of a 3-μg dose level, an additional unit dose strength was added. For participants 5 years of age, all positive RT-PCR cases confirmed by the central laboratory will undergo BioFire testing.
    10 Mar 2022
    Amendment 7: Given the emerging data in individuals 16 years of age and older, an additional (third) dose of BNT162b2 at least 5 months after Dose 2 to all Phase 2/3 participants enrolled to support obtaining serum samples for potential troponin I testing (≥5 to12 years of age, placebo-controlled, and ≥12 to 16 years of age, open-label):Clarified both symptomatic and asymptomatic COVID-19 infection will result in temporary delay of enrollment, randomization, or study intervention administration. Clarified that the dose interval for Phase 2/3 selected-dose participants enrolled in the ≥2 to 5 years age group who originally received placebo and will turn 5 years of age prior to crossing over to active vaccine will be the same as for the ≥5 to 12 years age group (ie, third dose administered at least 6 months after the second dose). Additional clarification for Phase 2/3 selected-dose parents/legal guardians that decline the blinded third dose. Added flexibility to inclusion and exclusion criteria (based on investigator’s judgment) for Phase 1 dose-finding participants when receiving Dose 3. Clarified that, for Phase 1 dose-finding participants, height and weight should be collected once at Visit 1 only as part of the physical examination; likewise, the participant’s randomization number and study intervention allocation are obtained using the IRT system at Visit 1 only. The timing of cases for these 2 groups are similar, therefore making it more likely to compare cases of the same variant. Added collection of maternal COVID-19 immunization and breastfeeding data for participants who are ≥6 months to 2 years of age in the Phase 2/3 selected-dose portion of the study. Updated the risk assessment to align with the current version of the IB.
    28 Apr 2023
    Amendment 8: Updated schedules of assessments and protocol text to identify study visits that no longer need to be completed.Updated study procedures to describe site actions following approval of protocol amendment 8.Removed the lower-dose-evaluation substudy of the protocol. The FDA has approved the request for the lower-dose evaluation postmarketing commitment release in November 2022. Provided further guidance for participants withdrawal from the study for Phase 2/3 selected-dose parents/legal guardians that decline the blinded third dose. Added a statement that participants in Mexico will not self collect nasal swabs per Mexican regulatory request. Clarified that the window for provision of a third dose of BNT162b2 for participants ≥5 years of age to 12 years of age in the US is in line with changing regulatory requirements (emergency use approvals). Removed blood sample collection for immunogenicity testing at certain study visits for Phase 1 dose-finding participants and Phase 2/3 selected-dose participants who are part of the immunogenicity subset to reduce the burden of procedures on participants and caregivers for those enrolling in study C4591048. Secondary/exploratory objectives with corresponding text throughout the protocol removed: To describe the efficacy of prophylactic BNT162b2 against asymptomatic infection in participants ≥5 to 12 years age in the selected-dose portion of the study without evidence of past SARS-CoV-2 infection. To describe the serological responses in Phase 2/3 participants in the selected-dose portion of the study to BNT162b2 at the dose level selected in each age group in cases of: Confirmed COVID-19 with and without coinfection or Confirmed severe COVID-19 or SARS-CoV-2 infection without confirmed COVID-19. Added exploratory objective to describe the incidence of confirmed COVID-19 through the entire study follow-up period. Added corresponding estimands, endpoints, and statistical analysis methods.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 12:22:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA